<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2 xmlns:ns2="local" rowCount="683"><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase IIa ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion</ProtocolTitle><Sponsor>Infectious Disease Research Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="231367"></Trial><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>ID93</Interventions><Reference>IDRI-TBVPX-203; NCT02465216</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>THIRST</ProtocolAcronym><ProtocolTitle>Tuberculosis and HIV Immune Reconstitution Syndrome Trial (THIRST)</ProtocolTitle><Sponsor>Duke University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="47398"></Trial><Drug id="26574">lamivudine + abacavir + zidovudine, GSK</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>70</Patients><Biomarkers>T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>70</EnrollmentCount><Interventions>lamivudine + abacavir + zidovudine</Interventions><Reference>NCT00851630; Pro00013131; THIRST</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>SQ109EBA</ProtocolAcronym><ProtocolTitle>EBA of SQ-109 in Adult Subjects with Pulmonary TB</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="71188"></Trial><Drug id="31010">SQ-109</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>90</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>rifampicin</Controls><EnrollmentCount>90</EnrollmentCount><Interventions>SQ109</Interventions><Reference>20100606; LMU-IMPH-SQ109-01; NCT01218217; PACTR201009000252144; SQ109EBA</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>TBTC S29B</ProtocolAcronym><ProtocolTitle>Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="68204"></Trial><Drug id="44303">midazolam hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>37</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>37</EnrollmentCount><Interventions>midazolam; rifapentine</Interventions><Reference>CDC-NCHHSTP-5779; NCT01162486; TBTC S29B; TBTC S29B</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in HIV-positive Adults</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="73200"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>240</Patients><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Blood platelets; Body temperature; CD40 ligand; Creatinine; Erythrocytes; Hemoglobin; Interferon gamma; Interleukin-2; Leukocyte count; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>240</EnrollmentCount><Interventions>M-72</Interventions><Reference>113935; NCT01262976</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial</ProtocolTitle><Sponsor>University of Minnesota - Clinical and Translational Science Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="199754"></Trial><Drug id="2807">atorvastatin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers>C-reactive protein</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>atorvastatin; dexamethasone; dexamethasone (decadron); once-daily naproxen (oral controlled release, pain), Alvogen; once-daily naproxen (oral controlled release, pain), Alvogen</Interventions><Reference>NCT01442428; WS967180</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Escalation Study on Safety and Immunogenicity of VPM-1-002 in Comparison to BCG in Healthy Volunteers in South Africa</ProtocolTitle><Sponsor>Vakzine Projekt Management GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="65984"></Trial><Drug id="55569">VPM-1002</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>24</Patients><Biomarkers>Ag85B; CD4+; CD8+; IFN-alpha; IFN-gamma; IL-2; PPD</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>VPM-1-002</Interventions><Reference>DOH-27-0210-3083; NCT01113281; VPM1002-ZA-1.10TB</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="23035"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>121</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>216</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyridoxine; rifampin; rifapentine</Interventions><Reference>06-0018; NCT00728507</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>USPHS-23</ProtocolAcronym><ProtocolTitle>Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen</ProtocolTitle><Sponsor>National Institutes of Health</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="10648"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>efavirenz; rifabutin</Interventions><Reference>NCRR-M01RR00030-0162; NCT00018083; USPHS-23</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>STRIDE</ProtocolAcronym><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><Sponsor>AIDS Clinical Trials Group</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10681"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>780</Patients><Biomarkers>T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>809</EnrollmentCount><Interventions>efavirenz; emtricitabine; tenofovir disoproxil fumarate; tenofovir disoproxil fumarate + emtricitabine</Interventions><Reference>1U01AI068636; ACTG A5221; ACTG A5221; NCT00108862; STRIDE</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10872"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>MVA85A</Interventions><Reference>AFTBVAC; NCT00423839</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Evaluate the Safety, Tolerability, and Efficacy of TMC-207 as Part of an Individualized Multi-Drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-Positive Pulmonary MDR-TB</ProtocolTitle><Sponsor>Johnson &amp; Johnson</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="56974"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>233</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>241</EnrollmentCount><Interventions>bedaquiline; bedaquiline; clofazimine</Interventions><Reference>2008-008444-25; CR012352; NCT00910871; NCT00980811; TMC207-TiDP13-C209</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>PETE</ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Emtricitabine/Tenofovir + Efavirenz in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Sponsor>Poverty Related Infection Oriented Research</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="10945"></Trial><Drug id="50038">tenofovir disoproxil fumarate + emtricitabine + efavirenz, Gilead/BMS/Merck &amp; Co</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>tenofovir disoproxil fumarate + emtricitabine + efavirenz</Interventions><Reference>NCT00474435; PETE; UMCN-AKF 04.03</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>"NVP"</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="114300"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>135</Patients><Biomarkers>BMI; Complete blood count; Erythrocyte sedimentation rate; Fasting blood glucose; Height; Hemoglobin; Serum albumin; Serum uric acid; Total body mass; Weight</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>135</EnrollmentCount><Interventions>efavirenz; lamivudine + zidovudine, GlaxoSmithKline; nevirapine; rifampicin</Interventions><Reference>"NVP"; NCT01805258; SKS/NACO-1/2006-07</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="210646"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>240</Patients><Biomarkers>Alanine transaminase; Aspartate aminotransferase; QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyraziminide; rifampicin</Controls><EnrollmentCount>240</EnrollmentCount><Interventions>bedaquiline; moxifloxacin; pretomanid; pyraziminide</Interventions><Reference>NC-005; NC-005-(J-M-PA-Z); NCT02193776</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="65639"></Trial><Drug id="3612">meningococcal C/CRM-197 conjugate vaccine, Chiron</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>302</Patients><Biomarkers>Alanine transaminase; Blood platelets; Body temperature; CD40 ligand; Creatinine; Cytotoxic T-Lymphocytes; Hemoglobin; Interferon gamma; Interleukin-2; Leukocyte count; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Menjugate; Polio Sabin; Prevnar; Tritanrix HB</Controls><EnrollmentCount>302</EnrollmentCount><Interventions>GSK-692342; GSK-692342a; Polio Sabin; Prevnar; Tritanrix HB</Interventions><Reference>112899; 2012-004380-44; NCT01098474; TUBERCULOSIS-013 PRI</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA-85A</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="69926"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>48</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>BCG; BCG; MVA-85A</Interventions><Reference>NCT01194180; TB023</Reference></Row><Row><ArmCount>6</ArmCount><ProtocolAcronym>DATiC</ProtocolAcronym><ProtocolTitle>Optimal Dosing of First-Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="89135"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>39</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>ethambutol; isoniazid; lopinavir + ritonavir; nevirapine; pyrazinamide; rifampicin</Interventions><Reference>DATiC; DATiC; NCT01637558</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy Against TB Disease, Safety, and Immunogenicity of MVA-85A/AERAS-485 in HIV-Infected Adults</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="67841"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>650</Patients><Biomarkers>Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-17A; Interleukin-2; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>650</EnrollmentCount><Interventions>MVA-85A</Interventions><Reference>C-030-485; NCT01151189</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EARNEST Rifabutin Pharmacokinetics (PK) Substudy</ProtocolTitle><Sponsor>Joint Clinical Research Centre, Medical Research Council</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="90175"></Trial><Drug id="54488">raltegravir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>140</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>140</EnrollmentCount><Interventions>Aluvia; raltegravir; rifabutin</Interventions><Reference>ISRCTN13074752; NCT01663168</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym>TBTC-27/28 PK</ProtocolAcronym><ProtocolTitle>TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10847"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>72</Patients><Biomarkers>Body Mass Index; C-reactive protein; MDR1; N-acetyltransferase  (NAT2); Solute carrier organic anion transporter family member 1B1; Total body mass; UDP-galactose translocator</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><EnrollmentCount>72</EnrollmentCount><Interventions>moxifloxacin; moxifloxacin; rifampin</Interventions><Reference>CDC-NCHSTP-4222; NCT00164463; TBTC-27/28 PK</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II, Placebo-Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections</ProtocolTitle><Sponsor>National Center for Research Resources</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="92426"></Trial><Drug id="8050">thalidomide, Celgene</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>thalidomide, Celgene</Interventions><Reference>199/11682; NCT00004276; RU-0300395</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/IIa Safety And Immunogenicity of AERAS-456 in HIV-Negative Adults With And Without Latent Tuberculosis Infection</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="136263"></Trial><Drug id="74849">SSI H56-IC31</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>98</Patients><Biomarkers>HIV negative; T-Helper Lymphocytes; T-Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>98</EnrollmentCount><Interventions>SSI H56-IC31</Interventions><Reference>C-035-456; NCT01865487</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug Resistant Tuberculosis</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="80386"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>511</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>antiretroviral therapy; optimized background regimen therapy</Controls><EnrollmentCount>511</EnrollmentCount><Interventions>antiretroviral therapy; delamanid; optimized background regimen therapy</Interventions><Reference>2010-022271-59; 242-09-213; NCT01424670</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="63801"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>182</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>182</EnrollmentCount><Interventions>levofloxacin; moxifloxacin</Interventions><Reference>H-0911-068-301; NCT01055145</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="161275"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>355</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; lamivudine; nevirapine; pyrazinamide; rifampicin; zidovudine</Interventions><Reference>NCT00698334; SKS/NACO/2006</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>STRIDE</ProtocolAcronym><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><Sponsor>AIDS Clinical Trials Group</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10681"></Trial><Drug id="4728">emtricitabine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>780</Patients><Biomarkers>T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>809</EnrollmentCount><Interventions>efavirenz; emtricitabine; tenofovir disoproxil fumarate; tenofovir disoproxil fumarate + emtricitabine</Interventions><Reference>1U01AI068636; ACTG A5221; ACTG A5221; NCT00108862; STRIDE</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym>NC-003</ProtocolAcronym><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC-207 (J)-PA-824 (Pa)-Pyrazinamide (Z)</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="92275"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>105</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour e</Controls><EnrollmentCount>105</EnrollmentCount><Interventions>PA-824; TMC-207; clofazimine; clofazimine; pyrazinamide; pyrazinamide</Interventions><Reference>NC-003; NC-003-(C-J-Pa-Z); NCT01691534</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>"NVP"</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="114300"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>135</Patients><Biomarkers>BMI; Complete blood count; Erythrocyte sedimentation rate; Fasting blood glucose; Height; Hemoglobin; Serum albumin; Serum uric acid; Total body mass; Weight</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>135</EnrollmentCount><Interventions>efavirenz; lamivudine + zidovudine, GlaxoSmithKline; nevirapine; rifampicin</Interventions><Reference>"NVP"; NCT01805258; SKS/NACO-1/2006-07</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="162886"></Trial><Drug id="10774">NeisVac-C</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Anti-Meningitis C antibodies; C-C motif chemokine 2; C-C motif chemokine 3; C-C motif chemokine 4; Cytokines; IgG; Interferon gamma; Interferon-alpha; Interleukin-1 alpha; Interleukin-1 beta; Interleukin-10; Interleukin-12; Interleukin-13; Interleukin-2; Interleukin-6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>BCG; Infanrix; Menitorix; NeisVac-C; Pentacel; Prevnar 13; Priorix; Rotarix</Interventions><Reference>2013-003488-71; BAM; NCT02002156; OVG-2013/04; UKCRN 15722</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Open-Label Study to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability and Pharmacokinetics of Multiple Doses (md) of TMC-207 Oral Solution (Os) and Isoniazid (JH), TMC-207 Os and Pyrazinamide (JZ), TMC-207 Os and Rifampin (JR) or TMC-207 Os and Isoniazid and Pyrazinamide (JHZ), Compared to the three Principle Drugs of Standard Anti-Tuberculosis Treatment (HRZ) in Treatment-Naive Subjects With Sputum-Smear Positive Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Janssen R&amp;D (Ireland)</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="131253"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>TMC-207; isoniazid; pyrazinamide</Controls><EnrollmentCount>60</EnrollmentCount><Interventions>TMC-207; isoniazid; pyrazinamide; rifampicin</Interventions><Reference>EudraCT 2004-005142-12; TMC207-C203</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Pharmacokinetics and Safety of indinavir/ritonavir With NRTIs in HIV/TB co-Infected Patients Receiving Rifampicin</ProtocolTitle><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10871"></Trial><Drug id="7310">ritonavir</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>indinavir; ritonavir</Interventions><Reference>HIV-NAT 044; NCT00411996</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Essentiality of INH in TB Therapy</ProtocolTitle><Sponsor>AIDS Clinical Trials Group</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="87091"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>69</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>69</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; rifampicin</Interventions><Reference>1U01AI068636; ACTG A5307; NCT01589497</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>TBTC-22</ProtocolAcronym><ProtocolTitle>TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10650"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1004</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid; rifampicin</Controls><EnrollmentCount>1000</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Reference>CDC-NCHSTP-1427; NCT00023335; TBTC Study 22; TBTC-22</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10646"></Trial><Drug id="4481">stavudine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>lamivudine; nelfinavir mesylate; rifabutin; stavudine; zidovudine</Interventions><Reference>AACTG A5062; ACTG A5062; NCT00004736</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10646"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>lamivudine; nelfinavir mesylate; rifabutin; stavudine; zidovudine</Interventions><Reference>AACTG A5062; ACTG A5062; NCT00004736</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment</ProtocolTitle><Sponsor>Instituto Nacional de Enfermedades Respiratorias</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="169697"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>63</Patients><Biomarkers>CD4 + cell</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>63</EnrollmentCount><Interventions>efavirenz; isoniazid; tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Interventions><Reference>C43-06; NCT00737724</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>N2R</ProtocolAcronym><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10947"></Trial><Drug id="4481">stavudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>145</Patients><Biomarkers>CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>142</EnrollmentCount><Interventions>efavirenz; nevirapine</Interventions><Reference>210041000824904203; N2R; NCT00483054</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA-85A, as a Way to Increase Immune Response and Avoid Anti-Vector Immunity</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="156675"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>37</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>37</EnrollmentCount><Interventions>MVA-85A</Interventions><Reference>13/SC/0329; 15209; 2013-002020-16; ISRCTN08234512; NCT01954563; TB035; UKCRN 15209</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>TBTC-29PK</ProtocolAcronym><ProtocolTitle>High-Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="63261"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Lung</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>rifampin</Controls><EnrollmentCount>60</EnrollmentCount><Interventions>rifapentine</Interventions><Reference>NCT01043575; TBTC Study 29PK; TBTC-29PK</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><Sponsor>Central Research Institute of Epidemiology</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="63729"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>abacavir; lamivudine; raltegravir</Interventions><Reference>NCT01059422; RAL/ABC/3TC - HIV/TB</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Leukapheresis Sampling for Immune Responses After BCG Vaccination in BCG-naive Healthy Adults in the US</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="227341"></Trial><Drug id="13624">BCG vaccine, Organon</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients>10</Patients><Biomarkers>Cytokines</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>TiceBCG</Interventions><Reference>A-046; NCT02413502</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial</ProtocolTitle><Sponsor>University of Stellenbosch</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="172626"></Trial><Drug id="3610">meloxicam</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>meloxicam</Interventions><Reference>NCT02060006; PRO13060453</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><Sponsor>Tuberculosis Research Centre</Sponsor><TrialStatus>Suspended</TrialStatus><Trial id="10863"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>116</Patients><Biomarkers>CD4+</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>180</EnrollmentCount><Interventions>didanosine; efavirenz; efavirenz +  didanosine + lamivudine; ethambutol; ethambutol + isoniazid + rifampicin + pyrazinamide; isoniazid; isoniazid + rifampicin; lamivudine; nevirapine; nevirapine + didanosine + lamivudine; pyrazinamide; rifampicin</Interventions><Reference>NCT00332306; trc23</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) in Healthy Adults</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11263"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>181</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>181</EnrollmentCount><Interventions>GSK-692342</Interventions><Reference>110345; NCT00621322</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>TEMPRANO</ProtocolAcronym><ProtocolTitle>Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="195741"></Trial><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1107</Patients><Biomarkers>Hepatitis B large envelope protein; Hepatitis B virus external core antigen; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>2073</EnrollmentCount><Interventions>efavirenz; isoniazid; lopinavir + ritonavir; tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Interventions><Reference>ANRS 12136 TEMPRANO; NCT00495651; TEMPRANO</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics of rifapentine and isoniazid and NAT2 and SLCO1B1 polymorphisms in pediatric Thai patients with latent tuberculosis infection</ProtocolTitle><Sponsor>Chulalongkorn University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="379095"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients></Patients><Biomarkers>Arylamine N-acetyltransferase 2; Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Reference>TCTR20190423002</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rifapentine-containing Tuberculosis Treatment Shortening Regimens</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="226815"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2516</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>2516</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyridoxine; rifampin; rifapentine</Interventions><Reference>6655; ACTG Study A5349; CTRI/2017/09/009772; NCT02410772; S31/A5349; TBTC Study 31</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention</ProtocolTitle><Sponsor>Huashan Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="228560"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>566</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>566</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Reference>81373064; NCT02430259</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>"NVP"</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="114300"></Trial><Drug id="16696">lamivudine + zidovudine, GlaxoSmithKline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>135</Patients><Biomarkers>BMI; Complete blood count; Erythrocyte sedimentation rate; Fasting blood glucose; Height; Hemoglobin; Serum albumin; Serum uric acid; Total body mass; Weight</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>135</EnrollmentCount><Interventions>efavirenz; lamivudine + zidovudine, GlaxoSmithKline; nevirapine; rifampicin</Interventions><Reference>"NVP"; NCT01805258; SKS/NACO-1/2006-07</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid</ProtocolTitle><Sponsor>St Stephens Aids Trust</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="265766"></Trial><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>26</Patients><Biomarkers>Blood platelets; Cytochrome P450 2B6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>35</EnrollmentCount><Interventions>efavirenz; lamivudine+ zidovudine; rifampicin + isoniazid (Rifinah); tenofovir disoproxil fumarate + emtricitabine; tenofovir+ lamivudine</Interventions><Reference>2014-002608-26; NCT02832778; SSAT062</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>TRUNCATE-TB</ProtocolAcronym><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><Sponsor>Syneos Health Inc, University College London</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="333435"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>900</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>900</EnrollmentCount><Interventions>bedaquiline; clofazimine; ethambutol; isoniazid; levofloxacin; linezolid; pyrazinamide; rifampicin; rifapentine</Interventions><Reference>2016-CT0376; NCT03474198; PHRR170327-001522; TRUNCATE-TB; TRUNCATE-TB</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>STREAM</ProtocolAcronym><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Sponsor>International Union Against Tuberculosis and Lung Diseases</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="228190"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>530</Patients><Biomarkers>4 beta-Hydroxycholesterol/Cholesterol ratio</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Lamprene; ethambutol (Myambutol); isoniazid (Nydrazid); kanamycin (Kantrex); moxifloxacin; prothionamide (Peteha); pyrazinamide (Zinamide)</Controls><EnrollmentCount>530</EnrollmentCount><Interventions>Lamprene; Regimen A locally-used WHO-approved MDR-TB regimen; bedaquiline; ethambutol (Myambutol); isoniazid (Nydrazid); kanamycin (Kantrex); levofloxacin; moxifloxacin; prothionamide (Peteha); pyrazinamide (Zinamide)</Interventions><Reference>18148631; 78372190; 78372190/18148631 (Stage 1/2); CTRI/2017/09/009693; ISRCTN78372190; NCT02409290; STREAM</Reference></Row><Row><ArmCount>6+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>NexGen EBA Radiological and Immunological Biomarkers of Sterilizing Drug Activity in Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="222933"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>262</Patients><Biomarkers>Chemokines; Cytokines</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>262</EnrollmentCount><Interventions>ethambutol; ethambutol; isonizaid; isonizaid; moxifloxacin; moxifloxacin; pyrazindamide; pyrazindamide; rifampicin; rifampicin</Interventions><Reference>15-I-N070; 999915070; NCT02371681</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>NEXT</ProtocolAcronym><ProtocolTitle>An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multidrug-resistant Tuberculosis</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="230529"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>300</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>kanamycin; moxifloxacin</Controls><EnrollmentCount>300</EnrollmentCount><Interventions>bedaqualine; ethionamide; isoniazid; levofloxacin; linezolid; pyrazinamide; terizidone</Interventions><Reference>NCT02454205; NEXT; NEXT-5001</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Latent Mycobacterium tuberculosis infection treatment among individuals with a history of prior tuberculosis: a randomized, controlled trial</ProtocolTitle><Sponsor>Chinese Academy of Medical Sciences &amp; Peking Union Medical College</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="352729"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>1500</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>1500</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Reference>ChiCTR1800018224</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 14-Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis</ProtocolTitle><Sponsor>Weill Medical College of Cornell University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="253491"></Trial><Drug id="11089">nitazoxanide</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampin</Controls><EnrollmentCount>30</EnrollmentCount><Interventions>ethambutol; isoniazid; nitazoxanide; pyrazinamide; rifampin</Interventions><Reference>NCT02684240; NZT001</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>TB-CHAMP trial</ProtocolAcronym><ProtocolTitle>Tuberculosis child multidrug-resistant preventive therapy</ProtocolTitle><Sponsor>University of Stellenbosch</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="259562"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1556</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>1556</EnrollmentCount><Interventions>levofloxacin</Interventions><Reference>ISRCTN92634082; MR/M007340/1; TB-CHAMP trial</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>TB-PRACTECAL</ProtocolAcronym><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Sponsor>Medecins Sans Frontieres</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="244304"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>630</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>630</EnrollmentCount><Interventions>Lamprene; bedaquiline; linezolid; moxifloxacin; pretomanid</Interventions><Reference>1541; NCT02589782; TB-PRACTECAL</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-Limited Settings</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="8820"></Trial><Drug id="2935">didanosine</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>592</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>592</EnrollmentCount><Interventions>didanosine; efavirenz; lamivudine; standard TB therapy</Interventions><Reference>CAPRISA 001; CAPRISA START; CIPRA; NCT00091936; START</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><Sponsor>Beijing Chest Hospital, Beijing Tuberculosis &amp; Thoracic Tumor Research Institute, Capital Medical University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="244777"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>clarithromycin; levofloxacin; moxifloxacin; moxifloxacin; rifabutin</Interventions><Reference>ChiCTR-IOR-15007291</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>RRHT</ProtocolAcronym><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="334027"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>230</Patients><Biomarkers>T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>230</EnrollmentCount><Interventions>Viread; efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; zidovudine</Interventions><Reference>2017ZX10202101-002; NCT03478033; RRHT</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-label, randomized, crossover study of the comparative pharmacokinetics and bioequivalence of drugs moxifloxacin film-coated tablets 400 mg (JSC "Synthesis", Russia) and Avelox tablets, film-coated 400 mg (Bayer Pharma AG, Germany) in healthy volunteers on an empty stomach</ProtocolTitle><Sponsor>Joint Stock Company Kurganskoye medicines and medical products" Synthesis</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="255583"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>32</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Avelox</Controls><EnrollmentCount>32</EnrollmentCount><Interventions>moxifloxacin, Synthesis</Interventions><Reference>21092015-MoxSin-001</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open, randomized, crossover study of comparative pharmacokinetics and bioequivalence of drugs Moxifloxacin tablets, film-coated, 400 mg (JSC "Pharmasyntez", Russia) and Avelox tablets, film-coated, 400 mg ("Bayer Pharma AG", Germany)</ProtocolTitle><Sponsor>Pharmasyntez</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="247038"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>42</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Avelox</Controls><EnrollmentCount>42</EnrollmentCount><Interventions>moxifloxacin, Pharmasyntez</Interventions><Reference>P03 / 2015</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Open, Prospective, Comparative, Randomized, Controlled Clinical Trial Of Efficacy And Safety Perhlozone Capsules (JSC 'Pharmasyntez', Russia), Used In Doses Of 9.5 And 12.5 mg/kg Night In The Complex Treatment Of Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Pharmasyntez</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="169098"></Trial><Drug id="87251">Perchlozone</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>Perchlozone</Interventions><Reference>PERHL-02-2012</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Metformin in tuberculosis</ProtocolTitle><Sponsor>Open Source Pharma Foundation, Tuberculosis Research Centre</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="325158"></Trial><Drug id="6050">metformin hydrochloride</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>316</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>316</EnrollmentCount><Interventions>ethambutol; isoniazid; metformin; pyrazinamide; rifampicin</Interventions><Reference>CTRI/2018/01/011176; Version 1.0</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>StAT-TB</ProtocolAcronym><ProtocolTitle>Statin Adjunctive Therapy for TB</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="331728"></Trial><Drug id="4155">pravastatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>ethambutol; isoniazid; pravastatin; pyrazinamide; rifampin</Interventions><Reference>IRB00145353; NCT03456102; StAT-TB</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol</ProtocolTitle><Sponsor>McMaster University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="219950"></Trial><Drug id="71323">Ad5Ag85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Cytokines; T-Lymphocytes</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>Ad5Ag85A</Interventions><Reference>M002; NCT02337270</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetic Study to Evaluate Anti-Mycobacterial Activity of TMC-207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE), Quintiles Philippines, Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="221523"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>background regimen therapy; bedaquiline</Interventions><Reference>2014-003372-23; 2016-CT0355; CR106371; CTRI/2018/03/012637; NCT02354014; PHRR160801-001314; TMC207-C211; TMC207-TIDP59-C211</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>RIFLOPI</ProtocolAcronym><ProtocolTitle>Rifabutin With Lopinavir/ritonavir in Patients Coinfected With Tuberculosis and HIV in Burkina Faso</ProtocolTitle><Sponsor>Institut de Recherche en Sciences de la Sante (IRSS), Burkina Faso</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="161441"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>lopinavir+ritonavir; rifabutin</Interventions><Reference>PACTR201310000629390; RIFLOPI</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><Sponsor>Beijing Chest Hospital</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="328802"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>140</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>gatifloxacin; levofloxacin; moxifloxacin; p-aminosalycilic acid; prothionamide</Controls><EnrollmentCount>320</EnrollmentCount><Interventions>clofazimine; gatifloxacin; levofloxacin; moxifloxacin; p-aminosalycilic acid; prothionamide</Interventions><Reference>ChiCTR1800014800</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>TRUNCATE-TB</ProtocolAcronym><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><Sponsor>Syneos Health Inc, University College London</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="333435"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>900</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>900</EnrollmentCount><Interventions>bedaquiline; clofazimine; ethambutol; isoniazid; levofloxacin; linezolid; pyrazinamide; rifampicin; rifapentine</Interventions><Reference>2016-CT0376; NCT03474198; PHRR170327-001522; TRUNCATE-TB; TRUNCATE-TB</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase IIa Evaluation of Early Bactericidal Activity of PA-824 in Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9381"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>69</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour e-275</Controls><EnrollmentCount>69</EnrollmentCount><Interventions>PA-824</Interventions><Reference>NCT00567840; PA-824-CL-007</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>CL-004</ProtocolAcronym><ProtocolTitle>A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="303299"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>6</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>6</EnrollmentCount><Interventions>PA-824</Interventions><Reference>CL-004; NCT03202693; PA 824-CL-004</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects</ProtocolTitle><Sponsor>ViiV Healthcare Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="298711"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>15</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Calcium; Carbon dioxide; Chlorides; Creatine kinase; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Glucose; Heart rate; Hematocrit; Hemoglobin; Leukocyte count; Lymphocytes; Mean corpuscular hemoglobin; Mean corpuscular volume; Monocytes; Neutrophils; Potassium; Reticulocytes; Sodium; Systolic blood pressure; Urea; gamma-Glutamyltransferase</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>15</EnrollmentCount><Interventions>cabotegravir; cabotegravir; rifabutin</Interventions><Reference>205712; NCT03149848</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>RRHT</ProtocolAcronym><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="334027"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>230</Patients><Biomarkers>T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>230</EnrollmentCount><Interventions>Viread; efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; zidovudine</Interventions><Reference>2017ZX10202101-002; NCT03478033; RRHT</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open, phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic parameters of Q-203 after single and multiple doses in healthy volunteers</ProtocolTitle><Sponsor>Infectex</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="255234"></Trial><Drug id="85970">telacebec</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>70</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>70</EnrollmentCount><Interventions>Q-203, Qurient / Infectex</Interventions><Reference>INX-Q101</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>ZeNiX</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre-XDR-TB or Non-responsive/Intolerant MDR-TB</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="293734"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>180</Patients><Biomarkers>Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>180</EnrollmentCount><Interventions>bedaquiline; linezolid; pretomanid</Interventions><Reference>NC-007- (B-Pa-L); NCT03086486; ZENIX (B-PA-L) NC-007; ZeNiX</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>RESWMEN</ProtocolAcronym><ProtocolTitle>Using econazole to attempt to shorten the duration of treatment in MDR tuberculosis</ProtocolTitle><Sponsor>Indian Council of Medical Research</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="374838"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>250</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>clofazimine; ethambutol; isoniazid; kanamycin; moxifloxacin; prothionamide; pyrazinamide</Controls><EnrollmentCount>250</EnrollmentCount><Interventions>clofazimine; econazole; ethambutol; isoniazid; kanamycin; moxifloxacin; prothionamide; pyrazinamide</Interventions><Reference>CTRI/2019/03/018237; PGI-MDR TB/01 version 2 dated 12.09.2018; RESWMEN</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SIMPLICITB</ProtocolAcronym><ProtocolTitle>Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients</ProtocolTitle><Sponsor>PPD Pharmaceutical Development Philippines Corporation, TB Alliance</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="319125"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>450</Patients><Biomarkers>Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>450</EnrollmentCount><Interventions>bedaquiline; moxifloxacin; pretomanid; pyrazinamide</Interventions><Reference>39186; B-Pa-M-Z; NC-008; NC-008 (B-Pa-M-Z); NC-008 (B-Pa-M-Z) 39186; NCT03338621; NMRR-17-2826-39186; PHRR180723-001867; SIMPLICITB; SIMPLICITB (B-PA-M-Z) NC-008</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Comparative Study of the Bactericidal and Sterilising Activity of Three Fluoroquinolones: Gatifloxacin, Moxifloxacin and Ofloxacin Substituted for Ethambutol in the Two Month Initial Phase of the Standard Anti-Tuberculosis Treatment Regimen Also Containing Rifampicin, Isoniazid and Pyrazinamide (South Africa)</ProtocolTitle><Sponsor>United Nations International Children's Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="152200"></Trial><Drug id="52139">ofloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>217</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>217</EnrollmentCount><Interventions>gatifloxacin; isoniazid; moxifloxacin; ofloxacin; pyrazinamide; rifampicin</Interventions><Reference>ISRCTN13670619; RPC078</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers</ProtocolTitle><Sponsor>National Institutes of Health Clinical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="260814"></Trial><Drug id="72148">darunavir + cobicistat (fixed dose, HIV infection), Janssen R&amp;D/ Gilead</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>75</Patients><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Bilirubin; Blood cells; Creatine kinase; Creatinine; Estimated glomerular filtration rate; Lipase; Lipids</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>75</EnrollmentCount><Interventions>Prezcobix; dolutegravir; isoniazid; rifapentine</Interventions><Reference>16-CC-0112; 160112; NCT02771249</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I clinical trial of single-dose of PA-824</ProtocolTitle><Sponsor>Shanghai Fosun Pharmaceutical (Group) Co Ltd, Shanghai Fosun Pharmaceutical Industry Development Co Ltd</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="362102"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>62</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>62</EnrollmentCount><Interventions>pretomanid</Interventions><Reference>CTR20181897; LSF-157-SD-P-V1.2</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23067"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>GSK-692342</Interventions><Reference>692342/001; CCTB001-01; NCT00730795</Reference></Row><Row><ArmCount>5+</ArmCount><ProtocolAcronym>endTB-Q</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance</ProtocolTitle><Sponsor>Mdecins Sans Frontires France</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="375499"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>500</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>bedaquiline; bedaquiline; clofazimine; clofazimine; delamanid; delamanid; linezolid; linezolid</Controls><EnrollmentCount>500</EnrollmentCount><Interventions>bedaquiline; clofazimine; delamanid; linezolid</Interventions><Reference>MSF ERB-1761; NCT03896685; endTB-Q</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-Negative Adults</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9540"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>AS-02</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>Mtb72F/AS02A</Interventions><Reference>102039; NCT00291889</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SURE</ProtocolAcronym><ProtocolTitle>Short Intensive Treatment For Children With Tuberculous Meningitis</ProtocolTitle><Sponsor>University College London</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="360104"></Trial><Drug id="44309">ranitidine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>400</Patients><Biomarkers>T-Helper Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>400</EnrollmentCount><Interventions>aspirin; isoniazid; levofloxacin; pyrazinamide; ranitidine; rifampicin</Interventions><Reference>ISRCTN40829906; SURE; SURE</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clofazimine treatment of multidrug-resistant tuberculosis (MDRTB)</ProtocolTitle><Sponsor>Novartis AG</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="284370"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>380</Patients><Biomarkers>Heart rate; PR interval; QRS complex; QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>380</EnrollmentCount><Interventions>Lamprene</Interventions><Reference>2015-004440-19; CLAM320B2202</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SIMPLE</ProtocolAcronym><ProtocolTitle>Pharmacokinetic Study of Linezolid for TB Meningitis</ProtocolTitle><Sponsor>Universitas Padjadjaran</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="340851"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Intracranial pressure</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>36</EnrollmentCount><Interventions>Gabriox; ethambutol; isoniazid; pyrazinamide; rifampicin</Interventions><Reference>NCT03537495; SIMPLE; TB-201805.01</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="307654"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>448</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Reference>CAP 020; InDEX; NCT03237182</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II/III Study To Check The Efficacy And Safety Of Recombinant BCG Vaccine In TB Patients In India</ProtocolTitle><Sponsor>Serum Institute of India Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="292836"></Trial><Drug id="55569">VPM-1002</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>2000</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>2000</EnrollmentCount><Interventions>VPM-1002</Interventions><Reference>CTRI/2017/03/008266; VPM1002-IN-3.01TBR Version 2.0</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>ESCALATE</ProtocolAcronym><ProtocolTitle>To observe if administration of drug namely linezolid along with standard four drug regimen in intensive(initial) phase of Tubercular meningitis will help reduce death and disability among patients when compared to standard four drug antitubercular drug therapy alone</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="383209"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin; streptomycin</Controls><EnrollmentCount>100</EnrollmentCount><Interventions>ethambutol; isoniazid; linezolid; pyrazinamide; rifampicin; streptomycin</Interventions><Reference>CTRI/2019/06/019501; ESCALATE</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>RRHT</ProtocolAcronym><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="334027"></Trial><Drug id="44316">zidovudine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>230</Patients><Biomarkers>T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>230</EnrollmentCount><Interventions>Viread; efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; zidovudine</Interventions><Reference>2017ZX10202101-002; NCT03478033; RRHT</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The safety and efficacy of high dose rifapentine in treatment of tuberculosis</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="359664"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>38</EnrollmentCount><Interventions>rifapentine</Interventions><Reference>ChiCTR1800019294</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="8801"></Trial><Drug id="26574">lamivudine + abacavir + zidovudine, GSK</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>350</Patients><Biomarkers>CD4+</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>350</EnrollmentCount><Interventions>lamivudine + abacavir + zidovudine</Interventions><Reference>1 R01 AI051219-01A2; 1R01AI051219-01A2; NCT00078247</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT-6CFP10 Allergen for Children</ProtocolTitle><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="285889"></Trial><Drug id="95442">ESAT-6CFP10</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>96</Patients><Biomarkers>Blood pressure; Body temperature; Heart rate; Respiratory frequency</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>96</EnrollmentCount><Interventions>ESAT-6CFP10; tuberculin purified protein derivative (AnHui Longcom Biologic Pharmacy Co Ltd)</Interventions><Reference>LTAO-EC III-CHILDREN; NCT03027154</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>A-042</ProtocolAcronym><ProtocolTitle>Phase Ib, Safety and Immunogenicity Trial of BCG Revaccination, H4:IC31 and H56:IC31 in Healthy, HIV-1-Uninfected Adolescents</ProtocolTitle><Sponsor>Aeras</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="223463"></Trial><Drug id="48499">H4:IC31</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>84</Patients><Biomarkers>Cytotoxic T-Lymphocytes; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>84</EnrollmentCount><Interventions>BCG; H4 + IC31; SSI H56-IC31</Interventions><Reference>A-042; HVTN 602 / AERAS A-042; NCT02378207</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence</ProtocolTitle><Sponsor>Aeras</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="337957"></Trial><Drug id="74849">SSI H56-IC31</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>900</Patients><Biomarkers>Cytokines; Immunoglobulin G</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>900</EnrollmentCount><Interventions>SSI H56-IC31</Interventions><Reference>A-055; NCT03512249</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="353987"></Trial><Drug id="104447">OPC-167832</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>125</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>delamanid; ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>125</EnrollmentCount><Interventions>OPC-167832; OPC-167832; delamanid</Interventions><Reference>323-201-00003; NCT03678688; OPP1178898</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Risk of Tuberculosis and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in Bangladesh</ProtocolTitle><Sponsor>Bangabandhu Sheikh Mujib Medical University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="337163"></Trial><Drug id="4567">etanercept</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>174</Patients><Biomarkers>C-reactive protein</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>etanercept</Controls><EnrollmentCount>174</EnrollmentCount><Interventions>tofacitinib</Interventions><Reference>2018/547; NCT03504072</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>RADIANT-TB</ProtocolAcronym><ProtocolTitle>Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="371202"></Trial><Drug id="59062">dolutegravir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>108</Patients><Biomarkers>T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>dolutegravir + lamivudine + tenofovir</Controls><EnrollmentCount>108</EnrollmentCount><Interventions>dolutegravir; dolutegravir + lamivudine + tenofovir</Interventions><Reference>CIDRI003; NCT03851588; RADIANT-TB</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>DORIIS</ProtocolAcronym><ProtocolTitle>Doravirine, Rifapentine and Isoniazid Interaction</ProtocolTitle><Sponsor>Thomas Jefferson University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="374387"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>11</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>11</EnrollmentCount><Interventions>doravirine; isoniazid; rifapentine</Interventions><Reference>12690; DORIIS; NCT03886701</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis (Category I) Patients</ProtocolTitle><Sponsor>Ministry of Science and Technology, India</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10866"></Trial><Drug id="55173">cadi-05</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>300</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>cadi-05</Interventions><Reference>CR-01C-1/2003-10; NCT00341328; NI-894</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="76946"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>400</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>400</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; rifampicin; stavudine; zidovudine</Interventions><Reference>2008ZX10001-008; NCT01344148</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11188"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>47</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>47</EnrollmentCount><Interventions>efavirenz; lopinavir + ritonavir; nevirapine; rifabutin</Interventions><Reference>ANRS12150b; NCT00651066</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>Doxy-TB</ProtocolAcronym><ProtocolTitle>Doxycycline in Human Pulmonary Tuberculosis</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="261320"></Trial><Drug id="46927">doxycycline hyclate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Matrix Metalloproteinases; Metalloproteinase inhibitor 1; Procollagen type III-N-terminal peptide</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; pyridoxine; rifampicin</Controls><EnrollmentCount>40</EnrollmentCount><Interventions>doxycycline hyclate; ethambutol; isoniazid; pyrazinamide; pyridoxine; rifampicin</Interventions><Reference>DOXY_TB; Doxy-TB; NCT02774993</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>Opti-Q</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB</ProtocolTitle><Sponsor>Boston University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="149562"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>101</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>111</EnrollmentCount><Interventions>levofloxacin; optimized background regimen therapy</Interventions><Reference>1U01AI100805 - 01A1; H-32150; NCT01918397; Opti-Q; TBTC Study 32</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetic Interaction Between Rifapentine or Rifampicin and a Single-dose of TMC-207 in Healthy Subjects</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="208141"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>32</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>32</EnrollmentCount><Interventions>bedaquiline; bedaquiline; rifampicin; rifampicin; rifapentine; rifapentine</Interventions><Reference>NCT02216331; TMC207-CL002</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>TBTC/UITB Study 28</ProtocolAcronym><ProtocolTitle>Evaluation of a Moxifloxacin-Based, Isoniazid-Sparing Regimen for Tuberculosis Treatment TBTC/UITB Study 28</ProtocolTitle><Sponsor>Tuberculosis Investigation Unit of Barcelona</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="155451"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>410</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>410</EnrollmentCount><Interventions>isoniazid; moxifloxacin</Interventions><Reference>EudraCT 2005-003312-29; TBTC/UITB Study 28</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>TBTC-23C</ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10657"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>15</Patients><Biomarkers>CD4+ T cell</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>efavirenz; rifabutin; rifabutin</Interventions><Reference>23C; CDC-NCHSTP-2588; NCT00023413; TBTC-23C</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>N2R</ProtocolAcronym><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10947"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>145</Patients><Biomarkers>CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>142</EnrollmentCount><Interventions>efavirenz; nevirapine</Interventions><Reference>210041000824904203; N2R; NCT00483054</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>IPEC-EFV</ProtocolAcronym><ProtocolTitle>Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X  800 mg</ProtocolTitle><Sponsor>Fundacao Oswaldo Cruz (Fiocruz)</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="11181"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>130</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>130</EnrollmentCount><Interventions>efavirenz; isoniazid; lamivudine; pyrazinamide; rifampicin; zidovudine</Interventions><Reference>CAAE-0017.1.009.000-03; IPEC-EFV; NCT00533390</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Immunogenicity and Impact of MVA-85A, on the Immunogenicity of the EPI Vaccines</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="52375"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>214</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>214</EnrollmentCount><Interventions>MVA-85A</Interventions><Reference>NCT00480454; TB012</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Open-Label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Haynemoks, 400 mg (Hayglans Laboratories Pvt. Ltd., India) and Avelox, 400 mg (Bayer Healthcare AG, Germany) in Healthy Volunteers</ProtocolTitle><Sponsor>HiGlance Laboratories Pvt ltd</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="168898"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>18</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>moxifloxacin; moxifloxacin (HiGlance Laboratories pvt.Ltd)</Interventions><Reference>CPM-09-2012</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="76946"></Trial><Drug id="44316">zidovudine</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>400</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>400</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; rifampicin; stavudine; zidovudine</Interventions><Reference>2008ZX10001-008; NCT01344148</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym>TBRU 10</ProtocolAcronym><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10869"></Trial><Drug id="7017">gatifloxacin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>70</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><EnrollmentCount>70</EnrollmentCount><Interventions>gatifloxacin; levofloxacin; linezolid; moxifloxacin</Interventions><Reference>01-553; NCT00396084; TBRU 10; TBRU 10</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA, Johnson &amp; Johnson</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="56959"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>TMC-207; nevirapine</Interventions><Reference>CR015793; NCT00910806; NCT00980668; TMC207-TiDP13-C117</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="71107"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>65</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour</Controls><EnrollmentCount>85</EnrollmentCount><Interventions>PA-824; Rifafour; TMC-207; moxifloxacin; pyrazinamide</Interventions><Reference>NC-001; NC-001-(J-M-Pa-Z); NCT01215851</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="59043"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>rifafour</Controls><EnrollmentCount>69</EnrollmentCount><Interventions>PA-824</Interventions><Reference>CL-010; NCT00944021; PA-824-CL-010</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy Participants</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="59134"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>28</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>TMC-207</Interventions><Reference>CR007504; NCT00946842; TMC207-TiDP13-C111</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety of Tuberculosis Vaccine, MVA-85A, Administered by the Intramuscular Route and the Intradermal Route</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="69212"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>MVA-85A</Interventions><Reference>076943; 2009-015973-11; ISRCTN46804531; NCT01181856; TB022</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>RIFRAL</ProtocolAcronym><ProtocolTitle>The Effect of Intermittent Rifampicin on Raltegravir</ProtocolTitle><Sponsor>The University of Liverpool</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="80394"></Trial><Drug id="54488">raltegravir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>18</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>raltegravir</Interventions><Reference>2010-021461-73; NCT01424826; RIFRAL; UKCRN 12695; UoL000643</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of AERAS-402 in Healthy Infants</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="70158"></Trial><Drug id="53975">AERAS-402</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>487</Patients><Biomarkers>Cytokines; Interferon gamma; Interleukin-2; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>487</EnrollmentCount><Interventions>AERAS-402</Interventions><Reference>C-029-402; NCT01198366; PACTR201203000306280</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>AERAS 422</ProtocolAcronym><ProtocolTitle>Study of AERAS-422 in Healthy Adults</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="76756"></Trial><Drug id="62397">AERAS-407 rBCG</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Cytokine</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>TiceBCG</Controls><EnrollmentCount>24</EnrollmentCount><Interventions>AERAS-422</Interventions><Reference>AERAS 422; C-007-422; NCT01340820</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Investigate Pharmacokinetics, Safety and Tolerability of TMC-207 in Patients With Moderately Impaired Hepatic Function</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="61895"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>TMC-207</Interventions><Reference>2009-016437-99; CR007501; NCT01012284; TMC207-TiDP13-C112</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10685"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>433</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampin</Controls><EnrollmentCount>433</EnrollmentCount><Interventions>ethambutol; moxifloxacin; pyrazinamide; rifampin</Interventions><Reference>CDC-NCHSTP-4448; NCT00144417</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate Safety and Immunogenicity of AERAS-402</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="78482"></Trial><Drug id="53975">AERAS-402</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>CD4; CD8</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>AERAS-402</Interventions><Reference>C004-402; NCT01378312</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Influence of Rifampicin Discontinuation on Rifampicin-Induced Cytochrome P450 Enzyme Activity</ProtocolTitle><Sponsor>Hamamatsu University School of Medicine</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="122291"></Trial><Drug id="3517">losartan</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>13</Patients><Biomarkers>Cytochrome (CYP) enzyme</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>13</EnrollmentCount><Interventions>caffeine; dextromethorphan; losartan; midazolam; omeprazole; rifampicin</Interventions><Reference>JPRN-UMIN000004083</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Open-Label, Sequential Non-Randomized Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir Superboosted With Ritonavir (1 : 1 Ratio) in the Presence of Rifampicin or Lopinavir Boosted With Ritonavir (4 : 1 Ratio) in the Absence of Rifampicin in HIV and TB Co-Infected Children in South Africa</ProtocolTitle><Sponsor>Drugs for Neglected Diseases Initiative</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="142540"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>90</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>Rimactane, Rifadin, Tubocin, Benemycin; lopinavir+ritonavir</Interventions><Reference>PACTR201302000426554</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>MVA(TB)029</ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity of MVA-85A Prime and Bacille Calmette-Guerin Boost Vaccination</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="89833"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>248</Patients><Biomarkers>CD4 T cells; CD8 T cells; IFN-gamma; IL-17; IL-2; TNF-alpha</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Candin</Controls><EnrollmentCount>248</EnrollmentCount><Interventions>MVA-85A</Interventions><Reference>G1100570; G1100570/1; MVA(TB)029; NCT01650389</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="162886"></Trial><Drug id="12813">Rotarix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Anti-Meningitis C antibodies; C-C motif chemokine 2; C-C motif chemokine 3; C-C motif chemokine 4; Cytokines; IgG; Interferon gamma; Interferon-alpha; Interleukin-1 alpha; Interleukin-1 beta; Interleukin-10; Interleukin-12; Interleukin-13; Interleukin-2; Interleukin-6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>BCG; Infanrix; Menitorix; NeisVac-C; Pentacel; Prevnar 13; Priorix; Rotarix</Interventions><Reference>2013-003488-71; BAM; NCT02002156; OVG-2013/04; UKCRN 15722</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Exploratory Study of TMC-207 in Japanese Participants with Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)</ProtocolTitle><Sponsor>Janssen Pharmaceutical KK</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="222400"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>6</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>6</EnrollmentCount><Interventions>amikacin; amoxicillin-clavulanate; bedaquiline; clofazimine; cycloserine; enviomycin; ethambutol; ethionamide; fluoroquinolone therapy; kanamycin; levofloxacin; linezolid; para-aminosalicylic acid; pyrazinamide; streptomycin</Interventions><Reference>CR105158; JapicCTI-163116; NCT02365623; TMC207TBC2001</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10646"></Trial><Drug id="8255">nelfinavir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>lamivudine; nelfinavir mesylate; rifabutin; stavudine; zidovudine</Interventions><Reference>AACTG A5062; ACTG A5062; NCT00004736</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>ANRS 1295 CAMELIA</ProtocolAcronym><ProtocolTitle>Early versus Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="145651"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>540</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>661</EnrollmentCount><Interventions>efavirenz; efavirenz + lamivudine + stavudine; lamivudine; stavudine</Interventions><Reference>ANRS 1295 CAMELIA; ANRS 1295 CAMELIA; CIPRA KH 001; NCT00226434; NCT00498823</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="161275"></Trial><Drug id="44316">zidovudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>355</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; lamivudine; nevirapine; pyrazinamide; rifampicin; zidovudine</Interventions><Reference>NCT00698334; SKS/NACO/2006</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>S30PK</ProtocolAcronym><ProtocolTitle>Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB)</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="48035"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>26</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>26</EnrollmentCount><Interventions>linezolid</Interventions><Reference>NCT00691392; S30PK; TBTC Study 30PK</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine</ProtocolTitle><Sponsor>National Center for Biotechnology of the Republic of Kazakhstan</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="235054"></Trial><Drug id="98373">TB/FLU-04L</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>TB/FLU-04L</Interventions><Reference>NCT02501421; VPT-I-01/2013</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy Safety Study Comparing two Doses of NVP After Initiating Rifampin-Containing TB Therapy</ProtocolTitle><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10946"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>42</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>42</EnrollmentCount><Interventions>nevirapine</Interventions><Reference>HIV-NAT 033; NCT00476853</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>TMC-435350-TiDP16-C105:  Phase I, Three-Way Crossover, Drug-Drug Interaction Between TMC-435350 and Rifampin After Multiple Dosing</ProtocolTitle><Sponsor>Janssen R&amp;D (Ireland)</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="25800"></Trial><Drug id="39069">simeprevir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>21</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>21</EnrollmentCount><Interventions>TMC-435; TMC-435; rifampin; rifampin</Interventions><Reference>CR015412; NCT00741169; TMC-435350-TiDP16-C105</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>N2R</ProtocolAcronym><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10947"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>145</Patients><Biomarkers>CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>142</EnrollmentCount><Interventions>efavirenz; nevirapine</Interventions><Reference>210041000824904203; N2R; NCT00483054</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11187"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>35</Patients><Biomarkers>Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>efavirenz; isoniazid; lamivudine; lopinavir + ritonavir; nevirapine; rifabutin; stavudine</Interventions><Reference>ANRS12150a; NCT00640887</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10646"></Trial><Drug id="44316">zidovudine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>lamivudine; nelfinavir mesylate; rifabutin; stavudine; zidovudine</Interventions><Reference>AACTG A5062; ACTG A5062; NCT00004736</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>PrOMPT</ProtocolAcronym><ProtocolTitle>Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment</ProtocolTitle><Sponsor>University of Amsterdam</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="182316"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>44</Patients><Biomarkers>T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>efavirenz; pyridoxine</Interventions><Reference>AIGHD_001; NCT01417988; PrOMPT</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of the drug Perhlozone in the treatment of patients with pulmonary MDR MBT, including the presence of HIV infection</ProtocolTitle><Sponsor>Pharmasyntez</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="183939"></Trial><Drug id="87251">Perchlozone</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>340</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>340</EnrollmentCount><Interventions>Perchlozone</Interventions><Reference>PERHL-03-2013</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>TEMPRANO</ProtocolAcronym><ProtocolTitle>Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="195741"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1107</Patients><Biomarkers>Hepatitis B large envelope protein; Hepatitis B virus external core antigen; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>2073</EnrollmentCount><Interventions>efavirenz; isoniazid; lopinavir + ritonavir; tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Interventions><Reference>ANRS 12136 TEMPRANO; NCT00495651; TEMPRANO</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SAPIT</ProtocolAcronym><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="201474"></Trial><Drug id="2935">didanosine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>642</Patients><Biomarkers>CD4 Positive T Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>642</EnrollmentCount><Interventions>didanosine; efavirenz; lamivudine; lamivudine + efavirenz + didanosine; trimethoprim + sulfamethoxazole</Interventions><Reference>CAPRISA 003; NCT00398996; SAPIT</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetic Interaction Between Rifapentine or Rifampicin and a Single-dose of TMC-207 in Healthy Subjects</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="208141"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>32</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>32</EnrollmentCount><Interventions>bedaquiline; bedaquiline; rifampicin; rifampicin; rifapentine; rifapentine</Interventions><Reference>NCT02216331; TMC207-CL002</Reference></Row><Row><ArmCount>8</ArmCount><ProtocolAcronym>TB-LION</ProtocolAcronym><ProtocolTitle>Tuberculosis - Learning the Impact of Nutrition</ProtocolTitle><Sponsor>Boston Medical Center Corp</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="347635"></Trial><Drug id="12132">albendazole</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>120</Patients><Biomarkers>Body Mass Index; Body height; Interferon gamma; Regulatory T-Lymphocytes; Th1 cells; Th2 cells; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>albendazole; ivermectin; metronidazole</Controls><EnrollmentCount>120</EnrollmentCount><Interventions>Nutritional Supplementation Meal; albendazole; ivermectin; metronidazole; multivitamin therapy</Interventions><Reference>6005415; CTRI/2019/05/018968; H-37473; NCT03598842; TB-LION</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>TBTC Study 25</ProtocolAcronym><ProtocolTitle>TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="8751"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>150</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Reference>25; CDC-NCHSTP-2404; HCK45; NCT00023426; TBTC Study 25</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of Perchlozone in the treatment of patients with pulmonary tuberculosis with MDR-TB, including HIV</ProtocolTitle><Sponsor>Pharmasyntez</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="291547"></Trial><Drug id="87251">Perchlozone</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>Perchlozone</Interventions><Reference>PERHL-03-2013-i</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability and Immunogenicity of the Vaccine Candidates ID-93 + AP10-602 and ID-93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="235751"></Trial><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>70</Patients><Biomarkers>Cytokines; Cytotoxic T-Lymphocytes; Immunoglobulin G; Interferon gamma; Interleukin-2; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Th1 cytokines; Th2 cytokines; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>70</EnrollmentCount><Interventions>AP10-602; GLA-SE; ID-93; ID-93</Interventions><Reference>12-0109; HHSN272201300020I; NCT02508376</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating Pharmacokinetics and Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Single-Doses of Tedizolid Plus Rifampicin in Healthy Volunteers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="331225"></Trial><Drug id="30819">tedizolid phosphate</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>rifampicin; torezolid</Interventions><Reference>2017/00909</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers</ProtocolTitle><Sponsor>National Institutes of Health Clinical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="260814"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>75</Patients><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Bilirubin; Blood cells; Creatine kinase; Creatinine; Estimated glomerular filtration rate; Lipase; Lipids</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>75</EnrollmentCount><Interventions>Prezcobix; dolutegravir; isoniazid; rifapentine</Interventions><Reference>16-CC-0112; 160112; NCT02771249</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Bioequivalence Study Comparing A Fixed Dose Combination Formulation, RIN-150 And Individual Reference Drugs In Healthy Volunteers</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="164292"></Trial><Drug id="89460">rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bicarbonates; Bilirubin; Blood platelets; Calcium; Chlorides; Creatine kinase; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Glucose; Heart rate; Hematocrit; Hemoglobin; Leukocyte count; Lymphocytes; Monocytes; Neutrophils; Potassium; Sodium; Systolic blood pressure; Total protein; Urea; Uric acid</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid; rifampicin</Controls><EnrollmentCount>28</EnrollmentCount><Interventions>rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer</Interventions><Reference>B3801003; NCT02014272</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>WHIP3TB</ProtocolAcronym><ProtocolTitle>Evaluation of the Effect of 3HP versus Periodic 3HP versus 6H in HIV-Positive Individuals</ProtocolTitle><Sponsor>Aurum Institute</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="281055"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>4027</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>4027</EnrollmentCount><Interventions>isoniazid; isoniazid; rifapentine</Interventions><Reference>3HP-AUR1-1-170; NCT02980016; WHIP3TB</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>ASTEROID</ProtocolAcronym><ProtocolTitle>Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="333384"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>3400</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid; rifampin; rifapentine</Controls><EnrollmentCount>3400</EnrollmentCount><Interventions>rifapentine</Interventions><Reference>ASTEROID; CDC-NCHSTP-7024; NCT03474029</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Efficacy and Safety of Early Double J Stent Placement in Treatment of Renal Tuberculosis: A Novel Renal Function Protective Strategy</ProtocolTitle><Sponsor>Shanghai Changzheng Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="132105"></Trial><Drug id="82062">ethambutol hydrochloride (250 mg) + pyrazinamide (400 mg) + rifampicin (120 mg) + isoniazid (120 mg) (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>Double J stent; ethambutol hydrochloride + pyrazinamide + rifampicin + isoniazid</Interventions><Reference>ACTRN12612001244897; U1111-1136-5967</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rifapentine-containing Tuberculosis Treatment Shortening Regimens</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="226815"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2516</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>2516</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyridoxine; rifampin; rifapentine</Interventions><Reference>6655; ACTG Study A5349; CTRI/2017/09/009772; NCT02410772; S31/A5349; TBTC Study 31</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>STREAM</ProtocolAcronym><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Sponsor>International Union Against Tuberculosis and Lung Diseases</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="228190"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>530</Patients><Biomarkers>4 beta-Hydroxycholesterol/Cholesterol ratio</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Lamprene; ethambutol (Myambutol); isoniazid (Nydrazid); kanamycin (Kantrex); moxifloxacin; prothionamide (Peteha); pyrazinamide (Zinamide)</Controls><EnrollmentCount>530</EnrollmentCount><Interventions>Lamprene; Regimen A locally-used WHO-approved MDR-TB regimen; bedaquiline; ethambutol (Myambutol); isoniazid (Nydrazid); kanamycin (Kantrex); levofloxacin; moxifloxacin; prothionamide (Peteha); pyrazinamide (Zinamide)</Interventions><Reference>18148631; 78372190; 78372190/18148631 (Stage 1/2); CTRI/2017/09/009693; ISRCTN78372190; NCT02409290; STREAM</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="280225"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients>419</Patients><Biomarkers>Creatinine; Human immunodeficiency virus RNA; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>419</EnrollmentCount><Interventions>efavirenz; emtricitabine; lamivudine; tenofovir</Interventions><Reference>15-1473; NCT02946762; Z 31501</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="303756"></Trial><Drug id="107523">TBA-7371</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>74</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>74</EnrollmentCount><Interventions>TBA-7371; TBA-7371; bupropion; midazolam</Interventions><Reference>NCT03199339; TBA-7371-CL001</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>TriDoRe</ProtocolAcronym><ProtocolTitle>Novel Triple-Dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More</ProtocolTitle><Sponsor>Institute of Tropical Medicine, Belgium</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="372353"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>3000</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>levofloxacin</Controls><EnrollmentCount>3000</EnrollmentCount><Interventions>isoniazid; rifampicin</Interventions><Reference>NCT03862248; TRIDORE; TriDoRe</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects</ProtocolTitle><Sponsor>Abbott Laboratories</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="25327"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>15</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>15</EnrollmentCount><Interventions>lopinavir + ritonavir; rifabutin</Interventions><Reference>M10-457; NCT00743470</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>APT</ProtocolAcronym><ProtocolTitle>Assessing PA-824 for Tuberculosis</ProtocolTitle><Sponsor>Johns Hopkins Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="213394"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>183</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampin</Controls><EnrollmentCount>183</EnrollmentCount><Interventions>isoniazid; pretomanid; pyrazinamide; rifabutin; rifampin</Interventions><Reference>#FD-R-004794-01; APT; NA_00093014; NCT02256696</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SIMPLICITB</ProtocolAcronym><ProtocolTitle>Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients</ProtocolTitle><Sponsor>PPD Pharmaceutical Development Philippines Corporation, TB Alliance</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="319125"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>450</Patients><Biomarkers>Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>450</EnrollmentCount><Interventions>bedaquiline; moxifloxacin; pretomanid; pyrazinamide</Interventions><Reference>39186; B-Pa-M-Z; NC-008; NC-008 (B-Pa-M-Z); NC-008 (B-Pa-M-Z) 39186; NCT03338621; NMRR-17-2826-39186; PHRR180723-001867; SIMPLICITB; SIMPLICITB (B-PA-M-Z) NC-008</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics and Safety of PA-824 in Subjects With Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="227410"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Body height; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>pretomanid</Interventions><Reference>13-0053; HHSN272201300017I; NCT02422524</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of GC-3107(BCG Vaccine) in Healthy Infants</ProtocolTitle><Sponsor>GC Pharma</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="380364"></Trial><Drug id="108779">GC-3107</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>750</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>BCG vaccine</Controls><EnrollmentCount>750</EnrollmentCount><Interventions>GC-3107</Interventions><Reference>GC3107_P3; NCT03947138; TCTR20190325003</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>DAZZLE</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin</ProtocolTitle><Sponsor>Boston University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="280651"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>WHO approved regimen-based therapy</Controls><EnrollmentCount></EnrollmentCount><Interventions>Deltyba; Levaquin; Zyvox; pyrazinamide</Interventions><Reference>DAZZLE; H-36160; NCT02975570</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="8647"></Trial><Drug id="2587">azithromycin</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>azithromycin</Interventions><Reference>058D; 066-169; NCT00002085</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>MVA-85A Aerosol Versus Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M tb) Infection</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="238674"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>2</Patients><Biomarkers>Cytokines</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>2</EnrollmentCount><Interventions>MVA-85A</Interventions><Reference>NCT02532036; TB040</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SIMPLICITB</ProtocolAcronym><ProtocolTitle>Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients</ProtocolTitle><Sponsor>PPD Pharmaceutical Development Philippines Corporation, TB Alliance</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="319125"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>450</Patients><Biomarkers>Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>450</EnrollmentCount><Interventions>bedaquiline; moxifloxacin; pretomanid; pyrazinamide</Interventions><Reference>39186; B-Pa-M-Z; NC-008; NC-008 (B-Pa-M-Z); NC-008 (B-Pa-M-Z) 39186; NCT03338621; NMRR-17-2826-39186; PHRR180723-001867; SIMPLICITB; SIMPLICITB (B-PA-M-Z) NC-008</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prospective, Randomized Control, Non-inferiority Study of the Use of Faropenem for Patients with etiology Positive Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Zhejiang University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="338648"></Trial><Drug id="4492">faropenem</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>400</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>standardized regimen</Controls><EnrollmentCount>400</EnrollmentCount><Interventions>faropenem</Interventions><Reference>ChiCTR1800015959</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="162886"></Trial><Drug id="6229">Infanrix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Anti-Meningitis C antibodies; C-C motif chemokine 2; C-C motif chemokine 3; C-C motif chemokine 4; Cytokines; IgG; Interferon gamma; Interferon-alpha; Interleukin-1 alpha; Interleukin-1 beta; Interleukin-10; Interleukin-12; Interleukin-13; Interleukin-2; Interleukin-6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>BCG; Infanrix; Menitorix; NeisVac-C; Pentacel; Prevnar 13; Priorix; Rotarix</Interventions><Reference>2013-003488-71; BAM; NCT02002156; OVG-2013/04; UKCRN 15722</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates</ProtocolTitle><Sponsor>Biofabri SL</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="340636"></Trial><Drug id="89744">MTBVAC</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>99</Patients><Biomarkers>Cytokines; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>BCG vaccine</Controls><EnrollmentCount>99</EnrollmentCount><Interventions>MTBVAC</Interventions><Reference>MTBVAC-03; NCT03536117</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Study of Safety and Immunogenicity of AERAS-456 in HIV-Negative Adults Treated for Drug-susceptible Pulmonary TB</ProtocolTitle><Sponsor>Aeras</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="223291"></Trial><Drug id="74849">SSI H56-IC31</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>22</Patients><Biomarkers>Cytokines; Immunoglobulin G; Interferon gamma</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>22</EnrollmentCount><Interventions>SSI H56-IC31</Interventions><Reference>C-037-456; NCT02375698</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, double-blind, placebo-controlled, phase II clinical trial of TB/FLU-04L TB vaccine in adult volunteers with signs of latent tuberculosis infection</ProtocolTitle><Sponsor>National Center for Biotechnology of the Republic of Kazakhstan</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="301908"></Trial><Drug id="98373">TB/FLU-04L</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>TB/FLU-04L</Interventions><Reference>VPT-II-01/2015</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>TBCOX2</ProtocolAcronym><ProtocolTitle>Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic</ProtocolTitle><Sponsor>Oslo University Hospital</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="235355"></Trial><Drug id="74849">SSI H56-IC31</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>39</Patients><Biomarkers>Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-2; Interleukin-2 receptor alpha chain ; Monocytes; Myeloid-derived suppressor cells; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>39</EnrollmentCount><Interventions>SSI H56-IC31; SSI H56-IC31; etoricoxib; etoricoxib</Interventions><Reference>2014-004986-26; 2015/692; NCT02503839; TBCOX2</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I study Evaluating the Safety, Tolerability and Pharmacokinetic Characteristics of RMX-2001</ProtocolTitle><Sponsor>Nome West (Shanghai) Pharmaceutical Technology Co., Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="381962"></Trial><Drug id="76307">delpazolid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>52</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>52</EnrollmentCount><Interventions>delpazolid</Interventions><Reference>CTR20190843; RMX2001-101</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis</ProtocolTitle><Sponsor>University Medical Center Groningen</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="298743"></Trial><Drug id="2587">azithromycin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Amyloid; C-reactive protein; Collagen type I; Collagen type III; Cytokines; Interferon gamma; Interleukin-10; Interleukin-17A; Interleukin-2; Interleukin-4; Interleukin-6; Interleukin-8; Leukocyte count; Leukocyte elastase; Matrix metalloproteinase-9; Myeloperoxidase; Neutrophil collagenase; Procalcitonin; Transforming Growth Factor beta; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>24</EnrollmentCount><Interventions>azithromycin; ethambutol; isoniazid; pyrazinamide; rifampicin</Interventions><Reference>2017-001929-40; AZT_DSTB_BB; NCT03160638</Reference></Row><Row><ArmCount>5+</ArmCount><ProtocolAcronym>endTB-Q</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance</ProtocolTitle><Sponsor>Mdecins Sans Frontires France</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="375499"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>500</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>bedaquiline; bedaquiline; clofazimine; clofazimine; delamanid; delamanid; linezolid; linezolid</Controls><EnrollmentCount>500</EnrollmentCount><Interventions>bedaquiline; clofazimine; delamanid; linezolid</Interventions><Reference>MSF ERB-1761; NCT03896685; endTB-Q</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence in India</ProtocolTitle><Sponsor>Serum Institute of India Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="298671"></Trial><Drug id="55569">VPM-1002</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>2000</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>2000</EnrollmentCount><Interventions>VPM-1002</Interventions><Reference>NCT03152903; VPM1002-IN-3.01TBR</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>ACT-TB</ProtocolAcronym><ProtocolTitle>Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis</ProtocolTitle><Sponsor>London School of Hygiene and Tropical Medicine</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="341686"></Trial><Drug id="44279">amoxicillin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1875</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Standard of care</Controls><EnrollmentCount>1875</EnrollmentCount><Interventions>amoxicillin; azithromycin</Interventions><Reference>15232; ACT-TB; NCT03545373</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>RESWMEN</ProtocolAcronym><ProtocolTitle>Using econazole to attempt to shorten the duration of treatment in MDR tuberculosis</ProtocolTitle><Sponsor>Indian Council of Medical Research</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="374838"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>250</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>clofazimine; ethambutol; isoniazid; kanamycin; moxifloxacin; prothionamide; pyrazinamide</Controls><EnrollmentCount>250</EnrollmentCount><Interventions>clofazimine; econazole; ethambutol; isoniazid; kanamycin; moxifloxacin; prothionamide; pyrazinamide</Interventions><Reference>CTRI/2019/03/018237; PGI-MDR TB/01 version 2 dated 12.09.2018; RESWMEN</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>GRACE-TB</ProtocolAcronym><ProtocolTitle>NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB</ProtocolTitle><Sponsor>Huashan Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="348056"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>488</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>amikacin; cycloserine; moxifloxacin; prothionamide; pyrazinamide</Controls><EnrollmentCount>488</EnrollmentCount><Interventions>amikacin; clofazimine; cycloserine; ethambutol; linezolid; moxifloxacin; prothionamide; pyrazinamide</Interventions><Reference>GRACE-TB; KY2018-291; NCT03604848</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>INSPIRING</ProtocolAcronym><ProtocolTitle>Open-Label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV)-Tuberculosis (TB) Co-infection</ProtocolTitle><Sponsor>ViiV Healthcare Ltd</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="201302"></Trial><Drug id="59062">dolutegravir</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>113</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Carbon dioxide; Chlorine; Creatine kinase; Creatinine; Eosinophils; Erythrocytes; Estimated glomerular filtration rate; Glucose; Hematocrit; Hemoglobin; High-density lipoprotein cholesterol; High-density lipoprotein cholesterol; Human immunodeficiency virus RNA; Lactate dehydrogenase; Leukocyte count; Lipase; Lipids; Lymphocytes; Mean corpuscular volume; Monocytes; Neutrophils; Ox-LDL/ LDL-C ratio; Ox-LDL/ LDL-C ratio; Phosphate; Potassium; Sodium; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; Total cholesterol; Total cholesterol; Triglycerides; Triglycerides; Urea</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>113</EnrollmentCount><Interventions>Group 1; Group 2; dolutegravir; ethambutol; isoniazid; pyrazinamide; rifampicin</Interventions><Reference>117175; ING117175; INSPIRING; NCT02178592</Reference></Row><Row><ArmCount>6</ArmCount><ProtocolAcronym>TBHDT</ProtocolAcronym><ProtocolTitle>TB Host Directed Therapy</ProtocolTitle><Sponsor>Aurum Institute</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="279898"></Trial><Drug id="59386">CC-11050</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>200</Patients><Biomarkers>C-reactive protein; Forced expiratory volume; Neopterin; Programmed cell death protein 1; Standardized uptake value; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>rifabutin-modified TB therapy</Controls><EnrollmentCount>200</EnrollmentCount><Interventions>CC-11050; auranofin; everolimus; rifabutin-modified TB therapy; vitamin D3</Interventions><Reference>NCT02968927; TBHDT; TBHDT-AUR1-8-178</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers</ProtocolTitle><Sponsor>National Institutes of Health Clinical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="260814"></Trial><Drug id="59062">dolutegravir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>75</Patients><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Bilirubin; Blood cells; Creatine kinase; Creatinine; Estimated glomerular filtration rate; Lipase; Lipids</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>75</EnrollmentCount><Interventions>Prezcobix; dolutegravir; isoniazid; rifapentine</Interventions><Reference>16-CC-0112; 160112; NCT02771249</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy, Safety and Pharmacokinetics of DTG With RIF</ProtocolTitle><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="359086"></Trial><Drug id="59062">dolutegravir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>200</Patients><Biomarkers>Human immunodeficiency virus RNA; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>dolutegravir; food intake; nucleoside reverse transcriptase inhibitor therapy; rifampicin</Interventions><Reference>HIV-NAT 254; NCT03731559</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of SQ-109 Plus PPI in Urea Breath Test-Positive Volunteers</ProtocolTitle><Sponsor>Sequella Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="72716"></Trial><Drug id="31010">SQ-109</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>SQ-109</Interventions><Reference>NCT01252108; SQ109-H001</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial</ProtocolTitle><Sponsor>University of Minnesota - Clinical and Translational Science Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="199754"></Trial><Drug id="12013">once-daily naproxen (oral controlled release, pain), Alvogen</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers>C-reactive protein</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>atorvastatin; dexamethasone; dexamethasone (decadron); once-daily naproxen (oral controlled release, pain), Alvogen; once-daily naproxen (oral controlled release, pain), Alvogen</Interventions><Reference>NCT01442428; WS967180</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>STRIDE</ProtocolAcronym><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><Sponsor>AIDS Clinical Trials Group</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10681"></Trial><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>780</Patients><Biomarkers>T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>809</EnrollmentCount><Interventions>efavirenz; emtricitabine; tenofovir disoproxil fumarate; tenofovir disoproxil fumarate + emtricitabine</Interventions><Reference>1U01AI068636; ACTG A5221; ACTG A5221; NCT00108862; STRIDE</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thrice-Weekly, 4- Months Moxifloxacin or Gatifloxacin Regimens for Pulmonary TB</ProtocolTitle><Sponsor>Indian Council of Medical Research</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="150332"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>416</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>429</EnrollmentCount><Interventions>ethambutol; gatifloxacin; isoniazid; moxifloxacin; pyrazinamide; rifampicin</Interventions><Reference>CTRI/2012/10/003060</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin</ProtocolTitle><Sponsor>University of Miami</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="93494"></Trial><Drug id="7310">ritonavir</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>9</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>9</EnrollmentCount><Interventions>Kaletra; rifampin; ritonavir</Interventions><Reference>20100325; NCT01700790</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With Tuberculosis (TB) Disease</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="80383"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>142</Patients><Biomarkers>Body temperature; CD40 ligand; Interferon gamma; Interleukin-17A; Interleukin-2; T-Helper Lymphocytes; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>142</EnrollmentCount><Interventions>MTB72F vaccine (tuberculosis), GSK/Aeras</Interventions><Reference>114886; NCT01424501</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10941"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>MVA85A</Interventions><Reference>NCT00456183; TB007</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>TIV_HIV_TB</ProtocolAcronym><ProtocolTitle>Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults</ProtocolTitle><Sponsor>University of Witwatersrand</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="116439"></Trial><Drug id="44409">Fluzone</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>301</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>301</EnrollmentCount><Interventions>Vaxigrip</Interventions><Reference>NCT01811823; TIV_HIV_TB; TIV_HIV_TB</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Trial for Comparing Safety and Efficacy of Bio-enhanced Rifampicin (Risorine) Capsule in newly diagnosed Pulmonary Tuberculosis in Adult Patients</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="295037"></Trial><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>144</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; piperine; pyrazinamide; rifampicin</Controls><EnrollmentCount>144</EnrollmentCount><Interventions>Risorine; ethambutol; pyrazinamide</Interventions><Reference>CTRI/2017/04/008329</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>TCell Turnover Following Vaccination With MVA-85A</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11182"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>MVA-85A</Interventions><Reference>EudraCT number: 2007001293-8; NCT00548444; TB018</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide</ProtocolTitle><Sponsor>Huashan Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="183613"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>152</Patients><Biomarkers>Glucose</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>amikacin; clarithromycin; isoniazid; levofloxacin; prothionamide; pyrazinamide</Interventions><Reference>2013ZX10003008-003; KY2013-260; NCT02120638</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PNU-100480 In Newly Diagnosed, Treatment Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay</ProtocolTitle><Sponsor>Sequella Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="71511"></Trial><Drug id="11088">sutezolid</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>59</Patients><Biomarkers>Alanine transaminase; QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour e275</Controls><EnrollmentCount>59</EnrollmentCount><Interventions>PNU-100480</Interventions><Reference>B1171003; NCT01225640</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>TBTC-23C</ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10657"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>15</Patients><Biomarkers>CD4+ T cell</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>efavirenz; rifabutin; rifabutin</Interventions><Reference>23C; CDC-NCHSTP-2588; NCT00023413; TBTC-23C</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Once-Daily Dose of Nevirapine (400 mg) Versus Twice Daily Dose (200 mg) of Nevirapine in HIV and Tuberculosis Infection</ProtocolTitle><Sponsor>National AIDS Control Organization</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="126486"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>100</Patients><Biomarkers>CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>efavirenz; lamivudine; nevirapine; nevirapine</Interventions><Reference>CTRI/2012/08/002923</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-Positive Adults</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="19230"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>37</Patients><Biomarkers>CD4/CD8 ratio; CD40 ligand; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-2; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>37</EnrollmentCount><Interventions>GSK-692342</Interventions><Reference>111517; NCT00707967</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative Evaluation of the Effect of Risorine in Patients With Newly Diagnosed Sputum Smear Positive Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Cadila Pharmaceuticals Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="118547"></Trial><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>144</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Mycocox-4; ethambutol; pyrazinamide</Controls><EnrollmentCount>144</EnrollmentCount><Interventions>Risorine</Interventions><Reference>CTRI/2012/06/002742</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>TIME</ProtocolAcronym><ProtocolTitle>Appropriate Timing of HAART in Co-infected HIV/TB Patients</ProtocolTitle><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="61991"></Trial><Drug id="14493">tenofovir disoproxil fumarate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>156</Patients><Biomarkers>CD4; albumin</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>156</EnrollmentCount><Interventions>efavirenz; lamivudine; lamivudine + efavirenz + tenofovir disoproxil fumarate; tenofovir disoproxil fumarate</Interventions><Reference>0435.3/1551; NCT01014481; TIME</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym>BBA</ProtocolAcronym><ProtocolTitle>Brief Bactericidal Activity of Anti-Tuberculosis Drugs</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="210083"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>150</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>capreomycin; isoniazid; moxifloxacin; rifabutin; rifampicin</Interventions><Reference>BBA; CDC-NCHHSTP-6435; NCT02236078</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase IIa EBA Trial of AZD-5847</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="84246"></Trial><Drug id="26493">posizolid</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>75</Patients><Biomarkers>Blood cells; Creatine phosphokinase; fbpB; hspX; icl1; rrnA-p1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour</Controls><EnrollmentCount>75</EnrollmentCount><Interventions>AZD-5847</Interventions><Reference>11-0006; N01AI70022C; NCT01516203</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Risorine Study in Sputum Positive Patients After 8 Weeks of Conventional Treatment</ProtocolTitle><Sponsor>Cadila Pharmaceuticals Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="138715"></Trial><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>Risorine</Interventions><Reference>CRSC12005 Version. 01; CTRI/2012/11/003096</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Once-Daily Dose of Nevirapine (400 mg) Versus Twice Daily Dose (200 mg) of Nevirapine in HIV and Tuberculosis Infection</ProtocolTitle><Sponsor>National AIDS Control Organization</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="126486"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>100</Patients><Biomarkers>CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>efavirenz; lamivudine; nevirapine; nevirapine</Interventions><Reference>CTRI/2012/08/002923</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym>TBRU 10</ProtocolAcronym><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10869"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>70</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><EnrollmentCount>70</EnrollmentCount><Interventions>gatifloxacin; levofloxacin; linezolid; moxifloxacin</Interventions><Reference>01-553; NCT00396084; TBRU 10; TBRU 10</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>TBTC Study 29</ProtocolAcronym><ProtocolTitle>Rifapentine During Intensive Phase Tuberculosis (TB) Treatment</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention, Tuberculosis Investigation Unit of Barcelona</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="17237"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>529</Patients><Biomarkers>Lung</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampin</Controls><EnrollmentCount>865</EnrollmentCount><Interventions>ethambutol; isoniazid; pyrazinamide; rifapentine</Interventions><Reference>2008-003633-24; CDC-NCHSTP-5399; NCT00694629; TBTC Study 29; UITB-Study-29</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Population Pharmacokinetics of Nevirapine in Combination With Rifampicin-Based Short Course Chemotherapy in HIV- and Tuberculosis-Infected South African Patients</ProtocolTitle><Sponsor>Uppsala University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="149504"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>53</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>53</EnrollmentCount><Interventions>nevirapine; rifampicin</Interventions><Reference>PMID:18751690</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="10943"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>15</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>15</EnrollmentCount><Interventions>moxifloxacin; moxifloxacin; rifapentine</Interventions><Reference>06-0050; NA_00007322; NCT00460759</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>ARTEM-TB STUDY</ProtocolAcronym><ProtocolTitle>Evaluating Pharmacokinetic Interactions Between Artemisinin-Based Therapies and Rifampacin-Based Tuberculosis Treatment in African Patients</ProtocolTitle><Sponsor>Infectious Diseases Institute of Makerer University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="142485"></Trial><Drug id="53724">artenimol + piperaquine (malaria), Sigma-Tau</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>artesunate; artesunate + amodiaquine; desethylamodiaquine; dihydroartemisinin; dihydroartemisinin + piperaquine; piperaquine</Interventions><Reference>ARTEM-TB STUDY; HS1294; PACTR201302000483287</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="63801"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>182</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>182</EnrollmentCount><Interventions>levofloxacin; moxifloxacin</Interventions><Reference>H-0911-068-301; NCT01055145</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir or Rifampin</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="86312"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>52</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>52</EnrollmentCount><Interventions>PA-824; efavirenz; lopinavir + ritonavir; rifampin</Interventions><Reference>11829; A5306; ACTG5306; NCT01571414</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study of Tuberculosis Vaccines AERAS-402 and MVA-85A</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="91280"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-2; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>AERAS-402; AERAS-402; MVA-85A</Interventions><Reference>2012-002007-18; NCT01683773; TB032; UKCRN 13671</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study of Tuberculosis Vaccines AERAS-402 and MVA-85A</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="91280"></Trial><Drug id="53975">AERAS-402</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-2; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>AERAS-402; AERAS-402; MVA-85A</Interventions><Reference>2012-002007-18; NCT01683773; TB032; UKCRN 13671</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-Dose TMC-207 on the QT/QTc Interval Under Fed Conditions</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="74529"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>88</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>moxifloxacin</Controls><EnrollmentCount>88</EnrollmentCount><Interventions>TMC-207</Interventions><Reference>CR017167; NCT01291563; TMC-207-TBC1003</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="162886"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Anti-Meningitis C antibodies; C-C motif chemokine 2; C-C motif chemokine 3; C-C motif chemokine 4; Cytokines; IgG; Interferon gamma; Interferon-alpha; Interleukin-1 alpha; Interleukin-1 beta; Interleukin-10; Interleukin-12; Interleukin-13; Interleukin-2; Interleukin-6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>BCG; Infanrix; Menitorix; NeisVac-C; Pentacel; Prevnar 13; Priorix; Rotarix</Interventions><Reference>2013-003488-71; BAM; NCT02002156; OVG-2013/04; UKCRN 15722</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>RIFART</ProtocolAcronym><ProtocolTitle>RIFART</ProtocolTitle><Sponsor>Azienda Ospedaliera Spedali Civili di Brescia</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="131240"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>efavirenz; emtricitabine; emtricitabine; lopinavir + ritonavir; rifabutin; rifampicin; tenofovir disoproxil fumarate; tenofovir disoproxil fumarate</Interventions><Reference>EudraCT 2007-007935-14; MI2-RIFART-2005; RIFART</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>TBTC-23</ProtocolAcronym><ProtocolTitle>Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10653"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>215</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>215</EnrollmentCount><Interventions>rifabutin</Interventions><Reference>CDC-NCHSTP-2174; NCT00023361; TBTC STUDY 23; TBTC-23</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis</ProtocolTitle><Sponsor>Makerere University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11184"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>18</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>nevirapine; rifampicin</Interventions><Reference>CPR 004; NCT00617643</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11188"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>47</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>47</EnrollmentCount><Interventions>efavirenz; lopinavir + ritonavir; nevirapine; rifabutin</Interventions><Reference>ANRS12150b; NCT00651066</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>Pred-ART</ProtocolAcronym><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="150793"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>240</Patients><Biomarkers>Alanine transaminase; Bilirubin; C-reactive protein; Glucose; Hemoglobin; Leukocyte count; Serum potassium; Serum sodium; White blood cell</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>240</EnrollmentCount><Interventions>prednisone</Interventions><Reference>CIDRI_001; DOH-27-0813-4336; NCT01924286; PACTR201304000511413; Pred-ART; SP.2011.41304.074</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="120522"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>pretomanid</Interventions><Reference>CL-003; NCT01828827; PA-824 CL-003</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="134374"></Trial><Drug id="48499">H4:IC31</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>243</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>243</EnrollmentCount><Interventions>H4+IC31</Interventions><Reference>C-015-404; C-015-404/ IMPAACT P1113; NCT01861730; U01AI068632</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="42128"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>bedaquiline; lopinavir + ritonavir</Interventions><Reference>CR002545; NCT00828529; NCT00980291</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>IPEC-EFV</ProtocolAcronym><ProtocolTitle>Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X  800 mg</ProtocolTitle><Sponsor>Fundacao Oswaldo Cruz (Fiocruz)</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="11181"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>130</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>130</EnrollmentCount><Interventions>efavirenz; isoniazid; lamivudine; pyrazinamide; rifampicin; zidovudine</Interventions><Reference>CAAE-0017.1.009.000-03; IPEC-EFV; NCT00533390</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA, Johnson &amp; Johnson</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="56959"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>TMC-207; nevirapine</Interventions><Reference>CR015793; NCT00910806; NCT00980668; TMC207-TiDP13-C117</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>TEMPRANO</ProtocolAcronym><ProtocolTitle>Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="195741"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1107</Patients><Biomarkers>Hepatitis B large envelope protein; Hepatitis B virus external core antigen; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>2073</EnrollmentCount><Interventions>efavirenz; isoniazid; lopinavir + ritonavir; tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Interventions><Reference>ANRS 12136 TEMPRANO; NCT00495651; TEMPRANO</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Antivirus Therapy for Population with HIV, HCV and TB Co-infection Clinical Trial</ProtocolTitle><Sponsor>Guangzhou eighth People's Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="162528"></Trial><Drug id="5369">ribavirin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>550</Patients><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Cluster of differentiation 4; Hepatitis C virus RNA; Hepatitis C virus-RNA</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>550</EnrollmentCount><Interventions>peg-interferon alpha-2a; ribavirin</Interventions><Reference>ChiCTR-TRC-00000407; ChiCTR-TRC-09000407</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="10943"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>15</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>15</EnrollmentCount><Interventions>moxifloxacin; moxifloxacin; rifapentine</Interventions><Reference>06-0050; NA_00007322; NCT00460759</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="162886"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Anti-Meningitis C antibodies; C-C motif chemokine 2; C-C motif chemokine 3; C-C motif chemokine 4; Cytokines; IgG; Interferon gamma; Interferon-alpha; Interleukin-1 alpha; Interleukin-1 beta; Interleukin-10; Interleukin-12; Interleukin-13; Interleukin-2; Interleukin-6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>BCG; Infanrix; Menitorix; NeisVac-C; Pentacel; Prevnar 13; Priorix; Rotarix</Interventions><Reference>2013-003488-71; BAM; NCT02002156; OVG-2013/04; UKCRN 15722</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="23035"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>121</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>216</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyridoxine; rifampin; rifapentine</Interventions><Reference>06-0018; NCT00728507</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried</ProtocolTitle><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="285854"></Trial><Drug id="81363">AEC/BC02</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>135</Patients><Biomarkers>Blood pressure; Body temperature; Cytokines; Heart rate; Interferon gamma; Respiratory frequency</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>135</EnrollmentCount><Interventions>AEC/BC02</Interventions><Reference>AEC/BCO2; LTAO; LTAO-AEC/BCO2--HEALTHY; NCT03026972</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tuberculosis Prevention for HIV Infected Adults</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="8790"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1148</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>1148</EnrollmentCount><Interventions>isoniazid; isoniazid; rifampin; rifapentine</Interventions><Reference>1R01AI48526-01A1; 5RO1AI048526-02; NCT00057122</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical study of freeze - dried recombinant tuberculosis vaccine (AEC/BC02)</ProtocolTitle><Sponsor>Chongqing Zhifei Biological Products Co Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="291253"></Trial><Drug id="81363">AEC/BC02</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>175</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>175</EnrollmentCount><Interventions>AEC/BC02; BC02</Interventions><Reference>201601; CTR20150383</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>CORTIS</ProtocolAcronym><ProtocolTitle>The Correlate of Risk Targeted Intervention Study</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="258043"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>2927</Patients><Biomarkers>Interferon gamma; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>2927</EnrollmentCount><Interventions>isoniazid; pyridoxine; rifapentine</Interventions><Reference>CORTIS; CORTIS-01; NCT02735590</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>HARAPAN II</ProtocolAcronym><ProtocolTitle>Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings</ProtocolTitle><Sponsor>National Institutes of Health, Yale University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="294801"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>500</Patients><Biomarkers>Alanine transaminase; Aspartate aminotransferase; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>500</EnrollmentCount><Interventions>isoniazid; isoniazid; methadone; naltrexone; rifapentine</Interventions><Reference>1R01DA041271; 2000020053; 33974; HARAPAN II; MECID.NO:201696-4220; NCT03089983; NMRR-17-19-33974</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Daily Rifapentine for Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="39550"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>153</Patients><Biomarkers>Alanine transaminase; Arylacetamide deacetylase; Bilirubin; Blood cells; Creatinine; Nuclear receptor subfamily 1 group I member 2; Nuclear receptor subfamily 1 group I member 3; Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampin</Controls><EnrollmentCount>153</EnrollmentCount><Interventions>ethambutol; isoniazid; pyrazinamide; rifapentine</Interventions><Reference>3524; NA_00019095; NCT00814671</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Exploratory Study of TMC-207 in Japanese Participants with Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)</ProtocolTitle><Sponsor>Janssen Pharmaceutical KK</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="222400"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>6</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>6</EnrollmentCount><Interventions>amikacin; amoxicillin-clavulanate; bedaquiline; clofazimine; cycloserine; enviomycin; ethambutol; ethionamide; fluoroquinolone therapy; kanamycin; levofloxacin; linezolid; para-aminosalicylic acid; pyrazinamide; streptomycin</Interventions><Reference>CR105158; JapicCTI-163116; NCT02365623; TMC207TBC2001</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>REFLATE TB2</ProtocolAcronym><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Sponsor>INSERM</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="214156"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>460</Patients><Biomarkers>Human immunodeficiency virus RNA; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; tenofovir disoproxil fumarate</Controls><EnrollmentCount>460</EnrollmentCount><Interventions>lamivudine; raltegravir; rifampin; tenofovir disoproxil fumarate</Interventions><Reference>ANRS 12300 REFLATE TB2; NCT02273765; REFLATE TB2</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 9-Month Isoniazid versus 3-Month Isoniazid plus Rifapentine for Treatment of Tuberculosis Infection in Rheumatic Patients: a Randomized, Controlled Trial</ProtocolTitle><Sponsor>Peking Union Medical College Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="352748"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>500</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>500</EnrollmentCount><Interventions>isoniazid; isoniazid; rifapentine</Interventions><Reference>ChiCTR1800018242</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>S31PK/PD</ProtocolAcronym><ProtocolTitle>Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="242269"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; pyridoxine; rifampin</Controls><EnrollmentCount>60</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyridoxine; rifampin; rifapentine</Interventions><Reference>CDC-NCHHSTP-6719; NCT02563327; S31PK/PD</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>endTB</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Sponsor>Mdecins Sans Frontires France</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="259506"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>750</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>pryrazinamide</Controls><EnrollmentCount>750</EnrollmentCount><Interventions>Lamprene; bedaquiline; delamanid; levofloxacin; linezolid; moxifloxacin; pryrazinamide</Interventions><Reference>MSF ERB-1555; NCT02754765; endTB</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>International, multicenter, double-blind, placebo-controlled, randomized trial to evaluate the efficacy, safety and pharmacokinetics of PBTZ-169 when used in combination therapy in patients with tuberculosis of respiratory organs with bacterial excretion and drug resistance</ProtocolTitle><Sponsor>Nearmedic Plus</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="316145"></Trial><Drug id="90085">macozinone</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>192</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>192</EnrollmentCount><Interventions>PBTZ-169</Interventions><Reference>PBTZ169-A15-C2b-1</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>DRAMATIC</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Sponsor>Boston University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="368916"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>WHO regimen therapy</Controls><EnrollmentCount></EnrollmentCount><Interventions>Deltyba; Lamprene; Levaquin; Sirturo; Zyvox</Interventions><Reference>DRAMATIC; H38212; NCT03828201</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>TBM-KIDS</ProtocolAcronym><ProtocolTitle>Optimizing Treatment to Improve TBM Outcomes in Children</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="278847"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; rifampicin</Controls><EnrollmentCount>120</EnrollmentCount><Interventions>ethambutol; isoniazid; levofloxacin; pyrazinamide; rifampicin</Interventions><Reference>CTRI/2017/03/008004; IRB00051196; NCT02958709; TBM-KIDS</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase III Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="219499"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>109</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>109</EnrollmentCount><Interventions>bedaquiline; bedaquiline; linezolid; pretomanid</Interventions><Reference>NCT02333799; NIX-TB-(B-L-PA)</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="307654"></Trial><Drug id="44406">imipenem + cilastatin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>448</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Reference>CAP 020; InDEX; NCT03237182</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Comparative study of different treatment regimes for brain tuberculosis</ProtocolTitle><Sponsor>Department of Science &amp; Technology</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="382387"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>75</Patients><Biomarkers>Cytokines</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>75</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; rifampicin</Interventions><Reference>CTRI/2019/05/019222</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym>BBA</ProtocolAcronym><ProtocolTitle>Brief Bactericidal Activity of Anti-Tuberculosis Drugs</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="210083"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>150</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>capreomycin; isoniazid; moxifloxacin; rifabutin; rifampicin</Interventions><Reference>BBA; CDC-NCHHSTP-6435; NCT02236078</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>DRAMATIC</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Sponsor>Boston University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="368916"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>WHO regimen therapy</Controls><EnrollmentCount></EnrollmentCount><Interventions>Deltyba; Lamprene; Levaquin; Sirturo; Zyvox</Interventions><Reference>DRAMATIC; H38212; NCT03828201</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Exploratory Study of TMC-207 in Japanese Participants with Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)</ProtocolTitle><Sponsor>Janssen Pharmaceutical KK</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="222400"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>6</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>6</EnrollmentCount><Interventions>amikacin; amoxicillin-clavulanate; bedaquiline; clofazimine; cycloserine; enviomycin; ethambutol; ethionamide; fluoroquinolone therapy; kanamycin; levofloxacin; linezolid; para-aminosalicylic acid; pyrazinamide; streptomycin</Interventions><Reference>CR105158; JapicCTI-163116; NCT02365623; TMC207TBC2001</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II, Multicenter, Uncontrolled, Open-label Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="242789"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>213</Patients><Biomarkers>Blood pressure; Body temperature; Heart rate; Hydrocortisone; Partial Thromboplastin Time; Prothrombin time; Total body mass; Visual acuity</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>213</EnrollmentCount><Interventions>delamanid</Interventions><Reference>242-07-208; EudraCT 2008-005107-26; NCT02573350</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Research on New Regimens for Retreatment Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Shanghai Pulmonary Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="220243"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin; streptomycin</Controls><EnrollmentCount>864</EnrollmentCount><Interventions>ethambutol; isoniazid aminosalicylate; moxifloxacin; pyrazinamide; rifabutin</Interventions><Reference>2013ZX10003009; NCT02331823</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IIb/III, international, multicenter, prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of chemotherapy regimens, including drug SQ-109 in patients with pulmonary multidrug-resistant mycobacterium tuberculosis</ProtocolTitle><Sponsor>Infectex</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="168785"></Trial><Drug id="31010">SQ-109</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>140</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>170</EnrollmentCount><Interventions>SQ-109; chemotherapy</Interventions><Reference>MOSQ-109</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis</ProtocolTitle><Sponsor>Janssen R&amp;D (Ireland)</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9315"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>75</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid; rifampin</Controls><EnrollmentCount>75</EnrollmentCount><Interventions>TMC-207</Interventions><Reference>CR002725; NCT00523926; TMC207-C202</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>TB-PRACTECAL</ProtocolAcronym><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Sponsor>Medecins Sans Frontieres</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="244304"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>630</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>630</EnrollmentCount><Interventions>Lamprene; bedaquiline; linezolid; moxifloxacin; pretomanid</Interventions><Reference>1541; NCT02589782; TB-PRACTECAL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="8780"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>isoniazid; levofloxacin; pyridoxine</Interventions><Reference>DATRI 008; NCT00000778</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>LINEZOLIDE</ProtocolAcronym><ProtocolTitle>Pharmacokinetic and Therapeutic Adaptation of Linezolid in the Treatment of Multi-Resistant Tuberculosis</ProtocolTitle><Sponsor>Groupe Hospitalier Paris Saint-Joseph</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="261481"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>31</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>31</EnrollmentCount><Interventions>linezolid</Interventions><Reference>LINEZOLIDE; LINEZOLIDE; NCT02778828</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>IMPAACT4TB</ProtocolAcronym><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><Sponsor>Aurum Institute</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="329251"></Trial><Drug id="14493">tenofovir disoproxil fumarate</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Human immunodeficiency virus RNA</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>dolutegravir; emtricitabine; isoniazid; rifapentine; tenofovir disoproxil fumarate</Interventions><Reference>3HP DTG AUR1-6-212 IMPAACT4TB; IMPAACT4TB; NCT03435146</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>TRUNCATE-TB</ProtocolAcronym><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><Sponsor>Syneos Health Inc, University College London</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="333435"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>900</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>900</EnrollmentCount><Interventions>bedaquiline; clofazimine; ethambutol; isoniazid; levofloxacin; linezolid; pyrazinamide; rifampicin; rifapentine</Interventions><Reference>2016-CT0376; NCT03474198; PHRR170327-001522; TRUNCATE-TB; TRUNCATE-TB</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tuberculosis Clinical Trials Consortium Study 35</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="359122"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>72</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>72</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Reference>6993; NCT03730181</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT-6-CFP-10</ProtocolTitle><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="219931"></Trial><Drug id="95442">ESAT-6CFP10</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>192</Patients><Biomarkers>Blood pressure; Body temperature; Heart rate; Interferon gamma</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>192</EnrollmentCount><Interventions>ESAT-6-CFP-10; TB-PPD</Interventions><Reference>LTao-IIb-patient; NCT02336542</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>endTB</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Sponsor>Mdecins Sans Frontires France</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="259506"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>750</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>pryrazinamide</Controls><EnrollmentCount>750</EnrollmentCount><Interventions>Lamprene; bedaquiline; delamanid; levofloxacin; linezolid; moxifloxacin; pryrazinamide</Interventions><Reference>MSF ERB-1555; NCT02754765; endTB</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, multicenter, controlled trial for clofazimine-containing protocol in the treatment of newly diagnosed multidrug-resistant tuberculosis</ProtocolTitle><Sponsor>Beijing Chest Hospital, Capital Medical University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="365020"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>144</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>144</EnrollmentCount><Interventions>clofazimine (oral, tuberculosis), Novartis</Interventions><Reference>ChiCTR1800020391</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, double-blind, phase I safety and tolerability study of pafuramidine maleate (DB-289) in healthy subjects</ProtocolTitle><Sponsor>Immtech Pharmaceuticals Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="17432"></Trial><Drug id="16755">pafuramidine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>175</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>pafuramidine</Interventions><Reference>C05-013; NCT00619346</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>CORTAIL</ProtocolAcronym><ProtocolTitle>Evaluation of clofazimine as a part of TB treatment in order to shorten the duration of treatment</ProtocolTitle><Sponsor>Indian Council of Medical Research</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="373668"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>320</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampin</Controls><EnrollmentCount>320</EnrollmentCount><Interventions>clofazimine; isoniazid; pyrazinamide; rifampin</Interventions><Reference>CORTAIL; CTRI/2019/03/018102</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study for latent tuberculosis infection intervention among close contacts of pulmonary tuberculosis patients</ProtocolTitle><Sponsor>The Chinese Centre for Disease Control and Prevention</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="361821"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>3000</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><EnrollmentCount>3000</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Reference>ChiCTR1800019658</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SUDOCU</ProtocolAcronym><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="381674"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>75</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>bedaquiline; delamanid; moxifloxacin</Controls><EnrollmentCount>75</EnrollmentCount><Interventions>bedaquiline; delamanid; midazolam; moxifloxacin; sutezolid</Interventions><Reference>NCT03959566; PANACEA-SUDOCU-01; SUDOCU</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Sponsor>Beijing Chest Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="369109"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>500</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>500</EnrollmentCount><Interventions>amikacin; bedaquiline; clarithromycin; clofazimine; cycloserine; ethambutol; linezolid; moxifloxacin; prothionamide; pyrazinamide; sodium para-aminosalicylate</Interventions><Reference>2018ZX10722301-001; NCT03830671</Reference></Row><Row><ArmCount>5+</ArmCount><ProtocolAcronym>endTB-Q</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance</ProtocolTitle><Sponsor>Mdecins Sans Frontires France</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="375499"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>500</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>bedaquiline; bedaquiline; clofazimine; clofazimine; delamanid; delamanid; linezolid; linezolid</Controls><EnrollmentCount>500</EnrollmentCount><Interventions>bedaquiline; clofazimine; delamanid; linezolid</Interventions><Reference>MSF ERB-1761; NCT03896685; endTB-Q</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>TRUNCATE-TB</ProtocolAcronym><ProtocolTitle>A 2 Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis</ProtocolTitle><Sponsor>Syneos Health Inc, University College London</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="333435"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>900</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>900</EnrollmentCount><Interventions>bedaquiline; clofazimine; ethambutol; isoniazid; levofloxacin; linezolid; pyrazinamide; rifampicin; rifapentine</Interventions><Reference>2016-CT0376; NCT03474198; PHRR170327-001522; TRUNCATE-TB; TRUNCATE-TB</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>DAR-PIA</ProtocolAcronym><ProtocolTitle>DAR-901 TB Booster Vaccine to Prevent TB in Adolescents</ProtocolTitle><Sponsor>Dartmouth-Hitchcock Medical Center</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="256110"></Trial><Drug id="90231">DAR-901</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>650</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>650</EnrollmentCount><Interventions>DAR-901</Interventions><Reference>29001; DAR-PIA; NCT02712424</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>Map2Co</ProtocolAcronym><ProtocolTitle>Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana</ProtocolTitle><Sponsor>kwame Nkrumah University of Science and Technology</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="214864"></Trial><Drug id="48140">doxycycline (once-daily, oral controlled release), CollaGenex</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>200</Patients><Biomarkers>Th1 cytokines</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>doxycycline (once-daily, oral controlled release), CollaGenex; doxycycline hyclate</Interventions><Reference>GZ:JA 1479/5-1; Map2Co; NCT02281643</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-negative, TB-negative, BCG-naive Adults</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="227111"></Trial><Drug id="48499">H4:IC31</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>70</Patients><Biomarkers>Cytokines; Cytotoxic T-Lymphocytes; T-Helper Lymphocytes</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>70</EnrollmentCount><Interventions>BCG SSI; HyVac4/IC-31 vaccine (tuberculosis), SSI/Aeras/Intercell</Interventions><Reference>C-013-404; NCT02420444</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Sponsor>Beijing Chest Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="369109"></Trial><Drug id="2829">clarithromycin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>500</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>500</EnrollmentCount><Interventions>amikacin; bedaquiline; clarithromycin; clofazimine; cycloserine; ethambutol; linezolid; moxifloxacin; prothionamide; pyrazinamide; sodium para-aminosalicylate</Interventions><Reference>2018ZX10722301-001; NCT03830671</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>RADIO</ProtocolAcronym><ProtocolTitle>A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers</ProtocolTitle><Sponsor>ST STEPHEN'S CLINICAL RESEARCH LIMITED</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="303292"></Trial><Drug id="59062">dolutegravir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>dolutegravir; rifampicin</Interventions><Reference>NCT03199690; RADIO; SSCR103</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>IMPAACT4TB</ProtocolAcronym><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><Sponsor>Aurum Institute</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="329251"></Trial><Drug id="59062">dolutegravir</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Human immunodeficiency virus RNA</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>dolutegravir; emtricitabine; isoniazid; rifapentine; tenofovir disoproxil fumarate</Interventions><Reference>3HP DTG AUR1-6-212 IMPAACT4TB; IMPAACT4TB; NCT03435146</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients</ProtocolTitle><Sponsor>University Medical Center Groningen</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="182646"></Trial><Drug id="2829">clarithromycin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>7</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>7</EnrollmentCount><Interventions>clarithromycin; linezolid; linezolid + clarithromycin</Interventions><Reference>2011-000513-39; NCT01521364; NL35534.042.11; NTR3260</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose-Escalation Study on Safety and Immunogenicity of VPM-1-002 in Comparison With BCG in Healthy Male Volunteers</ProtocolTitle><Sponsor>Vakzine Projekt Management GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="48943"></Trial><Drug id="55569">VPM-1002</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>80</Patients><Biomarkers>B cells; CD4+; CD8+; Cytotoxic T-Lymphocytes; Interferon-gamma; Interleukin-2; T-Helper Lymphocytes; Tumor necrosis factor-alpha (TNF)</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>VPM-1-002</Interventions><Reference>EudraCT 2007-002789-37; NCT00749034; VPM1002-GE-1.01TB</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Deworming Against Tuberculosis</ProtocolTitle><Sponsor>Linkoping University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="48176"></Trial><Drug id="12132">albendazole</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>140</Patients><Biomarkers>CD4-count; Eosinophils; IFN-gamma; IL5; IgE; Interleukin-10; TGF-beta; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>140</EnrollmentCount><Interventions>albendazole</Interventions><Reference>ALBP; HLF-20060245; NCT00857116</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effect of Ethnic on Moxifloxacin Induced QT Interval Prolongation in Korean and Japanese Healthy Subjects</ProtocolTitle><Sponsor>Inje University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="139433"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus><Patients>39</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>moxifloxacin</Interventions><Reference>12-166; NCT01876316</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I study of a new tuberculosis (TB) vaccine, MVA-85A, in healthy volunteers with HIV</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23059"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>MVA-85A</Interventions><Reference>NCT00731471; TB019</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><Sponsor>Tuberculosis Research Centre</Sponsor><TrialStatus>Suspended</TrialStatus><Trial id="10863"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>116</Patients><Biomarkers>CD4+</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>180</EnrollmentCount><Interventions>didanosine; efavirenz; efavirenz +  didanosine + lamivudine; ethambutol; ethambutol + isoniazid + rifampicin + pyrazinamide; isoniazid; isoniazid + rifampicin; lamivudine; nevirapine; nevirapine + didanosine + lamivudine; pyrazinamide; rifampicin</Interventions><Reference>NCT00332306; trc23</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11187"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>35</Patients><Biomarkers>Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>efavirenz; isoniazid; lamivudine; lopinavir + ritonavir; nevirapine; rifabutin; stavudine</Interventions><Reference>ANRS12150a; NCT00640887</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, open, balanced, two-component, two-period, crossover, with a single-dose study of comparative pharmacokinetics and bioequivalence of Primflo (moxifloxacin) 400 mg (Dr Reddy's Laboratories Ltd, India) and Avilox  (moxifloxacin) 400 mg (Bayer Healthcare AG, Germany), when taken orally on an empty stomach in healthy adult volunteers</ProtocolTitle><Sponsor>Dr Reddy's Laboratories Ltd</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="167750"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Primflo</Controls><EnrollmentCount>24</EnrollmentCount><Interventions>moxifloxacin</Interventions><Reference>DRL_RUS/MD/2012rmox1</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers</ProtocolTitle><Sponsor>Sequella Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="60906"></Trial><Drug id="11088">sutezolid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>59</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>59</EnrollmentCount><Interventions>PNU-100480</Interventions><Reference>B1171002; NCT00990990</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="192117"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>19</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>19</EnrollmentCount><Interventions>isoniazid; kanamycin; moxifloxacin; pyrazinamide; rifampicin</Interventions><Reference>09-I-N061; 999909061; NCT00816426</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>IMPRESS</ProtocolAcronym><ProtocolTitle>Improving Retreatment Success</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="182040"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>58</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>197</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; rifampicin</Interventions><Reference>CAP 011; IMPRESS; NCT02114684</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Linezolid to Treat Extensively-Drug Resistant Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23143"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>41</Patients><Biomarkers>Mitochondria</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>41</EnrollmentCount><Interventions>linezolid</Interventions><Reference>08-I-N167; 999908167; NCT00727844</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="66735"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>OPC-67683</Interventions><Reference>2009-014944-13; 242-08-210; NCT01131351</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Pharmacokinetics and Safety of indinavir/ritonavir With NRTIs in HIV/TB co-Infected Patients Receiving Rifampicin</ProtocolTitle><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10871"></Trial><Drug id="5321">indinavir</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>indinavir; ritonavir</Interventions><Reference>HIV-NAT 044; NCT00411996</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV</ProtocolTitle><Sponsor>AIDS Clinical Trials Group</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="87585"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>71</Patients><Biomarkers>CD4; Cytotoxic T-Lymphocytes; HIV viral load; Human immunodeficiency virus RNA; T-Helper Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Kaletra; ethambutol; isoniazid; pyrazinamide; pyridoxine; rifampin</Controls><EnrollmentCount>71</EnrollmentCount><Interventions>Kaletra; ethambutol; isoniazid; pyrazinamide; pyridoxine; raltegravir; rifabutin</Interventions><Reference>1U01AI068636; ACTG A5290; NCT01601626</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>PK-TB-HAART</ProtocolAcronym><ProtocolTitle>Bioavailability of the Fixed Dose Formulation Rifafour Containing Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and the World Health Organization (WHO) Recommended First Line Antiretroviral Drugs Zidovudine, Lamivudine, Efavirenz Administered to New Tuberculosis (TB) Patients at Different Levels of Immunosuppression</ProtocolTitle><Sponsor>World Health Organization</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="136052"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>Rifafour; Rifafour; efavirenz; lamivudine; zidovudine</Interventions><Reference>A40607; ISRCTN83323477; PK-TB-HAART</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>Staph</ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Antistaphylococcal Antibiotics in Infants</ProtocolTitle><Sponsor>Duke University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="98566"></Trial><Drug id="44370">clindamycin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>62</Patients><Biomarkers>Albumin; Orosomucoid; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>63</EnrollmentCount><Interventions>clindamycin; rifampin; ticarcillin-clavulanate</Interventions><Reference>NCT01728363; NICHD-2012-02-Staph Trio; Pro00037820; Staph</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>ANRS 1295 CAMELIA</ProtocolAcronym><ProtocolTitle>Early versus Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="145651"></Trial><Drug id="4481">stavudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>540</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>661</EnrollmentCount><Interventions>efavirenz; efavirenz + lamivudine + stavudine; lamivudine; stavudine</Interventions><Reference>ANRS 1295 CAMELIA; ANRS 1295 CAMELIA; CIPRA KH 001; NCT00226434; NCT00498823</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>CARINEMO</ProtocolAcronym><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10948"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>570</Patients><Biomarkers>Alanine aminotransferase; CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; stavudine</Controls><EnrollmentCount>570</EnrollmentCount><Interventions>Arm A; Arm B; Triomune; ethambutol; ethambutol; isoniazid; isoniazid; lamivudine; nevirapine; pyrazinamide; pyrazinamide; rifampicin; rifampicin; stavudine</Interventions><Reference>ANRS 12146 CARINEMO; ANRS 12146/12214; ANRS 12214; CARINEMO; NCT00495326</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Latency in Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Tuberculosis Research Centre</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="67984"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; rifampicin</Interventions><Reference>LTB01; NCT01154959</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>PK-TB-HAART</ProtocolAcronym><ProtocolTitle>Bioavailability of the Fixed Dose Formulation Rifafour Containing Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and the World Health Organization (WHO) Recommended First Line Antiretroviral Drugs Zidovudine, Lamivudine, Efavirenz Administered to New Tuberculosis (TB) Patients at Different Levels of Immunosuppression</ProtocolTitle><Sponsor>World Health Organization</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="136052"></Trial><Drug id="44316">zidovudine</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>Rifafour; Rifafour; efavirenz; lamivudine; zidovudine</Interventions><Reference>A40607; ISRCTN83323477; PK-TB-HAART</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB)</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="83489"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>207</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>207</EnrollmentCount><Interventions>DRMPa200Z regimen; HRZE regimen; MPa100Z regimen; MPa200Z regimen; PA-824; Rifafour; ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyrazinamide; rifampicin</Interventions><Reference>NC-002-(M-Pa-Z); NCT01498419</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>RIFLOPI</ProtocolAcronym><ProtocolTitle>Rifabutin With Lopinavir/ritonavir in Patients Coinfected With Tuberculosis and HIV in Burkina Faso</ProtocolTitle><Sponsor>Institut de Recherche en Sciences de la Sante (IRSS), Burkina Faso</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="161441"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>lopinavir+ritonavir; rifabutin</Interventions><Reference>PACTR201310000629390; RIFLOPI</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study of ChAdOx1-85A Vaccination With and Without MVA-85A Boost in Healthy Adults</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="120744"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>42</Patients><Biomarkers>T-Lymphocytes</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>42</EnrollmentCount><Interventions>ChAdOx1-85A; ChAdOx1-85A; MVA-85A</Interventions><Reference>NCT01829490; TB034; UKCRN 14241</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Challenge Model for Assessment of Human TB Immunity</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="149358"></Trial><Drug id="13624">BCG vaccine, Organon</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>BCG vaccine, Organon</Interventions><Reference>11-0033; HHSN272200800003C; N01AI80003C; NCT01868464</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="90512"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>74</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>74</EnrollmentCount><Interventions>PA-824; moxifloxacin</Interventions><Reference>10-0058; N01AI80024C; NCT01674218</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Placebo-Controlled, Phase II Trial to Evaluate OPC-67683 in Patients With Pulmonary Sputum Culture-Positive, Multidrug-Resistant Tuberculosis (TB)</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="15754"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>481</Patients><Biomarkers>Blood pressure; Body temperature; Heart rate; QT interval; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>481</EnrollmentCount><Interventions>Optimized background regimen; delamanid</Interventions><Reference>2007-005229-31; 242-07-204; NCT00685360; Trial 204</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>NEXT</ProtocolAcronym><ProtocolTitle>An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multidrug-resistant Tuberculosis</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="230529"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>300</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>kanamycin; moxifloxacin</Controls><EnrollmentCount>300</EnrollmentCount><Interventions>bedaqualine; ethionamide; isoniazid; levofloxacin; linezolid; pyrazinamide; terizidone</Interventions><Reference>NCT02454205; NEXT; NEXT-5001</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>HIV-TB Pharmagene</ProtocolAcronym><ProtocolTitle>Optimization of Tuberculosis and HIV Co-treatment in Africa</ProtocolTitle><Sponsor>Karolinska Institutet</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="131419"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>493</Patients><Biomarkers>ABCB1; CD4; CYP2B6; CYP3A5; Cytochrome P450 2B6; Cytochrome P450 3A5; Multidrug resistance protein 1; SLCO1B1; Solute carrier organic anion transporter family member 1B1; Total body mass; UDP-glucuronosyltransferase 2B7; UGT2B7; body mass index; plasma HIV-1 RNA load</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz</Controls><EnrollmentCount>800</EnrollmentCount><Interventions>efavirenz; rifampicin</Interventions><Reference>HIV-TB Pharmagene; PACTR2009040001261177</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SAPIT</ProtocolAcronym><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="201474"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>642</Patients><Biomarkers>CD4 Positive T Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>642</EnrollmentCount><Interventions>didanosine; efavirenz; lamivudine; lamivudine + efavirenz + didanosine; trimethoprim + sulfamethoxazole</Interventions><Reference>CAPRISA 003; NCT00398996; SAPIT</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Assess the Relative Bioavailability of TMC-207 Following Single-dose Administrations of Two Pediatric Formulations in Healthy Adult Participants</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="114087"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>bedaquiline</Interventions><Reference>2012-005492-13; CR100987; NCT01803373; TMC207TBC1002</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thrice-Weekly, 4- Months Moxifloxacin or Gatifloxacin Regimens for Pulmonary TB</ProtocolTitle><Sponsor>Indian Council of Medical Research</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="150332"></Trial><Drug id="7017">gatifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>416</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>429</EnrollmentCount><Interventions>ethambutol; gatifloxacin; isoniazid; moxifloxacin; pyrazinamide; rifampicin</Interventions><Reference>CTRI/2012/10/003060</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="90512"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>74</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>74</EnrollmentCount><Interventions>PA-824; moxifloxacin</Interventions><Reference>10-0058; N01AI80024C; NCT01674218</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease</ProtocolTitle><Sponsor>Institute of Liver and Biliary Sciences, India</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="90788"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>114</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>ethambutol; isoniazid; levofloxacin; pyrazinamide; rifampicin</Interventions><Reference>ILBS-ATT-01; NCT01677871</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10</ProtocolTitle><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="163196"></Trial><Drug id="95442">ESAT-6CFP10</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Blood pressure; Body temperature; Heart rate; Respiratory frequency</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>32</EnrollmentCount><Interventions>ESAT-6CFP10</Interventions><Reference>LTAO; LTAO-EC; NCT01999231</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-Endemic Region</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11563"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>45</Patients><Biomarkers>Antigen KI-67; CD4 T cells; Cytotoxic T-Lymphocytes; Interleukin 17; Ki67(+) T cells; T-Helper Lymphocytes; T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain; Th1 cytokine</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>GSK-692342</Interventions><Reference>110347; NCT00600782</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><Sponsor>Central Research Institute of Epidemiology</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="63729"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>abacavir; lamivudine; raltegravir</Interventions><Reference>NCT01059422; RAL/ABC/3TC - HIV/TB</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients</ProtocolTitle><Sponsor>Indian Government Department of Biotechnology</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10057"></Trial><Drug id="55173">cadi-05</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1020</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>1020</EnrollmentCount><Interventions>Mycobacterium w</Interventions><Reference>CR-01A/2003-10; NCT00265226; NI-705</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase III Clinical Study of Efficacy and Safety of Vaccae to Prevent Tuberculosis</ProtocolTitle><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="160177"></Trial><Drug id="81037">Wei Ka</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>10000</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>10000</EnrollmentCount><Interventions>Vaccae</Interventions><Reference>ChiCTR-PRC-13003741; LTAO; NCT01979900; U1111-1149-6525</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>DOT-LTBI</ProtocolAcronym><ProtocolTitle>Treatment of Latent Tuberculosis in Socially Marginalised Citizens</ProtocolTitle><Sponsor>Aarhus University Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="310930"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>150</Patients><Biomarkers>Alanine transaminase; Alkaline phosphatase; Bilirubin; Blood platelets; Hemoglobin; International Normalized Ratio; Leukocyte count</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><EnrollmentCount>150</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Reference>2016-003567-20; A101A; DOT-LTBI; NCT03266991</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter, Randomized, Controlled Study in Taiwan</ProtocolTitle><Sponsor>National Taiwan University Hospital</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207608"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>283</Patients><Biomarkers>Alanine transaminase; Aspartate aminotransferase</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><EnrollmentCount>283</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Reference>201309055MINC; NCT02208427</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Freeze-dried recombinant tuberculosis vaccine (AEC/BC02) phase I clinical human tolerance test</ProtocolTitle><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="329497"></Trial><Drug id="81363">AEC/BC02</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>135</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>135</EnrollmentCount><Interventions>AEC/BC02</Interventions><Reference>201601; CTR20180066</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>S31PK/PD</ProtocolAcronym><ProtocolTitle>Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="242269"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; pyridoxine; rifampin</Controls><EnrollmentCount>60</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyridoxine; rifampin; rifapentine</Interventions><Reference>CDC-NCHHSTP-6719; NCT02563327; S31PK/PD</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="303595"></Trial><Drug id="11088">sutezolid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>32</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>32</EnrollmentCount><Interventions>sutezolid</Interventions><Reference>NCT03199313; SUTEZOLID - CL001</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, Open-label, Comparative Study to Evaluate the Rifapentine in the Treatment of Patients Newly Diagnosed with Pulmonary Tuberculosis Negative and Smear-with Preserved Sensitivity of Mycobacteria</ProtocolTitle><Sponsor>S.P.Inkomed Pvt. Ltd</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="168261"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>92</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>92</EnrollmentCount><Interventions>rifapentine</Interventions><Reference>1/11</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>GamTBvac</ProtocolAcronym><ProtocolTitle>Evaluation of the Safety and Immunogenicity of the Recombinant Subunit Vaccine 'GamTBvac' Against the Tuberculosis</ProtocolTitle><Sponsor>Gamalei Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Collaborator</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="309614"></Trial><Drug id="107803">GamTBvac</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Immunoglobulin G</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>GamTBvac</Interventions><Reference>GAMTBVAC PH1; GamTBvac; NCT03255278</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to assess the bioequivalence of two oral formulations of levofloxacin tablets: FLEVOX (SERRAL, SA de CV), versus TAVANIC (Sanofi-Aventis of Mexico, SA de CV), after administration of a single dose- 500 mg to healthy adult subjects of both genders, in the fasting state</ProtocolTitle><Sponsor>Laboratorios Serral</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="227604"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>14</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>levofloxacin</Controls><EnrollmentCount>14</EnrollmentCount><Interventions>levofloxacin [Laboratorios Serral(MX)]</Interventions><Reference>LVFL-SRRL-03</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11187"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>35</Patients><Biomarkers>Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>efavirenz; isoniazid; lamivudine; lopinavir + ritonavir; nevirapine; rifabutin; stavudine</Interventions><Reference>ANRS12150a; NCT00640887</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="224811"></Trial><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>43</EnrollmentCount><Interventions>Augmentin; faropenem; rifampicin; rifampicin</Interventions><Reference>Faro-WBA; NCT02393586</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals</ProtocolTitle><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="364544"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2500</Patients><Biomarkers>Alanine transaminase; Alkaline phosphatase; Aspartate aminotransferase; Bilirubin; Blood cells; Creatinine; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>2500</EnrollmentCount><Interventions>isoniazid; pyridoxine; rifapentine</Interventions><Reference>HIV-NAT 255; NCT03785106</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SUDOCU</ProtocolAcronym><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="381674"></Trial><Drug id="44303">midazolam hydrochloride</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>75</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>bedaquiline; delamanid; moxifloxacin</Controls><EnrollmentCount>75</EnrollmentCount><Interventions>bedaquiline; delamanid; midazolam; moxifloxacin; sutezolid</Interventions><Reference>NCT03959566; PANACEA-SUDOCU-01; SUDOCU</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase IIa Clinical Trial of ID93 + GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers</ProtocolTitle><Sponsor>Quratis Co Ltd</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="366580"></Trial><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>107</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>107</EnrollmentCount><Interventions>ID-93</Interventions><Reference>CT-QTP101-001; NCT03806686</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>STREAM</ProtocolAcronym><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Sponsor>International Union Against Tuberculosis and Lung Diseases</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="228190"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>530</Patients><Biomarkers>4 beta-Hydroxycholesterol/Cholesterol ratio</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Lamprene; ethambutol (Myambutol); isoniazid (Nydrazid); kanamycin (Kantrex); moxifloxacin; prothionamide (Peteha); pyrazinamide (Zinamide)</Controls><EnrollmentCount>530</EnrollmentCount><Interventions>Lamprene; Regimen A locally-used WHO-approved MDR-TB regimen; bedaquiline; ethambutol (Myambutol); isoniazid (Nydrazid); kanamycin (Kantrex); levofloxacin; moxifloxacin; prothionamide (Peteha); pyrazinamide (Zinamide)</Interventions><Reference>18148631; 78372190; 78372190/18148631 (Stage 1/2); CTRI/2017/09/009693; ISRCTN78372190; NCT02409290; STREAM</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="280225"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients>419</Patients><Biomarkers>Creatinine; Human immunodeficiency virus RNA; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>419</EnrollmentCount><Interventions>efavirenz; emtricitabine; lamivudine; tenofovir</Interventions><Reference>15-1473; NCT02946762; Z 31501</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>RIFART</ProtocolAcronym><ProtocolTitle>RIFART</ProtocolTitle><Sponsor>Azienda Ospedaliera Spedali Civili di Brescia</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="131240"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>efavirenz; emtricitabine; emtricitabine; lopinavir + ritonavir; rifabutin; rifampicin; tenofovir disoproxil fumarate; tenofovir disoproxil fumarate</Interventions><Reference>EudraCT 2007-007935-14; MI2-RIFART-2005; RIFART</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety of RUTI Vaccination in MDR-TB Patients</ProtocolTitle><Sponsor>Archivel Farma SL</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="256039"></Trial><Drug id="57308">RUTI</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>27</Patients><Biomarkers>Interferon gamma</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>27</EnrollmentCount><Interventions>RUTI</Interventions><Reference>201600136; NCT02711735</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><Sponsor>Beijing Chest Hospital, Beijing Tuberculosis &amp; Thoracic Tumor Research Institute, Capital Medical University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="244777"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>clarithromycin; levofloxacin; moxifloxacin; moxifloxacin; rifabutin</Interventions><Reference>ChiCTR-IOR-15007291</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>DRAMATIC</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Sponsor>Boston University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="368916"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>WHO regimen therapy</Controls><EnrollmentCount></EnrollmentCount><Interventions>Deltyba; Lamprene; Levaquin; Sirturo; Zyvox</Interventions><Reference>DRAMATIC; H38212; NCT03828201</Reference></Row><Row><ArmCount>5+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd, Syneos Health Inc</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="224111"></Trial><Drug id="4492">faropenem</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>45</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>45</EnrollmentCount><Interventions>Augmentin; cefadroxil; cefadroxil; ethambutol; faropenem; faropenem; isoniazid; pyrazinamide; rifampicin</Interventions><Reference>2015-CT0284; FAROPENEM_TB; NCT02381470; PHRR160323-001194</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>REFLATE TB</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="40948"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>155</Patients><Biomarkers>Human immunodeficiency virus DNA; Human immunodeficiency virus RNA; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; tenofovir disoproxil fumarate</Controls><EnrollmentCount>155</EnrollmentCount><Interventions>lamivudine; raltegravir; tenofovir disoproxil fumarate</Interventions><Reference>2008-004970-41; ANRS 12 180; ANRS 12180 REFLATE TB; NCT00822315; REFLATE TB</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="224811"></Trial><Drug id="4492">faropenem</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>43</EnrollmentCount><Interventions>Augmentin; faropenem; rifampicin; rifampicin</Interventions><Reference>Faro-WBA; NCT02393586</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Verapamil Dose-finding Study in Adult Patients with Tuberculosis</ProtocolTitle><Sponsor>Indian Government Department of Biotechnology</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="261260"></Trial><Drug id="44437">verapamil</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>69</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>69</EnrollmentCount><Interventions>Verapamil; isoniazid; rifampicin</Interventions><Reference>CTRI/2016/05/006928</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of metformin on sputum smear conversion in pulmonary tuberculosis with type 2 diabetes mellitus</ProtocolTitle><Sponsor>Khonkaen Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="370128"></Trial><Drug id="6050">metformin hydrochloride</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>metformin</Interventions><Reference>TCTR20190128004</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="280225"></Trial><Drug id="14493">tenofovir disoproxil fumarate</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients>419</Patients><Biomarkers>Creatinine; Human immunodeficiency virus RNA; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>419</EnrollmentCount><Interventions>efavirenz; emtricitabine; lamivudine; tenofovir</Interventions><Reference>15-1473; NCT02946762; Z 31501</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>Stat-TB</ProtocolAcronym><ProtocolTitle>Statin Adjunctive Therapy for TB: A Phase IIb Dose-finding Study of Pravastatin in Adults With Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="374083"></Trial><Drug id="4155">pravastatin</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>Vitamin B6; ethambutol; isoniazid; pravastatin; pyrazinamide; rifampin</Interventions><Reference>38558; NCT03882177; Stat-TB</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>FS-1</ProtocolAcronym><ProtocolTitle>FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis</ProtocolTitle><Sponsor>Scientific Center for Anti-infectious Drugs, Kazakhstan</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="246553"></Trial><Drug id="104087">FS-1</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>480</Patients><Biomarkers>Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>480</EnrollmentCount><Interventions>FS-1; Standard DOTS</Interventions><Reference>FS-1; NCT02607449; TP-004 V 1.0</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="226801"></Trial><Drug id="53975">AERAS-402</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>72</Patients><Biomarkers>Carbon monoxide diffusing capacity; Cytotoxic T-Lymphocytes; Forced Vital Capacity; Forced expiratory volume; Interferon gamma; Interleukin-2; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>72</EnrollmentCount><Interventions>AERAS-402</Interventions><Reference>C-010-402; NCT02414828</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym>EMPIRICAL</ProtocolAcronym><ProtocolTitle>Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia</ProtocolTitle><Sponsor>Hospital Universitario 12 de Octubre</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="377163"></Trial><Drug id="25182">valganciclovir</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>624</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Standard of Care; ampicillin; benzylpenicillin; ceftriaxone; cotrimoxazole; gentamicin; prednisolone; sulfamethoxazole; trimethoprim</Controls><EnrollmentCount>624</EnrollmentCount><Interventions>Standard or Care; rifampicin + isoniazid + ethambutol; rifampicin + isoniazid + pyrazinamide; valganciclovir; valganciclovir</Interventions><Reference>19/096; 2019-001749-42; EDCTP RIA2017MC-2013EMPIRICAL; EMPIRICAL; NCT03915366; PACTR201904797961340; U1111-1231-4736</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>endTB</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Sponsor>Mdecins Sans Frontires France</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="259506"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>750</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>pryrazinamide</Controls><EnrollmentCount>750</EnrollmentCount><Interventions>Lamprene; bedaquiline; delamanid; levofloxacin; linezolid; moxifloxacin; pryrazinamide</Interventions><Reference>MSF ERB-1555; NCT02754765; endTB</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="307654"></Trial><Drug id="3616">meropenem</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>448</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Reference>CAP 020; InDEX; NCT03237182</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SUDOCU</ProtocolAcronym><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="381674"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>75</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>bedaquiline; delamanid; moxifloxacin</Controls><EnrollmentCount>75</EnrollmentCount><Interventions>bedaquiline; delamanid; midazolam; moxifloxacin; sutezolid</Interventions><Reference>NCT03959566; PANACEA-SUDOCU-01; SUDOCU</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Sponsor>Beijing Chest Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="369109"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>500</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>500</EnrollmentCount><Interventions>amikacin; bedaquiline; clarithromycin; clofazimine; cycloserine; ethambutol; linezolid; moxifloxacin; prothionamide; pyrazinamide; sodium para-aminosalicylate</Interventions><Reference>2018ZX10722301-001; NCT03830671</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="42128"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>bedaquiline; lopinavir + ritonavir</Interventions><Reference>CR002545; NCT00828529; NCT00980291</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>PHOENIx MDR-TB</ProtocolAcronym><ProtocolTitle>Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="344335"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>5610</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>5610</EnrollmentCount><Interventions>delamanid; isoniazid; pyridoxine</Interventions><Reference>12041; A5300B/I2003B/PHOENIX; NCT03568383; PHOENIx MDR-TB</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-Positive Adults</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9528"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>38</Patients><Biomarkers>C-reactive protein; Cytokines; IFN-gamma; Total IgE; anti-Mtb72F-T-cell; anti-Mtb72F-antibody</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>38</EnrollmentCount><Interventions>AS02; MTB72F vaccine (tuberculosis), GSK/Aeras</Interventions><Reference>102374; NCT00146744</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Optimization of Clinical Treatment Schemes for Multidrug - Resistant Pulmonary Tuberculosis Based on Host - Mediate</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="276708"></Trial><Drug id="4718">zileuton</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>90</Patients><Biomarkers>Dinoprostone; Interferon beta; Interferon-alpha; Interleukin-1 receptor antagonist protein; Prostaglandin G/H synthase 2</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>Zyflo</Interventions><Reference>ChiCTR-OPN-16009545</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="307654"></Trial><Drug id="2587">azithromycin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>448</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Reference>CAP 020; InDEX; NCT03237182</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>ZeNiX</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre-XDR-TB or Non-responsive/Intolerant MDR-TB</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="293734"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>180</Patients><Biomarkers>Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>180</EnrollmentCount><Interventions>bedaquiline; linezolid; pretomanid</Interventions><Reference>NC-007- (B-Pa-L); NCT03086486; ZENIX (B-PA-L) NC-007; ZeNiX</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA-85A Vaccine in Healthy Volunteers</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9320"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>14</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>14</EnrollmentCount><Interventions>MVA-85A</Interventions><Reference>NCT00423566; TB002</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym>LASER-TBM</ProtocolAcronym><ProtocolTitle>Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="378146"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>100</Patients><Biomarkers>Leukotriene A-4 hydrolase</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Standard of care anti-tubercular therapy; Standard of care anti-tubercular therapy; dexamethasone; isoniazid; rifampicin; rifampicin + isoniazid + ethambutol + pyrazinamide</Controls><EnrollmentCount>100</EnrollmentCount><Interventions>Intensified anti-tubercular therapy; aspirin; dexamethasone; linezolid; rifampicin</Interventions><Reference>LASER-TBM; LASER-TBM; NCT03927313</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT-6CFP10 Allergen</ProtocolTitle><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="247763"></Trial><Drug id="95442">ESAT-6CFP10</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1090</Patients><Biomarkers>Blood pressure; Body temperature; Heart rate; Interferon-alpha; Respiratory frequency</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>1090</EnrollmentCount><Interventions>ESAT-6CFP10; tuberculin purified protein derivative (TB-PPD)</Interventions><Reference>ChiCTR-DID-16007837; LTAO-EC III-PATIENT; NCT02623556</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>REFLATE TB2</ProtocolAcronym><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Sponsor>INSERM</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="214156"></Trial><Drug id="54488">raltegravir</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>460</Patients><Biomarkers>Human immunodeficiency virus RNA; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; tenofovir disoproxil fumarate</Controls><EnrollmentCount>460</EnrollmentCount><Interventions>lamivudine; raltegravir; rifampin; tenofovir disoproxil fumarate</Interventions><Reference>ANRS 12300 REFLATE TB2; NCT02273765; REFLATE TB2</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Simvastatin and sputum conversion in pulmonary tuberculosis: a double-blinded, randomized, controlled trial</ProtocolTitle><Sponsor>Khonkaen Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="330023"></Trial><Drug id="44313">simvastatin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>321</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>321</EnrollmentCount><Interventions>simvastatin</Interventions><Reference>TCTR20180219002</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>IMPAACT4TB</ProtocolAcronym><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><Sponsor>Aurum Institute</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="329251"></Trial><Drug id="4728">emtricitabine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Human immunodeficiency virus RNA</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>dolutegravir; emtricitabine; isoniazid; rifapentine; tenofovir disoproxil fumarate</Interventions><Reference>3HP DTG AUR1-6-212 IMPAACT4TB; IMPAACT4TB; NCT03435146</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="65639"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>302</Patients><Biomarkers>Alanine transaminase; Blood platelets; Body temperature; CD40 ligand; Creatinine; Cytotoxic T-Lymphocytes; Hemoglobin; Interferon gamma; Interleukin-2; Leukocyte count; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Menjugate; Polio Sabin; Prevnar; Tritanrix HB</Controls><EnrollmentCount>302</EnrollmentCount><Interventions>GSK-692342; GSK-692342a; Polio Sabin; Prevnar; Tritanrix HB</Interventions><Reference>112899; 2012-004380-44; NCT01098474; TUBERCULOSIS-013 PRI</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="76946"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>400</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>400</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; rifampicin; stavudine; zidovudine</Interventions><Reference>2008ZX10001-008; NCT01344148</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>RIFAQUIN</ProtocolAcronym><ProtocolTitle>An International, Multicenter, Controlled Clinical Trial to Evaluate High-Dose Rifapentine and a Quinolone in the Treatment of Pulmonary Tuberculosis</ProtocolTitle><Sponsor>St Georges University of London</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="153990"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>827</Patients><Biomarkers>Arylacetamide deacetylase; Nuclear receptor subfamily 1 group I member 2; Nuclear receptor subfamily 1 group I member 3; Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>1250</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; rifampicin; rifapentine</Interventions><Reference>10.1186/ISRCTN44153044; ISRCTN44153044; RIFAQUIN</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>REFLATE TB</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="40948"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>155</Patients><Biomarkers>Human immunodeficiency virus DNA; Human immunodeficiency virus RNA; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; tenofovir disoproxil fumarate</Controls><EnrollmentCount>155</EnrollmentCount><Interventions>lamivudine; raltegravir; tenofovir disoproxil fumarate</Interventions><Reference>2008-004970-41; ANRS 12 180; ANRS 12180 REFLATE TB; NCT00822315; REFLATE TB</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10868"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>20</Patients><Biomarkers>CD4; Human immunodeficiency virus ribonucleic acid</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>MVA85A</Interventions><Reference>NCT00395720; TB010</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11188"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>47</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>47</EnrollmentCount><Interventions>efavirenz; lopinavir + ritonavir; nevirapine; rifabutin</Interventions><Reference>ANRS12150b; NCT00651066</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="65639"></Trial><Drug id="4144">Prevnar</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>302</Patients><Biomarkers>Alanine transaminase; Blood platelets; Body temperature; CD40 ligand; Creatinine; Cytotoxic T-Lymphocytes; Hemoglobin; Interferon gamma; Interleukin-2; Leukocyte count; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Menjugate; Polio Sabin; Prevnar; Tritanrix HB</Controls><EnrollmentCount>302</EnrollmentCount><Interventions>GSK-692342; GSK-692342a; Polio Sabin; Prevnar; Tritanrix HB</Interventions><Reference>112899; 2012-004380-44; NCT01098474; TUBERCULOSIS-013 PRI</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics (PK) and Safety of Two Different Doses of Lopinavir/Ritonavir in HIV/Tuberculosis (TB) Co-Infected Patients Receiving Rifampicin Containing Anti-Tuberculosis Therapy</ProtocolTitle><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="67098"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers>CD4; Human immunodeficiency virus RNA; T-Helper Lymphocytes</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>lopinavir + ritonavir; rifampicin</Interventions><Reference>HIV-NAT 104; NCT01138202</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>TIME</ProtocolAcronym><ProtocolTitle>Appropriate Timing of HAART in Co-infected HIV/TB Patients</ProtocolTitle><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="61991"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>156</Patients><Biomarkers>CD4; albumin</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>156</EnrollmentCount><Interventions>efavirenz; lamivudine; lamivudine + efavirenz + tenofovir disoproxil fumarate; tenofovir disoproxil fumarate</Interventions><Reference>0435.3/1551; NCT01014481; TIME</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>STRIDE</ProtocolAcronym><ProtocolTitle>Immediate Versus Deferred Start of Anti-HIV Therapy in HIV Infected Adults Being Treated for Tuberculosis</ProtocolTitle><Sponsor>AIDS Clinical Trials Group</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10681"></Trial><Drug id="14493">tenofovir disoproxil fumarate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>780</Patients><Biomarkers>T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>809</EnrollmentCount><Interventions>efavirenz; emtricitabine; tenofovir disoproxil fumarate; tenofovir disoproxil fumarate + emtricitabine</Interventions><Reference>1U01AI068636; ACTG A5221; ACTG A5221; NCT00108862; STRIDE</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>AERAS 422</ProtocolAcronym><ProtocolTitle>Study of AERAS-422 in Healthy Adults</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="76756"></Trial><Drug id="13624">BCG vaccine, Organon</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Cytokine</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>TiceBCG</Controls><EnrollmentCount>24</EnrollmentCount><Interventions>AERAS-422</Interventions><Reference>AERAS 422; C-007-422; NCT01340820</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EARNEST Rifabutin Pharmacokinetics (PK) Substudy</ProtocolTitle><Sponsor>Joint Clinical Research Centre, Medical Research Council</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="90175"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>140</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>140</EnrollmentCount><Interventions>Aluvia; raltegravir; rifabutin</Interventions><Reference>ISRCTN13074752; NCT01663168</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals Candidate Tuberculosis (TB) Vaccine GSK-692342</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="90314"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers>CD40 ligand; Cytotoxic T-Lymphocytes; IFN-gamma; Interleukin-13; Interleukin-17A; Interleukin-2; Mononuclear leukocytes; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>GSK-692342</Interventions><Reference>116777; 2012-002541-37; NCT01669096</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="71046"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>68</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour</Controls><EnrollmentCount>68</EnrollmentCount><Interventions>bedaquiline</Interventions><Reference>NCT01215110; TMC207-CL001</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-Infection in Vietnam</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11188"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>47</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>47</EnrollmentCount><Interventions>efavirenz; lopinavir + ritonavir; nevirapine; rifabutin</Interventions><Reference>ANRS12150b; NCT00651066</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults</ProtocolTitle><Sponsor>Bayer AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="198748"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>moxifloxacin</Interventions><Reference>14413; 2009-017070-21; NCT01073891</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir or Rifampin</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="86312"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>52</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>52</EnrollmentCount><Interventions>PA-824; efavirenz; lopinavir + ritonavir; rifampin</Interventions><Reference>11829; A5306; ACTG5306; NCT01571414</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>RUTISAPH2</ProtocolAcronym><ProtocolTitle>Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI Following 1 Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection</ProtocolTitle><Sponsor>Archivel Farma SL</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="67014"></Trial><Drug id="57308">RUTI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>90</Patients><Biomarkers>Body temperature; Diastolic blood pressure; Heart rate; Peripheral mononuclear cells; Respiratory frequency; Systolic blood pressure; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>95</EnrollmentCount><Interventions>RUTI</Interventions><Reference>NCT01136161; RUTISAPH2; RUTISAPH2</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Influence of Rifampicin Discontinuation on Rifampicin-Induced Cytochrome P450 Enzyme Activity</ProtocolTitle><Sponsor>Hamamatsu University School of Medicine</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="122291"></Trial><Drug id="44303">midazolam hydrochloride</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>13</Patients><Biomarkers>Cytochrome (CYP) enzyme</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>13</EnrollmentCount><Interventions>caffeine; dextromethorphan; losartan; midazolam; omeprazole; rifampicin</Interventions><Reference>JPRN-UMIN000004083</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Influence of Rifampicin Discontinuation on Rifampicin-Induced Cytochrome P450 Enzyme Activity</ProtocolTitle><Sponsor>Hamamatsu University School of Medicine</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="122291"></Trial><Drug id="44305">omeprazole</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>13</Patients><Biomarkers>Cytochrome (CYP) enzyme</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>13</EnrollmentCount><Interventions>caffeine; dextromethorphan; losartan; midazolam; omeprazole; rifampicin</Interventions><Reference>JPRN-UMIN000004083</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>Pred-ART</ProtocolAcronym><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="150793"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>240</Patients><Biomarkers>Alanine transaminase; Bilirubin; C-reactive protein; Glucose; Hemoglobin; Leukocyte count; Serum potassium; Serum sodium; White blood cell</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>240</EnrollmentCount><Interventions>prednisone</Interventions><Reference>CIDRI_001; DOH-27-0813-4336; NCT01924286; PACTR201304000511413; Pred-ART; SP.2011.41304.074</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="215072"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>113</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>113</EnrollmentCount><Interventions>linezolid</Interventions><Reference>LIN-CL001; NCT02279875</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="158535"></Trial><Drug id="74849">SSI H56-IC31</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>25</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>25</EnrollmentCount><Interventions>SSI H56-IC31</Interventions><Reference>C-032-456; NCT01967134</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK</ProtocolTitle><Sponsor>LegoChem Bioscience Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="265899"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>64</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol hydrochloride; isoniazid; linezolid; pyrazinamide; rifampicin</Controls><EnrollmentCount>64</EnrollmentCount><Interventions>LCB01-0371</Interventions><Reference>2016-0642; KCT0003975; LCB01-0371-15-2-01; NCT02836483</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Once-Daily Dose of Nevirapine (400 mg) Versus Twice Daily Dose (200 mg) of Nevirapine in HIV and Tuberculosis Infection</ProtocolTitle><Sponsor>National AIDS Control Organization</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="126486"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>100</Patients><Biomarkers>CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>efavirenz; lamivudine; nevirapine; nevirapine</Interventions><Reference>CTRI/2012/08/002923</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase III Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="219499"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>109</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>109</EnrollmentCount><Interventions>bedaquiline; bedaquiline; linezolid; pretomanid</Interventions><Reference>NCT02333799; NIX-TB-(B-L-PA)</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="71107"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>65</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour</Controls><EnrollmentCount>85</EnrollmentCount><Interventions>PA-824; Rifafour; TMC-207; moxifloxacin; pyrazinamide</Interventions><Reference>NC-001; NC-001-(J-M-Pa-Z); NCT01215851</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="161275"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>355</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; lamivudine; nevirapine; pyrazinamide; rifampicin; zidovudine</Interventions><Reference>NCT00698334; SKS/NACO/2006</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>TBTC-26 PK</ProtocolAcronym><ProtocolTitle>Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10687"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>230</Patients><Biomarkers>C24; MDR1; N-acetyltransferase; P-glycoprotein</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><EnrollmentCount>230</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Reference>CDC-NCHSTP-4679; NCT00164450; TBTC-26 PK</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>TBTC-23A</ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10652"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>102</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>isoniazid; rifabutin</Interventions><Reference>23A; CDC-NCHSTP-2173; NCT00023348; TBTC-23A</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><Sponsor>Tuberculosis Research Centre</Sponsor><TrialStatus>Suspended</TrialStatus><Trial id="10863"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>116</Patients><Biomarkers>CD4+</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>180</EnrollmentCount><Interventions>didanosine; efavirenz; efavirenz +  didanosine + lamivudine; ethambutol; ethambutol + isoniazid + rifampicin + pyrazinamide; isoniazid; isoniazid + rifampicin; lamivudine; nevirapine; nevirapine + didanosine + lamivudine; pyrazinamide; rifampicin</Interventions><Reference>NCT00332306; trc23</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>N2R</ProtocolAcronym><ProtocolTitle>Efavirenz-Based Versus Nevirapine-Based Antiretroviral Therapy Among HIV-Infected Patients Receiving Rifampin</ProtocolTitle><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10947"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>145</Patients><Biomarkers>CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>142</EnrollmentCount><Interventions>efavirenz; nevirapine</Interventions><Reference>210041000824904203; N2R; NCT00483054</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>PREVENT TB</ProtocolAcronym><ProtocolTitle>A 3 Months of Weekly Rifapentine and Isoniazid for M Tuberculosis Infection</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10659"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>7731</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><EnrollmentCount>8053</EnrollmentCount><Interventions>isoniazid; rifapentine; rifapentine+isoniazid</Interventions><Reference>CDC TBTC Study 26; CDC-NCHSTP-3041; NCT00023452; PREVENT TB; TBTC Study 26; TBTC Study 26/ACTG 5259</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Moxifloxacin_QT Study in Chinese Healthy Volunteer</ProtocolTitle><Sponsor>Peking University Third Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="89715"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>moxifloxacin</Interventions><Reference>DCTC_2012001; NCT01653990</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="132087"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>13</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>37</EnrollmentCount><Interventions>delamanid; optimized background regimen therapy</Interventions><Reference>2012-004473-25; 242-12-232; CTR# 2012-CT0060; NCT01856634; PHRR160526-001027</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Comparative Study of the Bactericidal and Sterilising Activity of Three Fluoroquinolones: Gatifloxacin, Moxifloxacin and Ofloxacin Substituted for Ethambutol in the Two Month Initial Phase of the Standard Anti-Tuberculosis Treatment Regimen Also Containing Rifampicin, Isoniazid and Pyrazinamide (South Africa)</ProtocolTitle><Sponsor>United Nations International Children's Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="152200"></Trial><Drug id="7017">gatifloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>217</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>217</EnrollmentCount><Interventions>gatifloxacin; isoniazid; moxifloxacin; ofloxacin; pyrazinamide; rifampicin</Interventions><Reference>ISRCTN13670619; RPC078</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC-207 in Treatment of Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Johnson &amp; Johnson</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="150059"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>75</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>75</EnrollmentCount><Interventions>bedaquiline; isoniazid; rifampin</Interventions><Reference>PMID:18505852</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Trial Evaluating Safety and Immunogenicity of MVA-85A-IMX3-13 Compared to MVA-85A in BCG Vaccinated Adults</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="142322"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Interferon gamma</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>MVA-85A</Controls><EnrollmentCount>30</EnrollmentCount><Interventions>IMX-461</Interventions><Reference>NCT01879163; TB028; UKCRN 15787</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>Pred-ART</ProtocolAcronym><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="150793"></Trial><Drug id="14493">tenofovir disoproxil fumarate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>240</Patients><Biomarkers>Alanine transaminase; Bilirubin; C-reactive protein; Glucose; Hemoglobin; Leukocyte count; Serum potassium; Serum sodium; White blood cell</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>240</EnrollmentCount><Interventions>prednisone</Interventions><Reference>CIDRI_001; DOH-27-0813-4336; NCT01924286; PACTR201304000511413; Pred-ART; SP.2011.41304.074</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment</ProtocolTitle><Sponsor>Instituto Nacional de Enfermedades Respiratorias</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="169697"></Trial><Drug id="49219">tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>63</Patients><Biomarkers>CD4 + cell</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>63</EnrollmentCount><Interventions>efavirenz; isoniazid; tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Interventions><Reference>C43-06; NCT00737724</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study of ChAdOx1-85A Vaccination With and Without MVA-85A Boost in Healthy Adults</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="120744"></Trial><Drug id="84564">ChAdOx1-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>42</Patients><Biomarkers>T-Lymphocytes</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>42</EnrollmentCount><Interventions>ChAdOx1-85A; ChAdOx1-85A; MVA-85A</Interventions><Reference>NCT01829490; TB034; UKCRN 14241</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Trial to Study the Effectiveness and Safety of 3- and 4-Month Regimens as Compared to the Standard 6-Month Regimen for the Treatment of Infectious Pulmonary Tuberculosis Patients</ProtocolTitle><Sponsor>Indian Council of Medical Research</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="121916"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1650</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>1650</EnrollmentCount><Interventions>moxifloxacin</Interventions><Reference>CTRI/2008/091/000024</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>MTBVAC</ProtocolAcronym><ProtocolTitle>Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine</ProtocolTitle><Sponsor>Biofabri SL</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="164024"></Trial><Drug id="89744">MTBVAC</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>BCG; MTBVAC</Interventions><Reference>MTBVAC; MTBVAC-01; NCT02013245</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Hepatoprotective Effect of Picroliv in Patients Receiving Multi Drug Therapy of Tuberculosis</ProtocolTitle><Sponsor>Central Drug Research Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="127798"></Trial><Drug id="9354">picroliv</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>260</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>260</EnrollmentCount><Interventions>picroliv</Interventions><Reference>CTRI/2012/08/002850; KGMC-CDRI</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>INSPIRING</ProtocolAcronym><ProtocolTitle>Open-Label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV)-Tuberculosis (TB) Co-infection</ProtocolTitle><Sponsor>ViiV Healthcare Ltd</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="201302"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>113</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Carbon dioxide; Chlorine; Creatine kinase; Creatinine; Eosinophils; Erythrocytes; Estimated glomerular filtration rate; Glucose; Hematocrit; Hemoglobin; High-density lipoprotein cholesterol; High-density lipoprotein cholesterol; Human immunodeficiency virus RNA; Lactate dehydrogenase; Leukocyte count; Lipase; Lipids; Lymphocytes; Mean corpuscular volume; Monocytes; Neutrophils; Ox-LDL/ LDL-C ratio; Ox-LDL/ LDL-C ratio; Phosphate; Potassium; Sodium; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; Total cholesterol; Total cholesterol; Triglycerides; Triglycerides; Urea</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>113</EnrollmentCount><Interventions>Group 1; Group 2; dolutegravir; ethambutol; isoniazid; pyrazinamide; rifampicin</Interventions><Reference>117175; ING117175; INSPIRING; NCT02178592</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>ELVIS</ProtocolAcronym><ProtocolTitle>A Trial Investigating the Influence of BCG and Hepatitis B Immunization at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study</ProtocolTitle><Sponsor>Murdoch Childrens Research Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="229498"></Trial><Drug id="6748">Recombivax HB</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>185</Patients><Biomarkers>C-C motif chemokine 2; C-C motif chemokine 3; C-C motif chemokine 4; C-X-C motif chemokine 9; Cytokines; Interferon gamma; Interleukin 1 beta; Interleukin-10; Interleukin-6; Interleukin-8; Macrophage migration inhibitory factor; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>185</EnrollmentCount><Interventions>BCG Vaccine; BCG Vaccine; Recombivax HB; Recombivax HB</Interventions><Reference>ELVIS; NCT02444611; VAC/01 ELVIS</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>iAdhere</ProtocolAcronym><ProtocolTitle>Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention, Tuberculosis Investigation Unit of Barcelona</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="177457"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>1002</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>1002</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Reference>2012-002094-58; CDC-NCHHSTP 6222; NCT01582711; Study 33; TBTC STUDY 33; UITB-TBTC-Estudio33; iAdhere</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open, phase I study to study the pharmacokinetics, safety and tolerability of Perhlozone (400 mg capsules) in healthy volunteers after a single dose</ProtocolTitle><Sponsor>Pharmasyntez</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="167779"></Trial><Drug id="87251">Perchlozone</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>Perchlozone</Interventions><Reference>PERHL-11-2011</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac</ProtocolTitle><Sponsor>Gamalei Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Collaborator</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="373676"></Trial><Drug id="107803">GamTBvac</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>180</Patients><Biomarkers>Immunoglobulin G; Interferon gamma; Interleukin-2; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>180</EnrollmentCount><Interventions>GamTBvac</Interventions><Reference>01-GAMTBVAC-2018; NCT03878004</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>ARTEM-TB STUDY</ProtocolAcronym><ProtocolTitle>Evaluating Pharmacokinetic Interactions Between Artemisinin-Based Therapies and Rifampacin-Based Tuberculosis Treatment in African Patients</ProtocolTitle><Sponsor>Infectious Diseases Institute of Makerer University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="142485"></Trial><Drug id="53041">artesunate + amodiaquine combination tablet (malaria), DNDi/sanofi-aventis</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>artesunate; artesunate + amodiaquine; desethylamodiaquine; dihydroartemisinin; dihydroartemisinin + piperaquine; piperaquine</Interventions><Reference>ARTEM-TB STUDY; HS1294; PACTR201302000483287</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The phase Ia clinical trial of pyrifazimine</ProtocolTitle><Sponsor>Beijing Union Pharmaceutical Factory, Xiyuan Hospital China Academy Of Chinese Medical Sciences</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="356451"></Trial><Drug id="101474">small molecule therapeutic, Beijing Union Pharmaceutical Factory/Institute of Materia Medica</Drug><DevStatus id="C1A">Phase 1a Clinical</DevStatus><Patients>58</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>58</EnrollmentCount><Interventions>pyrifazimine</Interventions><Reference>BUSPF-1801; CTR20181736; ChiCTR1800018780</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>STAND</ProtocolAcronym><ProtocolTitle>Shortening Treatment by Advancing Novel Drugs</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="221844"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>284</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>284</EnrollmentCount><Interventions>moxifloxacin; pretomanid; pyrazinamide</Interventions><Reference>2014-CT0249; NC-006-(M-PA-Z); NC-006-(M-Pa-Z); NC-006-(M-Pa-Z) 21522; NCT02342886; NMRR-14-702-21522; PHRR150114-000899; STAND</Reference></Row><Row><ArmCount>5+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd, Syneos Health Inc</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="224111"></Trial><Drug id="46931">cefadroxil</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>45</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>45</EnrollmentCount><Interventions>Augmentin; cefadroxil; cefadroxil; ethambutol; faropenem; faropenem; isoniazid; pyrazinamide; rifampicin</Interventions><Reference>2015-CT0284; FAROPENEM_TB; NCT02381470; PHRR160323-001194</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SUDOCU</ProtocolAcronym><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="381674"></Trial><Drug id="11088">sutezolid</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>75</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>bedaquiline; delamanid; moxifloxacin</Controls><EnrollmentCount>75</EnrollmentCount><Interventions>bedaquiline; delamanid; midazolam; moxifloxacin; sutezolid</Interventions><Reference>NCT03959566; PANACEA-SUDOCU-01; SUDOCU</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><Sponsor>Beijing Chest Hospital, Beijing Tuberculosis &amp; Thoracic Tumor Research Institute, Capital Medical University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="244777"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>clarithromycin; levofloxacin; moxifloxacin; moxifloxacin; rifabutin</Interventions><Reference>ChiCTR-IOR-15007291</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-Limited Settings</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="8820"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>592</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>592</EnrollmentCount><Interventions>didanosine; efavirenz; lamivudine; standard TB therapy</Interventions><Reference>CAPRISA 001; CAPRISA START; CIPRA; NCT00091936; START</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>MDR-END</ProtocolAcronym><ProtocolTitle>Treatment Shortening of MDR-TB Using Existing and New Drugs</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="247456"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>238</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>pyrazinamide</Controls><EnrollmentCount>238</EnrollmentCount><Interventions>delamanid; levofloxacin; linezolid; pyrazinamide</Interventions><Reference>MDR-END; NCT02619994</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa</ProtocolTitle><Sponsor>International AIDS Vaccine Initiative</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="275657"></Trial><Drug id="89744">MTBVAC</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>120</Patients><Biomarkers>Cytokines; Cytotoxic T-Lymphocytes; T-Helper Lymphocytes; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>BCG vaccine</Controls><EnrollmentCount>120</EnrollmentCount><Interventions>MTBVAC</Interventions><Reference>A-050; NCT02933281</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>LAST ACT</ProtocolAcronym><ProtocolTitle>Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis</ProtocolTitle><Sponsor>Oxford University Clinical Research Unit, Vietnam</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="293087"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>640</Patients><Biomarkers>Bilirubin; International Normalized Ratio; Leukotriene A-4 hydrolase; Transaminases</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>640</EnrollmentCount><Interventions>dexamethasone</Interventions><Reference>27TB; LAST ACT; NCT03100786</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase III Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="219499"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>109</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>109</EnrollmentCount><Interventions>bedaquiline; bedaquiline; linezolid; pretomanid</Interventions><Reference>NCT02333799; NIX-TB-(B-L-PA)</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>DAZZLE</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin</ProtocolTitle><Sponsor>Boston University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="280651"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>WHO approved regimen-based therapy</Controls><EnrollmentCount></EnrollmentCount><Interventions>Deltyba; Levaquin; Zyvox; pyrazinamide</Interventions><Reference>DAZZLE; H-36160; NCT02975570</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>REFLATE TB2</ProtocolAcronym><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Sponsor>INSERM</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="214156"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>460</Patients><Biomarkers>Human immunodeficiency virus RNA; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; tenofovir disoproxil fumarate</Controls><EnrollmentCount>460</EnrollmentCount><Interventions>lamivudine; raltegravir; rifampin; tenofovir disoproxil fumarate</Interventions><Reference>ANRS 12300 REFLATE TB2; NCT02273765; REFLATE TB2</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>TB-PRACTECAL</ProtocolAcronym><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Sponsor>Medecins Sans Frontieres</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="244304"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>630</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>630</EnrollmentCount><Interventions>Lamprene; bedaquiline; linezolid; moxifloxacin; pretomanid</Interventions><Reference>1541; NCT02589782; TB-PRACTECAL</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>The V-QUIN MDR Trial</ProtocolAcronym><ProtocolTitle>A randomized, controlled trial of 6 months of daily levofloxacin for the prevention of tuberculosis among household contacts of patients with multi-drug resistant tuberculosis</ProtocolTitle><Sponsor>University of Sydney</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="269403"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2006</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>2006</EnrollmentCount><Interventions>levofloxacin</Interventions><Reference>2014/929; 4040/QD-BYT; ACTRN12616000215426; ANZCTR369817; NHMRC APP#1081443; The V-QUIN MDR Trial; U1111-1177-9052</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetic study and safety of levofloxacin in pediatric tuberculosis treatment</ProtocolTitle><Sponsor>Center of Excellence for Pediatric Infectious Diseases and Vaccines</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="381490"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Creatinine</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>levofloxacin</Interventions><Reference>IRB 607/61; TCTR20190515001</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>BDQ Crush</ProtocolAcronym><ProtocolTitle>TASK-002: Bioequivalence of Bedaquiline 400 mg Administered in Crushed Form Compared to Tablet Form in Healthy Male and Female Adults Under Fed Conditions</ProtocolTitle><Sponsor>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="286376"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>Sirturo</Interventions><Reference>BDQ Crush; NCT03032367; TASK-002</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="307654"></Trial><Drug id="7017">gatifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>448</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Reference>CAP 020; InDEX; NCT03237182</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of rosuvastatin on HIV TB coinfection</ProtocolTitle><Sponsor>Armed Forces Medical College</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="292154"></Trial><Drug id="12420">rosuvastatin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>50</Patients><Biomarkers>C-reactive protein; Erythrocyte sedimentation rate; T-Helper Lymphocytes; T-Lymphocytes; T-cell surface glycoprotein CD4; Total body mass; Vitamin D</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>rosuvastatin</Interventions><Reference>CTRI/2017/03/008171</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating the Pharmacokinetics, Safety and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases, National Institutes of Health</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="297373"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>48</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>delamanid; optimized multidrug background regimen therapy</Interventions><Reference>20721; CTRI/2018/01/011298; IMPAACT 2005; NCT03141060</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="307654"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>448</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Reference>CAP 020; InDEX; NCT03237182</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="307654"></Trial><Drug id="52139">ofloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>448</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Reference>CAP 020; InDEX; NCT03237182</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>STREAM</ProtocolAcronym><ProtocolTitle>The Evaluation of a Standard Treatment Regimen of Anti-Tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Sponsor>International Union Against Tuberculosis and Lung Diseases</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="228190"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>530</Patients><Biomarkers>4 beta-Hydroxycholesterol/Cholesterol ratio</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Lamprene; ethambutol (Myambutol); isoniazid (Nydrazid); kanamycin (Kantrex); moxifloxacin; prothionamide (Peteha); pyrazinamide (Zinamide)</Controls><EnrollmentCount>530</EnrollmentCount><Interventions>Lamprene; Regimen A locally-used WHO-approved MDR-TB regimen; bedaquiline; ethambutol (Myambutol); isoniazid (Nydrazid); kanamycin (Kantrex); levofloxacin; moxifloxacin; prothionamide (Peteha); pyrazinamide (Zinamide)</Interventions><Reference>18148631; 78372190; 78372190/18148631 (Stage 1/2); CTRI/2017/09/009693; ISRCTN78372190; NCT02409290; STREAM</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>PRACTECAL-PRO</ProtocolAcronym><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><Sponsor>Medecins Sans Frontieres, Netherlands</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="379769"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>54</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Directly observed therapy</Controls><EnrollmentCount>54</EnrollmentCount><Interventions>bedaquiline; clofazimine; linezolid; moxifloxacin; pretomanid</Interventions><Reference>NCT03942354; PRACTECAL-PRO; PRACTECAL-PRO</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study on Tuberculosis Resistant to Treatment</ProtocolTitle><Sponsor>Indian Council of Medical Research, Tuberculosis Research Centre</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="369747"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>165</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>165</EnrollmentCount><Interventions>Zyvox; bedaquiline; clofazimine; delamanid</Interventions><Reference>CTRI/2019/01/017310; Version Number: 3.1</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>PRACTECAL-PRO</ProtocolAcronym><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><Sponsor>Medecins Sans Frontieres, Netherlands</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="379769"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>54</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Directly observed therapy</Controls><EnrollmentCount>54</EnrollmentCount><Interventions>bedaquiline; clofazimine; linezolid; moxifloxacin; pretomanid</Interventions><Reference>NCT03942354; PRACTECAL-PRO; PRACTECAL-PRO</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of faropenem and cefadroxil (in combination with amoxicillin/clavulanic acid and standard TB drugs) in patients with pulmonary tuberculosis: measurement of early bactericidal activity and effects on novel biomarkers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="360329"></Trial><Drug id="44279">amoxicillin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>45</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>amoxicillin; cefadroxil; clavulanic acid; ethambutol; faropenem; isoniazid; pyrazinamide; rifampicin</Interventions><Reference>2018-CT0454; 20180710115454; Faropenem_TB; PHRR181108-001980</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>THYB-04</ProtocolAcronym><ProtocolTitle>THYB-04</ProtocolTitle><Sponsor>Statens Serum Institut</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="285704"></Trial><Drug id="53784">Ag85B-ESAT-6 vaccine (IC31 adjuvant, tuberculosis), SSI/ Valneva</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>240</Patients><Biomarkers>Interferon gamma; Interleukin-2; T-Helper Lymphocytes; T-Lymphocytes; T-cell surface glycoprotein CD4; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>240</EnrollmentCount><Interventions>Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Interventions><Reference>DoH-27-0612-3947; PACTR201403000646306; THYB-04</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Trial Evaluating Safety and Immunogenicity of MVA-85A-IMX3-13 Compared to MVA-85A in BCG Vaccinated Adults</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="142322"></Trial><Drug id="66409">IMX-461</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Interferon gamma</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>MVA-85A</Controls><EnrollmentCount>30</EnrollmentCount><Interventions>IMX-461</Interventions><Reference>NCT01879163; TB028; UKCRN 15787</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="307654"></Trial><Drug id="2829">clarithromycin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>448</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Reference>CAP 020; InDEX; NCT03237182</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Study of H56:IC31 in Healthy Adolescents</ProtocolTitle><Sponsor>Aeras, Aeras Global TB Vaccine Foundation</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="310653"></Trial><Drug id="74849">SSI H56-IC31</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients></Patients><Biomarkers>Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-2; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>SSI H56-IC31</Interventions><Reference>A-043; NCT03265977; PACTR201704002006214</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating the Safety, Tolerability and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="243619"></Trial><Drug id="59062">dolutegravir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>84</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>84</EnrollmentCount><Interventions>bedaquiline; bedaquiline; delamanid; delamanid; dolutegravir</Interventions><Reference>12005; A5343; NCT02583048</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects</ProtocolTitle><Sponsor>ViiV Healthcare Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="298711"></Trial><Drug id="69974">cabotegravir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>15</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Calcium; Carbon dioxide; Chlorides; Creatine kinase; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Glucose; Heart rate; Hematocrit; Hemoglobin; Leukocyte count; Lymphocytes; Mean corpuscular hemoglobin; Mean corpuscular volume; Monocytes; Neutrophils; Potassium; Reticulocytes; Sodium; Systolic blood pressure; Urea; gamma-Glutamyltransferase</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>15</EnrollmentCount><Interventions>cabotegravir; cabotegravir; rifabutin</Interventions><Reference>205712; NCT03149848</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, comparative, controlled, open-label clinical study of efficacy and safety of Ingaron (recombinant human interferon gamma) production of "NPP" FARMAKLON, Russia in the treatment of patients with pulmonary tuberculosis</ProtocolTitle><Sponsor>PHARMACLON LLC</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="194177"></Trial><Drug id="81264">interferon gamma follow-on biologic, PHARMACLON LLC</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>90</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>Ingaron</Interventions><Reference>ING-08-12</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>TB036</ProtocolAcronym><ProtocolTitle>Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA-85A in BCG-vaccinated African Adolescents</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="201409"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Cytokines</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>MVA-85A</Interventions><Reference>NCT02178748; TB036; TB036</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>BRIEF TB</ProtocolAcronym><ProtocolTitle>Brief Rifapentine-Isoniazid Evaluation for TB Prevention</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="79741"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>3000</Patients><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Bilirubin; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid; isoniazid; pyridoxine</Controls><EnrollmentCount>3000</EnrollmentCount><Interventions>efavirenz; isoniazid; pyridoxine; rifapentine</Interventions><Reference>10848; A5279; ACTG A5279; BRIEF TB; BRIEF TB/A5279; NCT01404312</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability And Pharmacokinetics Study Of Single-Doses Of PNU-100480 In Healthy Adults</ProtocolTitle><Sponsor>Sequella Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="50188"></Trial><Drug id="11088">sutezolid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>19</Patients><Biomarkers>CPK</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>19</EnrollmentCount><Interventions>PNU-100480</Interventions><Reference>B1171001; NCT00871949</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized Clinical Trial to Study the Efficacy and Tolerability of a 4-Month Regimen Containing Ofloxacin Compared to the Standard 6-Month Regimen in the Treatment of Patients with Superficial Lymphnode Tuberculosis</ProtocolTitle><Sponsor>Indian Council of Medical Research</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="142516"></Trial><Drug id="52139">ofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>420</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>420</EnrollmentCount><Interventions>isoniazid; ofloxacin; pyrazinamide; rifampicin</Interventions><Reference>CTRI/2013/03/003481</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="210646"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>240</Patients><Biomarkers>Alanine transaminase; Aspartate aminotransferase; QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyraziminide; rifampicin</Controls><EnrollmentCount>240</EnrollmentCount><Interventions>bedaquiline; moxifloxacin; pretomanid; pyraziminide</Interventions><Reference>NC-005; NC-005-(J-M-PA-Z); NCT02193776</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>Pred-ART</ProtocolAcronym><ProtocolTitle>Preventing TB-IRIS in High-risk Patients: a Randomized, Placebo-controlled Trial of Prednisone</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="150793"></Trial><Drug id="4728">emtricitabine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>240</Patients><Biomarkers>Alanine transaminase; Bilirubin; C-reactive protein; Glucose; Hemoglobin; Leukocyte count; Serum potassium; Serum sodium; White blood cell</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>240</EnrollmentCount><Interventions>prednisone</Interventions><Reference>CIDRI_001; DOH-27-0813-4336; NCT01924286; PACTR201304000511413; Pred-ART; SP.2011.41304.074</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>OPTI-NNRTI</ProtocolAcronym><ProtocolTitle>A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV</ProtocolTitle><Sponsor>Stanford University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="11177"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>5</Patients><Biomarkers>CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>5</EnrollmentCount><Interventions>efavirenz; nevirapine</Interventions><Reference>NCT00523458; OPTI-NNRTI; Stanford Protocol ID: 95564</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="62096"></Trial><Drug id="53975">AERAS-402</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>26</Patients><Biomarkers>85A; 85B; CD4; CD8; Cytotoxic T-Lymphocytes; IFN-gamma; IL-2; T-Helper Lymphocytes; T-Lymphocytes; TB10.4; TNF-alpha</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>26</EnrollmentCount><Interventions>AERAS-402</Interventions><Reference>C-017-402; NCT01017536</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Linezolid in Adults with Pulmonary Tuberculosis</ProtocolTitle><Sponsor></Sponsor><TrialStatus>Completed</TrialStatus><Trial id="150522"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>19</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>19</EnrollmentCount><Interventions>linezolid</Interventions><Reference>PMC2737850; PMID:19564361</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11187"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>35</Patients><Biomarkers>Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>efavirenz; isoniazid; lamivudine; lopinavir + ritonavir; nevirapine; rifabutin; stavudine</Interventions><Reference>ANRS12150a; NCT00640887</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><Sponsor>Central Research Institute of Epidemiology</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="63729"></Trial><Drug id="54488">raltegravir</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>abacavir; lamivudine; raltegravir</Interventions><Reference>NCT01059422; RAL/ABC/3TC - HIV/TB</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-Tuberculosis Treatment</ProtocolTitle><Sponsor>Tuberculosis Research Centre</Sponsor><TrialStatus>Suspended</TrialStatus><Trial id="10863"></Trial><Drug id="2935">didanosine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>116</Patients><Biomarkers>CD4+</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>180</EnrollmentCount><Interventions>didanosine; efavirenz; efavirenz +  didanosine + lamivudine; ethambutol; ethambutol + isoniazid + rifampicin + pyrazinamide; isoniazid; isoniazid + rifampicin; lamivudine; nevirapine; nevirapine + didanosine + lamivudine; pyrazinamide; rifampicin</Interventions><Reference>NCT00332306; trc23</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Treatment of Tuberculosis in HIV-Infected Patients</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10643"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>650</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>650</EnrollmentCount><Interventions>ethambutol hydrochloride; isoniazid; levofloxacin; pyrazinamide; pyridoxine hydrochloride; rifampin</Interventions><Reference>11199; ACTG 222; CPCRA 019; NCT00001033</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of Sputum Conversion Rates, Plasma Rifampicin Levels and Cyp 450 Activity Pulmonary Tuberculosis Patients Have Received 8 Weeks of Intensive Phase Therapy With Standard Dose Regimen Versus Risorine Kit</ProtocolTitle><Sponsor>Cadila Pharmaceuticals Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="142231"></Trial><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Cyp 450</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Mycocox-4</Controls><EnrollmentCount>100</EnrollmentCount><Interventions>Risorine; ethambutol; pyrazinamide</Interventions><Reference>CRSC12004; CTRI/2012/11/003097</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of MVA-85A, in Asymptomatic Volunteers Infected With TB, HIV or Both</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="14589"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>48</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>MVA-85A</Interventions><Reference>NCT00480558; TB011</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Raltegravir + ABC/3TC in HIV/TB Co-Infected Patients</ProtocolTitle><Sponsor>Central Research Institute of Epidemiology</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="63729"></Trial><Drug id="6242">abacavir</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>abacavir; lamivudine; raltegravir</Interventions><Reference>NCT01059422; RAL/ABC/3TC - HIV/TB</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients</ProtocolTitle><Sponsor>University Medical Center Groningen</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="182646"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>7</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>7</EnrollmentCount><Interventions>clarithromycin; linezolid; linezolid + clarithromycin</Interventions><Reference>2011-000513-39; NCT01521364; NL35534.042.11; NTR3260</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>CARINEMO</ProtocolAcronym><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10948"></Trial><Drug id="4481">stavudine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>570</Patients><Biomarkers>Alanine aminotransferase; CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; stavudine</Controls><EnrollmentCount>570</EnrollmentCount><Interventions>Arm A; Arm B; Triomune; ethambutol; ethambutol; isoniazid; isoniazid; lamivudine; nevirapine; pyrazinamide; pyrazinamide; rifampicin; rifampicin; stavudine</Interventions><Reference>ANRS 12146 CARINEMO; ANRS 12146/12214; ANRS 12214; CARINEMO; NCT00495326</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of SQ-109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="109063"></Trial><Drug id="31010">SQ-109</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>365</Patients><Biomarkers>Visual acuity</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>365</EnrollmentCount><Interventions>SQ-109; ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyridoxine; rifampicin</Interventions><Reference>NCT01785186; PACTR201205000383208; PanACEA-MAMS-TB-01</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>REFLATE TB</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="40948"></Trial><Drug id="14493">tenofovir disoproxil fumarate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>155</Patients><Biomarkers>Human immunodeficiency virus DNA; Human immunodeficiency virus RNA; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; tenofovir disoproxil fumarate</Controls><EnrollmentCount>155</EnrollmentCount><Interventions>lamivudine; raltegravir; tenofovir disoproxil fumarate</Interventions><Reference>2008-004970-41; ANRS 12 180; ANRS 12180 REFLATE TB; NCT00822315; REFLATE TB</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>ANRS 1295 CAMELIA</ProtocolAcronym><ProtocolTitle>Early versus Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="145651"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>540</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>661</EnrollmentCount><Interventions>efavirenz; efavirenz + lamivudine + stavudine; lamivudine; stavudine</Interventions><Reference>ANRS 1295 CAMELIA; ANRS 1295 CAMELIA; CIPRA KH 001; NCT00226434; NCT00498823</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Early Access of TMC-207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="82132"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>295</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>295</EnrollmentCount><Interventions>bedaquiline</Interventions><Reference>2010-021125-12; CR017233; NCT01464762; TMC207TBC3001</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym>NC-003</ProtocolAcronym><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC-207 (J)-PA-824 (Pa)-Pyrazinamide (Z)</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="92275"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>105</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour e</Controls><EnrollmentCount>105</EnrollmentCount><Interventions>PA-824; TMC-207; clofazimine; clofazimine; pyrazinamide; pyrazinamide</Interventions><Reference>NC-003; NC-003-(C-J-Pa-Z); NCT01691534</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I, ID93 + GLA-SE Vaccine Trial in BCG-vaccinated Healthy Adult Volunteers</ProtocolTitle><Sponsor>Infectious Disease Research Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="151743"></Trial><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>66</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>66</EnrollmentCount><Interventions>ID-93</Interventions><Reference>IDRI-TBVPX-114; NCT01927159</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>05TB</ProtocolAcronym><ProtocolTitle>A randomized, double-blind, placebo-controlled trial to investigate the effect of intensified treatment with high dose rifampicin and levofloxacin for adult patients with tuberculous meningitis</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="75317"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>817</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>750</EnrollmentCount><Interventions>ethambutol; isoniazid; levofloxacin; pyrazinamide; rifampicin; streptomycin</Interventions><Reference>05TB; 084253; 084253; ISRCTN61649292; OXTREC No 33/09</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="162886"></Trial><Drug id="15298">Pentacel</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Anti-Meningitis C antibodies; C-C motif chemokine 2; C-C motif chemokine 3; C-C motif chemokine 4; Cytokines; IgG; Interferon gamma; Interferon-alpha; Interleukin-1 alpha; Interleukin-1 beta; Interleukin-10; Interleukin-12; Interleukin-13; Interleukin-2; Interleukin-6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>BCG; Infanrix; Menitorix; NeisVac-C; Pentacel; Prevnar 13; Priorix; Rotarix</Interventions><Reference>2013-003488-71; BAM; NCT02002156; OVG-2013/04; UKCRN 15722</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>USPHS-23</ProtocolAcronym><ProtocolTitle>Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen</ProtocolTitle><Sponsor>National Institutes of Health</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="10648"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>efavirenz; rifabutin</Interventions><Reference>NCRR-M01RR00030-0162; NCT00018083; USPHS-23</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>CARINEMO</ProtocolAcronym><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10948"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>570</Patients><Biomarkers>Alanine aminotransferase; CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; stavudine</Controls><EnrollmentCount>570</EnrollmentCount><Interventions>Arm A; Arm B; Triomune; ethambutol; ethambutol; isoniazid; isoniazid; lamivudine; nevirapine; pyrazinamide; pyrazinamide; rifampicin; rifampicin; stavudine</Interventions><Reference>ANRS 12146 CARINEMO; ANRS 12146/12214; ANRS 12214; CARINEMO; NCT00495326</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Glutoxim in the Surgical Treatment of Patients With Pulmonary Tuberculosis</ProtocolTitle><Sponsor></Sponsor><TrialStatus>Completed</TrialStatus><Trial id="149224"></Trial><Drug id="28379">Glutoxim</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>54</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>54</EnrollmentCount><Interventions>Glutoxim</Interventions><Reference>PMID:17598458</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IIa clinical trial for a novel molecule (LL-3858) developed by Lupin Limited which has the potential of treating the Pulmonary tuberculosis patients effectively</ProtocolTitle><Sponsor>Lupin Ltd</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="103573"></Trial><Drug id="49162">LL-3858</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>LL-3858</Interventions><Reference>CTRI/2009/091/000741; LRP/CTP/022/3858/II/01</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects</ProtocolTitle><Sponsor>Abbott Laboratories</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="25327"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>15</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>15</EnrollmentCount><Interventions>lopinavir + ritonavir; rifabutin</Interventions><Reference>M10-457; NCT00743470</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>PK-TB-HAART</ProtocolAcronym><ProtocolTitle>Bioavailability of the Fixed Dose Formulation Rifafour Containing Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and the World Health Organization (WHO) Recommended First Line Antiretroviral Drugs Zidovudine, Lamivudine, Efavirenz Administered to New Tuberculosis (TB) Patients at Different Levels of Immunosuppression</ProtocolTitle><Sponsor>World Health Organization</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="136052"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>Rifafour; Rifafour; efavirenz; lamivudine; zidovudine</Interventions><Reference>A40607; ISRCTN83323477; PK-TB-HAART</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11187"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>35</Patients><Biomarkers>Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>efavirenz; isoniazid; lamivudine; lopinavir + ritonavir; nevirapine; rifabutin; stavudine</Interventions><Reference>ANRS12150a; NCT00640887</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Combination of Two Drugs in Tuberculosis Treatment</ProtocolTitle><Sponsor>SRM University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="224091"></Trial><Drug id="69440">rifampicin + isoniazid + piperine (fixed dose combination, tuberculosis), Cadila Pharmaceuticals</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>60</EnrollmentCount><Interventions>Risorine</Interventions><Reference>CTRI/2015/01/005475</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>IPEC-EFV</ProtocolAcronym><ProtocolTitle>Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X  800 mg</ProtocolTitle><Sponsor>Fundacao Oswaldo Cruz (Fiocruz)</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="11181"></Trial><Drug id="44316">zidovudine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>130</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>130</EnrollmentCount><Interventions>efavirenz; isoniazid; lamivudine; pyrazinamide; rifampicin; zidovudine</Interventions><Reference>CAAE-0017.1.009.000-03; IPEC-EFV; NCT00533390</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>TIME</ProtocolAcronym><ProtocolTitle>Appropriate Timing of HAART in Co-infected HIV/TB Patients</ProtocolTitle><Sponsor>Bamrasnaradura Infectious Diseases Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="61991"></Trial><Drug id="3474">lamivudine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>156</Patients><Biomarkers>CD4; albumin</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>156</EnrollmentCount><Interventions>efavirenz; lamivudine; lamivudine + efavirenz + tenofovir disoproxil fumarate; tenofovir disoproxil fumarate</Interventions><Reference>0435.3/1551; NCT01014481; TIME</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>Map2Co</ProtocolAcronym><ProtocolTitle>Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana</ProtocolTitle><Sponsor>kwame Nkrumah University of Science and Technology</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="214864"></Trial><Drug id="46927">doxycycline hyclate</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>200</Patients><Biomarkers>Th1 cytokines</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>doxycycline (once-daily, oral controlled release), CollaGenex; doxycycline hyclate</Interventions><Reference>GZ:JA 1479/5-1; Map2Co; NCT02281643</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intervention study in rural residents (50 to 70 years old) with latent Mycobacterium tuberculosis infection</ProtocolTitle><Sponsor>Chinese Academy of Medical Sciences &amp; Peking Union Medical College</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="243294"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>3738</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>3900</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Reference>ChiCTR-IOR-15007202</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TBA-354 in Healthy Adult Subjects</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="215600"></Trial><Drug id="71742">TBA-354</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>48</Patients><Biomarkers>Heart rate; PR interval; QRS complex; QT interval; T-wave</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>TBA-354</Interventions><Reference>NCT02288481; TBA-354-CL-001</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ-169 in Multiple Dosing</ProtocolTitle><Sponsor>Innovative Medicines for Tuberculosis</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="363587"></Trial><Drug id="90085">macozinone</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>32</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>32</EnrollmentCount><Interventions>PBTZ-169</Interventions><Reference>IM-006-13; NCT03776500</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EMaBS TB Vaccine Study</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="354327"></Trial><Drug id="84564">ChAdOx1-85A</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>72</Patients><Biomarkers>B-lymphocytes; Neutrophils; T-Lymphocytes</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>BCG vaccine</Controls><EnrollmentCount>72</EnrollmentCount><Interventions>ChAdOx1-85A; ChAdOx1-85A; MVA-85A</Interventions><Reference>NCT03681860; TB042</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="300655"></Trial><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>88</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>88</EnrollmentCount><Interventions>Augmentin; Merrem; rifampin</Interventions><Reference>FD-R-05724; IRB00119017; NCT03174184</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Population Pharmacokinetics and Pharmacodynamics Modeling to Optimize Dosage Regimen of Levofloxacin</ProtocolTitle><Sponsor>Prince of Songkla University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="254949"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>45</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>levofloxacin</Interventions><Reference>LEVO-57-356141; NCT02699658</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB</ProtocolTitle><Sponsor>Drugs for Neglected Diseases Initiative</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="220686"></Trial><Drug id="105321">superboosted lopinavir + ritonavir (pediatric oral formulation, HIV infection), DNDi</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>96</Patients><Biomarkers>Alanine transaminase</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>96</EnrollmentCount><Interventions>rifampicin; superboosted lopinavir + ritonavir (pediatric oral formulation, HIV infection), DNDi</Interventions><Reference>DNDiHIVPed001; NCT02348177</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="307654"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>448</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Reference>CAP 020; InDEX; NCT03237182</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>PRIDE-HT</ProtocolAcronym><ProtocolTitle>PK Study of Rifampicin Interactions With DMPA and Efaviranz in TB</ProtocolTitle><Sponsor>AIDS Clinical Trials Group</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="227340"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>62</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>62</EnrollmentCount><Interventions>depot medroxyprogesterone acetate; efavirenz; isoniazid; rifampicin</Interventions><Reference>ACTG A5338; NCT02412436; PRIDE-HT; UM1AI068636</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>GRACE-TB</ProtocolAcronym><ProtocolTitle>NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB</ProtocolTitle><Sponsor>Huashan Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="348056"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>488</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>amikacin; cycloserine; moxifloxacin; prothionamide; pyrazinamide</Controls><EnrollmentCount>488</EnrollmentCount><Interventions>amikacin; clofazimine; cycloserine; ethambutol; linezolid; moxifloxacin; prothionamide; pyrazinamide</Interventions><Reference>GRACE-TB; KY2018-291; NCT03604848</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Task Foundation NPC</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="220739"></Trial><Drug id="4492">faropenem</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour e275; ethambutol; isoniazid; pyrazinamide; rifampin</Controls><EnrollmentCount>46</EnrollmentCount><Interventions>amoxicillin + clavulanate potassium, GSK; faropenem; meropenem</Interventions><Reference>NCT02349841; TASK-001</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Task Foundation NPC</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="220739"></Trial><Drug id="3616">meropenem</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour e275; ethambutol; isoniazid; pyrazinamide; rifampin</Controls><EnrollmentCount>46</EnrollmentCount><Interventions>amoxicillin + clavulanate potassium, GSK; faropenem; meropenem</Interventions><Reference>NCT02349841; TASK-001</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="37985"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>155</Patients><Biomarkers>Cytochrome P450 2B6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>155</EnrollmentCount><Interventions>efavirenz; neucleotide reverse transcriptase inhibitors; rifampin</Interventions><Reference>10633; IMPAACT P1070; NCT00802802; P1070</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>STAND</ProtocolAcronym><ProtocolTitle>Shortening Treatment by Advancing Novel Drugs</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="221844"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>284</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>284</EnrollmentCount><Interventions>moxifloxacin; pretomanid; pyrazinamide</Interventions><Reference>2014-CT0249; NC-006-(M-PA-Z); NC-006-(M-Pa-Z); NC-006-(M-Pa-Z) 21522; NCT02342886; NMRR-14-702-21522; PHRR150114-000899; STAND</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating the Safety, Tolerability and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="243619"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>84</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>84</EnrollmentCount><Interventions>bedaquiline; bedaquiline; delamanid; delamanid; dolutegravir</Interventions><Reference>12005; A5343; NCT02583048</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Anti-bacterial Activity, Safety, and Tolerability of TMC-207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB)</ProtocolTitle><Sponsor>Janssen R&amp;D (Ireland)</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9302"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>160</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>208</EnrollmentCount><Interventions>bedaquiline</Interventions><Reference>2007-004462-40; CR011929; NCT00449644; NCT00614627; NCT00980265; TMC207-TIDP13-C208</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>MDR-END</ProtocolAcronym><ProtocolTitle>Treatment Shortening of MDR-TB Using Existing and New Drugs</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="247456"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>238</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>pyrazinamide</Controls><EnrollmentCount>238</EnrollmentCount><Interventions>delamanid; levofloxacin; linezolid; pyrazinamide</Interventions><Reference>MDR-END; NCT02619994</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Study Effect of Two Vaccines in Preventing Spread of Tuberculosis in Persons Living With New Tuberculosis Patients</ProtocolTitle><Sponsor>Indian Council of Medical Research</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="366261"></Trial><Drug id="55569">VPM-1002</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>12000</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>12000</EnrollmentCount><Interventions>Immuvac; VPM-1002</Interventions><Reference>CTRI/2019/01/017026; ICMR/ITRC/VAC/001/2018, Version 1.5, dated 3rd october 2018</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>DAZZLE</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin</ProtocolTitle><Sponsor>Boston University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="280651"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>WHO approved regimen-based therapy</Controls><EnrollmentCount></EnrollmentCount><Interventions>Deltyba; Levaquin; Zyvox; pyrazinamide</Interventions><Reference>DAZZLE; H-36160; NCT02975570</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Single Ascending Dose Study Of BTZ-043</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="346718"></Trial><Drug id="70901">BTZ-043</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>BTZ-043</Interventions><Reference>LMU-IMPH-BTZ043-01; NCT03590600</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>PRACTECAL-PRO</ProtocolAcronym><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><Sponsor>Medecins Sans Frontieres, Netherlands</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="379769"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>54</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Directly observed therapy</Controls><EnrollmentCount>54</EnrollmentCount><Interventions>bedaquiline; clofazimine; linezolid; moxifloxacin; pretomanid</Interventions><Reference>NCT03942354; PRACTECAL-PRO; PRACTECAL-PRO</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>ZeNiX</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre-XDR-TB or Non-responsive/Intolerant MDR-TB</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="293734"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>180</Patients><Biomarkers>Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>180</EnrollmentCount><Interventions>bedaquiline; linezolid; pretomanid</Interventions><Reference>NC-007- (B-Pa-L); NCT03086486; ZENIX (B-PA-L) NC-007; ZeNiX</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis</ProtocolTitle><Sponsor>Food and Drug Administration, Johns Hopkins University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="8791"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>146</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol</Controls><EnrollmentCount>170</EnrollmentCount><Interventions>moxifloxacin</Interventions><Reference>FD-R-002135-01; NCT00082173</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>PANDEMIC</ProtocolAcronym><ProtocolTitle>A study on the uptake, distribution and excretion of bedaquiline, a medicine against tuberculosis, in people with type 2 diabetes</ProtocolTitle><Sponsor>University Medical Center Groningen</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="331962"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Cytochrome P450 3A4; Hemoglobin A, glycosylated; Total body mass; Urinary albumin to creatinine ratio</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>bedaquiline</Interventions><Reference>2017-004490-14; 2017-004490-14 201700787; NTR7045; PANDEMIC</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK-3036656 in Healthy Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="290705"></Trial><Drug id="70581">GSK-3036656</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Body temperature; Calcium; Creatinine; Diastolic blood pressure; Eosinophils; Glucose; Heart rate; Heart rate; Hematocrit; Hemoglobin; Ketones; Lymphocytes; Mean corpuscular hemoglobin; Monocytes; Neutrophils; PR interval; Potassium; QRS complex; QT interval; Reticulocytes; Sodium; Systolic blood pressure; Total cholesterol; Total protein; Triglycerides; Troponin; Urea nitrogen</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>GSK-3036656</Interventions><Reference>201040; 2015-003654-41; NCT03075410</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="245694"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>18</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>celecoxib; celecoxib; pyrazinamide; pyrazinamide; rifampicin; rifampicin</Interventions><Reference>CELECOXIB_WBA; NCT02602509</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Trial to Study Four Different Doses of the Vaccine RUTI in Healthy Volunteers</ProtocolTitle><Sponsor>Germans Trias i Pujol Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="8888"></Trial><Drug id="57308">RUTI</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>RUTI</Interventions><Reference>EudraCT Number: 2006-000690-29; FA/MI/01; NCT00546273</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="375406"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>48</Patients><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Bilirubin; Blood pressure; Body temperature; Creatinine; Estimated glomerular filtration rate; Heart rate; Hemoglobin; Magnesium; Potassium; QT interval; Urea nitrogen</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>pretomanid</Interventions><Reference>15-0037; HHSN272201300021I; NCT03896750</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>DRAMATIC</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Sponsor>Boston University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="368916"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>WHO regimen therapy</Controls><EnrollmentCount></EnrollmentCount><Interventions>Deltyba; Lamprene; Levaquin; Sirturo; Zyvox</Interventions><Reference>DRAMATIC; H38212; NCT03828201</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18 to 65</ProtocolTitle><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="224675"></Trial><Drug id="95442">ESAT-6CFP10</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>1044</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>1044</EnrollmentCount><Interventions>BCG; ESAT6-CFP10</Interventions><Reference>EC-IIB-HEALTHY; NCT02389322</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Early Bactericidal Activity, Safety and Tolerability of GSK-3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="343050"></Trial><Drug id="70581">GSK-3036656</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>80</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bilirubin; Blood platelets; Body temperature; Calcium; Chlorides; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Glucose; Heart rate; Hematocrit; Hemoglobin; Ketones; Lactate dehydrogenase; Leukocyte count; Lymphocytes; Mean corpuscular hemoglobin; Mean corpuscular volume; Monocytes; Neutrophils; Nitrite; Potassium; QT interval; Respiratory frequency; Reticulocytes; Sodium; Systolic blood pressure; Total protein; Urea nitrogen; Urobilinogen; gamma-Glutamyltransferase</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour e-275</Controls><EnrollmentCount>80</EnrollmentCount><Interventions>GSK-3036656</Interventions><Reference>201214; NCT03557281</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Synergistically acting Rifampicin and Faropenem in Tuberculosis</ProtocolTitle><Sponsor>Indian Council of Medical Research</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="377088"></Trial><Drug id="4492">faropenem</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>56</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>standard of care treatment</Controls><EnrollmentCount>56</EnrollmentCount><Interventions>clavulanate; faropenem; rifampicin; standard of care treatment</Interventions><Reference>CTRI/2019/04/018577</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SUDOCU</ProtocolAcronym><ProtocolTitle>PanACEA Sutezolid Dose-finding and Combination Evaluation</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="381674"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>75</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>bedaquiline; delamanid; moxifloxacin</Controls><EnrollmentCount>75</EnrollmentCount><Interventions>bedaquiline; delamanid; midazolam; moxifloxacin; sutezolid</Interventions><Reference>NCT03959566; PANACEA-SUDOCU-01; SUDOCU</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Recombinant Mycobacterium tuberculosis allergen ESAT6-CFP10 for 18 to 65 years old healthy people: randomized, blinded, parallel-group phase III clinical trial</ProtocolTitle><Sponsor>Jiangsu Provincial Academy Of Environmental Science</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="252783"></Trial><Drug id="95442">ESAT-6CFP10</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers>Interferon gamma</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>ESAT-6CFP10</Interventions><Reference>ChiCTR-IIR-16007904</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>TB-TRUST</ProtocolAcronym><ProtocolTitle>Refining MDR-TB Treatment Regimens for Ultra Short Therapy</ProtocolTitle><Sponsor>Huashan Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="372676"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>220</Patients><Biomarkers>Glucose</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>amikacin; clofazimine; cycloserine; ethambutol; isoniazid; kanamycin; levofloxacin; prothionamide; pyrazinamide</Controls><EnrollmentCount>220</EnrollmentCount><Interventions>clofazimine; cycloserine; levofloxacin; linezolid; prothionamide; pyrazinamide</Interventions><Reference>KY2018-331; NCT03867136; TB-TRUST</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>REFLATE TB</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Two Raltegravir Doses in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="40948"></Trial><Drug id="54488">raltegravir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>155</Patients><Biomarkers>Human immunodeficiency virus DNA; Human immunodeficiency virus RNA; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; tenofovir disoproxil fumarate</Controls><EnrollmentCount>155</EnrollmentCount><Interventions>lamivudine; raltegravir; tenofovir disoproxil fumarate</Interventions><Reference>2008-004970-41; ANRS 12 180; ANRS 12180 REFLATE TB; NCT00822315; REFLATE TB</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The research of new regimen for multidrug-resistant tuberculosis treatment</ProtocolTitle><Sponsor>Beijing Chest Hospital, Beijing Tuberculosis &amp; Thoracic Tumor Research Institute, Capital Medical University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="244777"></Trial><Drug id="2829">clarithromycin</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>clarithromycin; levofloxacin; moxifloxacin; moxifloxacin; rifabutin</Interventions><Reference>ChiCTR-IOR-15007291</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="303756"></Trial><Drug id="44303">midazolam hydrochloride</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>74</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>74</EnrollmentCount><Interventions>TBA-7371; TBA-7371; bupropion; midazolam</Interventions><Reference>NCT03199339; TBA-7371-CL001</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>DORIIS</ProtocolAcronym><ProtocolTitle>Doravirine, Rifapentine and Isoniazid Interaction</ProtocolTitle><Sponsor>Thomas Jefferson University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="374387"></Trial><Drug id="74480">doravirine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>11</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>11</EnrollmentCount><Interventions>doravirine; isoniazid; rifapentine</Interventions><Reference>12690; DORIIS; NCT03886701</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV</ProtocolTitle><Sponsor>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="187839"></Trial><Drug id="44363">trimethoprim + sulphamethoxazole</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>1354</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>1354</EnrollmentCount><Interventions>isoniazid; trimethoprim + sulphamethoxazole</Interventions><Reference>IMPAACT P1041; NCT00080119; PACTG P1041; U01AI068632</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="76946"></Trial><Drug id="4481">stavudine</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>400</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>400</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; rifampicin; stavudine; zidovudine</Interventions><Reference>2008ZX10001-008; NCT01344148</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>TMC-207 +/- Rifabutin/Rifampin</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="76765"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>33</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>33</EnrollmentCount><Interventions>TMC-207; TMC-207; rifabutin; rifampin</Interventions><Reference>10-0043; HHSN272201500007I; N01AI80026C; NCT01341184</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid</ProtocolTitle><Sponsor>St Stephens Aids Trust</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="265766"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>26</Patients><Biomarkers>Blood platelets; Cytochrome P450 2B6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>35</EnrollmentCount><Interventions>efavirenz; lamivudine+ zidovudine; rifampicin + isoniazid (Rifinah); tenofovir disoproxil fumarate + emtricitabine; tenofovir+ lamivudine</Interventions><Reference>2014-002608-26; NCT02832778; SSAT062</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase Ic Study of Safety and PK of SQ-109 300 mg Daily</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="77682"></Trial><Drug id="31010">SQ-109</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>SQ-109</Interventions><Reference>09-0111; N01AI80024C; NCT01358162</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>RIFART</ProtocolAcronym><ProtocolTitle>RIFART</ProtocolTitle><Sponsor>Azienda Ospedaliera Spedali Civili di Brescia</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="131240"></Trial><Drug id="4728">emtricitabine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>efavirenz; emtricitabine; emtricitabine; lopinavir + ritonavir; rifabutin; rifampicin; tenofovir disoproxil fumarate; tenofovir disoproxil fumarate</Interventions><Reference>EudraCT 2007-007935-14; MI2-RIFART-2005; RIFART</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SAPIT</ProtocolAcronym><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="201474"></Trial><Drug id="44363">trimethoprim + sulphamethoxazole</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>642</Patients><Biomarkers>CD4 Positive T Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>642</EnrollmentCount><Interventions>didanosine; efavirenz; lamivudine; lamivudine + efavirenz + didanosine; trimethoprim + sulfamethoxazole</Interventions><Reference>CAPRISA 003; NCT00398996; SAPIT</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="210646"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>240</Patients><Biomarkers>Alanine transaminase; Aspartate aminotransferase; QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyraziminide; rifampicin</Controls><EnrollmentCount>240</EnrollmentCount><Interventions>bedaquiline; moxifloxacin; pretomanid; pyraziminide</Interventions><Reference>NC-005; NC-005-(J-M-PA-Z); NCT02193776</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV</ProtocolTitle><Sponsor>AIDS Clinical Trials Group</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="87585"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>71</Patients><Biomarkers>CD4; Cytotoxic T-Lymphocytes; HIV viral load; Human immunodeficiency virus RNA; T-Helper Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Kaletra; ethambutol; isoniazid; pyrazinamide; pyridoxine; rifampin</Controls><EnrollmentCount>71</EnrollmentCount><Interventions>Kaletra; ethambutol; isoniazid; pyrazinamide; pyridoxine; raltegravir; rifabutin</Interventions><Reference>1U01AI068636; ACTG A5290; NCT01601626</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Comparative Study of Itraconazole in Various Doses Schedule in the Treatment of Pulmonary Aspergilloma in Treated  with the Patients of Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Sawai ManSingh Medical College</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="131456"></Trial><Drug id="3411">itraconazole</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>itraconazole</Interventions><Reference>CTRI/2013/02/003374</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10873"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>MVA85A</Interventions><Reference>NCT00427453; TB004</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10874"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>MVA85A</Interventions><Reference>NCT00427830; TB005</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="65639"></Trial><Drug id="12862">Tritanrix HB</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>302</Patients><Biomarkers>Alanine transaminase; Blood platelets; Body temperature; CD40 ligand; Creatinine; Cytotoxic T-Lymphocytes; Hemoglobin; Interferon gamma; Interleukin-2; Leukocyte count; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Menjugate; Polio Sabin; Prevnar; Tritanrix HB</Controls><EnrollmentCount>302</EnrollmentCount><Interventions>GSK-692342; GSK-692342a; Polio Sabin; Prevnar; Tritanrix HB</Interventions><Reference>112899; 2012-004380-44; NCT01098474; TUBERCULOSIS-013 PRI</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)</ProtocolTitle><Sponsor>International Centre For Diarrhoeal Disease Research, Bangladesh</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="142323"></Trial><Drug id="12014">VP-101</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>288</Patients><Biomarkers>25(OH)D3; Calcium; LL-37; Macrophages; Total body mass; Weight; cough clearance</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>288</EnrollmentCount><Interventions>chemotherapy; cholecalciferol (Vigantol oil); cholecalciferol (Vigantol oil); sodium phenylbutyrate; sodium phenylbutyrate</Interventions><Reference>NCT01580007; PR-09068</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>OFLOTUB</ProtocolAcronym><ProtocolTitle>A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Institut de Recherche pour le Developpement (IRD)</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="10855"></Trial><Drug id="7017">gatifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1836</Patients><Biomarkers>Body Mass Index; Glucose</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; gatifloxacin</Controls><EnrollmentCount>2070</EnrollmentCount><Interventions>gatifloxacin; isoniazid; rifampin</Interventions><Reference>ICA4-CT 2002-10057; NCT00216385; OFLOTUB</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate Safety and Immunogenicity of VPM-1-002 in Comparison With BCG in Newborn Infants in South Africa</ProtocolTitle><Sponsor>Vakzine Projekt Management GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="82764"></Trial><Drug id="55569">VPM-1002</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>48</Patients><Biomarkers>CD4+ T-lymphocytes; CD8+ T-lymphocytes; CD8-Positive T-Lymphocytes; Interferon-gamma; Interleukin-17A; Interleukin-2; Interlukenin-2; T-Helper Lymphocytes; TNF-alpha</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>BCG</Controls><EnrollmentCount>48</EnrollmentCount><Interventions>VPM-1-002</Interventions><Reference>DOH-27-0911-3677; NCT01479972; VPM1002-ZA-2.12TB</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single-Dose or in Divided Doses to Healthy Adults</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="86389"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>rifapentine</Interventions><Reference>11859; A5311; ACTG 5311; NCT01574638</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK</ProtocolTitle><Sponsor>LegoChem Bioscience Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="265899"></Trial><Drug id="76307">delpazolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>64</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol hydrochloride; isoniazid; linezolid; pyrazinamide; rifampicin</Controls><EnrollmentCount>64</EnrollmentCount><Interventions>LCB01-0371</Interventions><Reference>2016-0642; KCT0003975; LCB01-0371-15-2-01; NCT02836483</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>THYB-02</ProtocolAcronym><ProtocolTitle>A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers</ProtocolTitle><Sponsor>Statens Serum Institut</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="58503"></Trial><Drug id="53784">Ag85B-ESAT-6 vaccine (IC31 adjuvant, tuberculosis), SSI/ Valneva</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>Ag85B-ESAT-6 vaccine (tuberculosis), SSI/Aeras/sanofi pasteur/Valneva</Interventions><Reference>NCT00929396; THYB-02; THYB-02</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of MVA-85A in Healthy Infants</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="59405"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>2797</Patients><Biomarkers>Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-2; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>2797</EnrollmentCount><Interventions>MVA-85A</Interventions><Reference>084785; C-020-485; ISRCTN39705371; NCT00953927; Oxford TB020</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="71107"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>65</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour</Controls><EnrollmentCount>85</EnrollmentCount><Interventions>PA-824; Rifafour; TMC-207; moxifloxacin; pyrazinamide</Interventions><Reference>NC-001; NC-001-(J-M-Pa-Z); NCT01215851</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin</ProtocolTitle><Sponsor>University of Miami</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="93494"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>9</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>9</EnrollmentCount><Interventions>Kaletra; rifampin; ritonavir</Interventions><Reference>20100325; NCT01700790</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I ID-93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers</ProtocolTitle><Sponsor>Infectious Disease Research Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="87507"></Trial><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Immunoglobulin G; T-Lymphocytes</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>ID-93; ID-93 + GLA-SE</Interventions><Reference>IDRI-TBVPX-113; NCT01599897</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="161831"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>428</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>429</EnrollmentCount><Interventions>ethambutol; isoniazid; linezolid; pyrazinamide; rifampicin</Interventions><Reference>J-1310-026-523; NCT01994460</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Acquired Immunodeficiency Syndrome (AIDS) and Tuberculosis (TB) Co-Infection Treatment Strategies Study of China</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="76946"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>400</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>400</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; rifampicin; stavudine; zidovudine</Interventions><Reference>2008ZX10001-008; NCT01344148</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EARNEST Rifabutin Pharmacokinetics (PK) Substudy</ProtocolTitle><Sponsor>Joint Clinical Research Centre, Medical Research Council</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="90175"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>140</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>140</EnrollmentCount><Interventions>Aluvia; raltegravir; rifabutin</Interventions><Reference>ISRCTN13074752; NCT01663168</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>TBTC-27</ProtocolAcronym><ProtocolTitle>TBTC Study 27: Moxifloxacin versus Ethambutol for TB Treatment</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10684"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>350</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>350</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; rifampin</Interventions><Reference>CDC-NCHSTP-3716; NCT00140309; TBTC-27</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir or Rifampin</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="86312"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>52</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>52</EnrollmentCount><Interventions>PA-824; efavirenz; lopinavir + ritonavir; rifampin</Interventions><Reference>11829; A5306; ACTG5306; NCT01571414</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating the Safety, Tolerance, and Pharmacokinetics of a Raltegravir-containing Antiretroviral Therapy (ART) Regimen in Infants and Children Infected With HIV and TB</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="102102"></Trial><Drug id="54488">raltegravir</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>108</Patients><Biomarkers>Human immunodeficiency virus RNA</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>108</EnrollmentCount><Interventions>raltegravir; rifampicin</Interventions><Reference>11831; IMPAACT P1101; NCT01751568; P1101</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>REMoxTB</ProtocolAcronym><ProtocolTitle>Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="49258"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1931</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>1931</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; rifampicin</Interventions><Reference>10.1186/ISRCTN85595810; CTR20140130; CTRI/2011/05/001745; ISRCTN85595810; NCT00864383; NMRR-09-963-4872; PACTR201110000124315; REMoxTB; REMoxTB</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>TMC-207 +/- Rifabutin/Rifampin</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="76765"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>33</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>33</EnrollmentCount><Interventions>TMC-207; TMC-207; rifabutin; rifampin</Interventions><Reference>10-0043; HHSN272201500007I; N01AI80026C; NCT01341184</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety of Tuberculosis Vaccine, MVA-85A, Administered by the Aerosol Route and the Intradermal Route</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="83464"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers>T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>MVA-85A</Interventions><Reference>NCT01497769; TB026</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-Dose TMC-207 on the QT/QTc Interval Under Fed Conditions</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="74529"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>88</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>moxifloxacin</Controls><EnrollmentCount>88</EnrollmentCount><Interventions>TMC-207</Interventions><Reference>CR017167; NCT01291563; TMC-207-TBC1003</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Efficacy and Safety of TMC-207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="87533"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers>Albumin</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>bedaquiline</Interventions><Reference>2011-000653-23; CR100807; NCT01600963; PHRR130402-000059; TMC207-TIDP13-C210; U1111-1135-7013</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics and Safety of Moxifloxacin</ProtocolTitle><Sponsor>University Medical Center Groningen</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="76086"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>9</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>9</EnrollmentCount><Interventions>moxifloxacin</Interventions><Reference>2010-023491-25; MFX468; NCT01329250</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interferon Alpha-2b in the Complex Therapy of Patients With Pulmonary Tuberculosis Concurrent With Broncho-obstructive Syndrome</ProtocolTitle><Sponsor></Sponsor><TrialStatus>Completed</TrialStatus><Trial id="149989"></Trial><Drug id="45998">interferon alfa-2b</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>70</Patients><Biomarkers>T-Lymphocytes</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>70</EnrollmentCount><Interventions>interferon alfa-2b</Interventions><Reference>PMID:20095375</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10646"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>lamivudine; nelfinavir mesylate; rifabutin; stavudine; zidovudine</Interventions><Reference>AACTG A5062; ACTG A5062; NCT00004736</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>TBTC-23B</ProtocolAcronym><ProtocolTitle>Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10656"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>nelfinavir; rifabutin</Interventions><Reference>23B; CDC-NCHSTP-2587; NCT00023400; TBTC-23B</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>LiMiT</ProtocolAcronym><ProtocolTitle>Pilot Study Examining the Safety and Tolerability of Low Dose Linezolid in the Treatment of Multi-Drug Resistant Tuberculosis</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention, Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11219"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>linezolid</Interventions><Reference>CDC-NCHHSTP-5356; LiMiT; NCT00664313</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>TBTC-23B</ProtocolAcronym><ProtocolTitle>Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10656"></Trial><Drug id="8255">nelfinavir</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>nelfinavir; rifabutin</Interventions><Reference>23B; CDC-NCHSTP-2587; NCT00023400; TBTC-23B</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>ANRS 12154 PECAN</ProtocolAcronym><ProtocolTitle>Pharmacokinetics of efavirenz in combination of rimfampin in HIV-infected adults</ProtocolTitle><Sponsor>INSERM, Institut Pasteur Du Cambodge</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="145595"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>312</Patients><Biomarkers>CYP 2B6 516GG; CYP 2B6 516TT; CYP2B6 516G&gt;T; CYP2B6 516GT; Cytochrome P450 2B6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>312</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazide; pyrazinamide; rifampin; stavudine + lamivudine</Interventions><Reference>ANRS 12154 PECAN</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>OPTI-NNRTI</ProtocolAcronym><ProtocolTitle>A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV</ProtocolTitle><Sponsor>Stanford University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="11177"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>5</Patients><Biomarkers>CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>5</EnrollmentCount><Interventions>efavirenz; nevirapine</Interventions><Reference>NCT00523458; OPTI-NNRTI; Stanford Protocol ID: 95564</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym>TBRU 10</ProtocolAcronym><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10869"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>70</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><EnrollmentCount>70</EnrollmentCount><Interventions>gatifloxacin; levofloxacin; linezolid; moxifloxacin</Interventions><Reference>01-553; NCT00396084; TBRU 10; TBRU 10</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Glutoxim in the Complex Treatment of Tuberculosis</ProtocolTitle><Sponsor>IM Sechenov Moscow Medical Academy</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="149460"></Trial><Drug id="28379">Glutoxim</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>42</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>42</EnrollmentCount><Interventions>Glutoxim</Interventions><Reference>PMID:12087719</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Open-Label Study to Evaluate the Effects on Mycobacterium Tuberculosis, Safety, Tolerability and Pharmacokinetics of Single Doses of R-207910, in Treatment Naive Patients With Mycobacterium Tuberculosis Infection</ProtocolTitle><Sponsor>Janssen Diagnostics BVBA, Johnson &amp; Johnson</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="129536"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>bedaquiline</Interventions><Reference>BAC2001; EudraCT 2004-002202-30; R207910BAC2001</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>TBTC-25</ProtocolAcronym><ProtocolTitle>Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10655"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>35</Patients><Biomarkers>Albumin</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Reference>CDC-NCHSTP-2558; NCT00023387; TBTC Study 25PK; TBTC-25</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers</ProtocolTitle><Sponsor>Sequella Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="60906"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>59</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>59</EnrollmentCount><Interventions>PNU-100480</Interventions><Reference>B1171002; NCT00990990</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 6-Month Safety, Efficacy and PK Trial of Delamanid in Pediatric Patients With Multidrug Resistant Tuberculosis</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="133567"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>37</Patients><Biomarkers>Body height; QT interval; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>37</EnrollmentCount><Interventions>delamanid</Interventions><Reference>2012-004620-38; 2012-CT0079; 242-12-233; NCT01859923; P/281/2014; PHRR160526-001029</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Placebo-Controlled, Partially-Blinded, Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="176219"></Trial><Drug id="48499">H4:IC31</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>990</Patients><Biomarkers>CD107a; CD154; CD4+ T cells; Cytotoxic T-Lymphocytes; Interferon-gamma; Interleukin-17; Interleukin-2; Interleukin-22; T-Helper Lymphocytes; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Bacillus Calmette-Guerin vaccine</Controls><EnrollmentCount>990</EnrollmentCount><Interventions>H4+IC31</Interventions><Reference>C-040-404; NCT02075203</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>BRIEF TB</ProtocolAcronym><ProtocolTitle>Brief Rifapentine-Isoniazid Evaluation for TB Prevention</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="79741"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>3000</Patients><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Bilirubin; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid; isoniazid; pyridoxine</Controls><EnrollmentCount>3000</EnrollmentCount><Interventions>efavirenz; isoniazid; pyridoxine; rifapentine</Interventions><Reference>10848; A5279; ACTG A5279; BRIEF TB; BRIEF TB/A5279; NCT01404312</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SAPIT</ProtocolAcronym><ProtocolTitle>A Study to Compare Three Existing Starting Points of Antiretroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="201474"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>642</Patients><Biomarkers>CD4 Positive T Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>642</EnrollmentCount><Interventions>didanosine; efavirenz; lamivudine; lamivudine + efavirenz + didanosine; trimethoprim + sulfamethoxazole</Interventions><Reference>CAPRISA 003; NCT00398996; SAPIT</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Using electronic monitors and a smartphone app to improve treatment adherence of new pulmonary tuberculosis patients in Tibet, China</ProtocolTitle><Sponsor>The Chinese Centre for Disease Control and Prevention</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="359917"></Trial><Drug id="98013">isoniazid + rifampicin + pyrazinamide + ethambutol</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>300</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid + rifampicin + pyrazinamide + ethambutol</Controls><EnrollmentCount>300</EnrollmentCount><Interventions>FLOW e-monitor box; isoniazid + rifampicin + pyrazinamide + ethambutol; smartphone app</Interventions><Reference>ISRCTN52132803; TB REACH, GRANT NUMBER: STBP/TBREACH/GSA/W6-5</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-Infected and HIV-1-Uninfected Pregnant and Postpartum Women With Latent Tuberculosis Infection</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="250483"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>isoniazid; pyridoxine; rifapentine</Interventions><Reference>12026; IMPAACT 2001; NCT02651259</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Research on New Regimens for Retreatment Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Shanghai Pulmonary Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="220243"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin; streptomycin</Controls><EnrollmentCount>864</EnrollmentCount><Interventions>ethambutol; isoniazid aminosalicylate; moxifloxacin; pyrazinamide; rifabutin</Interventions><Reference>2013ZX10003009; NCT02331823</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EMaBS TB Vaccine Study</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="354327"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>72</Patients><Biomarkers>B-lymphocytes; Neutrophils; T-Lymphocytes</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>BCG vaccine</Controls><EnrollmentCount>72</EnrollmentCount><Interventions>ChAdOx1-85A; ChAdOx1-85A; MVA-85A</Interventions><Reference>NCT03681860; TB042</Reference></Row><Row><ArmCount>5+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd, Syneos Health Inc</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="224111"></Trial><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>45</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>45</EnrollmentCount><Interventions>Augmentin; cefadroxil; cefadroxil; ethambutol; faropenem; faropenem; isoniazid; pyrazinamide; rifampicin</Interventions><Reference>2015-CT0284; FAROPENEM_TB; NCT02381470; PHRR160323-001194</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of PBTZ-169</ProtocolTitle><Sponsor>Nearmedic Plus</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="286724"></Trial><Drug id="90085">macozinone</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>35</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>35</EnrollmentCount><Interventions>PBTZ-169</Interventions><Reference>NCT03036163; PBTZ169-Z00-C01-1</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV co-Infection in South Africa</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11187"></Trial><Drug id="4481">stavudine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>35</Patients><Biomarkers>Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>efavirenz; isoniazid; lamivudine; lopinavir + ritonavir; nevirapine; rifabutin; stavudine</Interventions><Reference>ANRS12150a; NCT00640887</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase IIa Study of PBTZ-169</ProtocolTitle><Sponsor>Nearmedic Plus</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="318771"></Trial><Drug id="90085">macozinone</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><EnrollmentCount>16</EnrollmentCount><Interventions>PBTZ-169</Interventions><Reference>NCT03334734; PBTZ169-A15-C2A-1</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A clinical trial to study the effects of moxifloxacin with regular anti-tuberculosis drugs in Tuberculosis patients</ProtocolTitle><Sponsor>Vels University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="255644"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>131</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>conventional TB treatment</Controls><EnrollmentCount>131</EnrollmentCount><Interventions>conventional TB treatment; moxifloxacin</Interventions><Reference>CTRI/2016/03/006713</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics and Safety of Rifabutin 150 mg qd Versus Rifabutin 300 mg tiw</ProtocolTitle><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="226826"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers>T-Lymphocytes; T-cell surface glycoprotein CD4; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>Kaletra; rifabutin</Interventions><Reference>HIV-NAT 116; NCT02415985</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="307654"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>448</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Reference>CAP 020; InDEX; NCT03237182</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-Limited Settings</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="8820"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>592</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>592</EnrollmentCount><Interventions>didanosine; efavirenz; lamivudine; standard TB therapy</Interventions><Reference>CAPRISA 001; CAPRISA START; CIPRA; NCT00091936; START</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SAEFRIF</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy</ProtocolTitle><Sponsor>Makerere University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="384080"></Trial><Drug id="59062">dolutegravir</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>dolutegravir; efavirenz; isoniazid + ethambutol + pyrazinamide; rifampin</Interventions><Reference>NCT03982277; SAEFRIF; ST/224/219</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity Study of GX-70 in TB Patient</ProtocolTitle><Sponsor>Yonsei University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="298965"></Trial><Drug id="53019">GX-70</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients></Patients><Biomarkers>Interferon gamma; SL cytokine</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>GX-70</Interventions><Reference>4-2016-1144; NCT03159975</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating the Safety, Tolerability and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="243619"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>84</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>84</EnrollmentCount><Interventions>bedaquiline; bedaquiline; delamanid; delamanid; dolutegravir</Interventions><Reference>12005; A5343; NCT02583048</Reference></Row><Row><ArmCount>6</ArmCount><ProtocolAcronym>TBHDT</ProtocolAcronym><ProtocolTitle>TB Host Directed Therapy</ProtocolTitle><Sponsor>Aurum Institute</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="279898"></Trial><Drug id="13340">everolimus</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>200</Patients><Biomarkers>C-reactive protein; Forced expiratory volume; Neopterin; Programmed cell death protein 1; Standardized uptake value; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>rifabutin-modified TB therapy</Controls><EnrollmentCount>200</EnrollmentCount><Interventions>CC-11050; auranofin; everolimus; rifabutin-modified TB therapy; vitamin D3</Interventions><Reference>NCT02968927; TBHDT; TBHDT-AUR1-8-178</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>endTB</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Sponsor>Mdecins Sans Frontires France</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="259506"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>750</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>pryrazinamide</Controls><EnrollmentCount>750</EnrollmentCount><Interventions>Lamprene; bedaquiline; delamanid; levofloxacin; linezolid; moxifloxacin; pryrazinamide</Interventions><Reference>MSF ERB-1555; NCT02754765; endTB</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>RRHT</ProtocolAcronym><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="334027"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>230</Patients><Biomarkers>T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>230</EnrollmentCount><Interventions>Viread; efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; zidovudine</Interventions><Reference>2017ZX10202101-002; NCT03478033; RRHT</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>MDR-END</ProtocolAcronym><ProtocolTitle>Treatment Shortening of MDR-TB Using Existing and New Drugs</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="247456"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>238</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>pyrazinamide</Controls><EnrollmentCount>238</EnrollmentCount><Interventions>delamanid; levofloxacin; linezolid; pyrazinamide</Interventions><Reference>MDR-END; NCT02619994</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>REFLATE TB2</ProtocolAcronym><ProtocolTitle>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</ProtocolTitle><Sponsor>INSERM</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="214156"></Trial><Drug id="14493">tenofovir disoproxil fumarate</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>460</Patients><Biomarkers>Human immunodeficiency virus RNA; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; tenofovir disoproxil fumarate</Controls><EnrollmentCount>460</EnrollmentCount><Interventions>lamivudine; raltegravir; rifampin; tenofovir disoproxil fumarate</Interventions><Reference>ANRS 12300 REFLATE TB2; NCT02273765; REFLATE TB2</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="300655"></Trial><Drug id="3616">meropenem</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>88</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>88</EnrollmentCount><Interventions>Augmentin; Merrem; rifampin</Interventions><Reference>FD-R-05724; IRB00119017; NCT03174184</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>LEVOF</ProtocolAcronym><ProtocolTitle>MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="8644"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>levofloxacin</Interventions><Reference>LEVOF; LEVOF_L_00972; NCT00495339</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SAEFRIF</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy</ProtocolTitle><Sponsor>Makerere University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="384080"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>dolutegravir; efavirenz; isoniazid + ethambutol + pyrazinamide; rifampin</Interventions><Reference>NCT03982277; SAEFRIF; ST/224/219</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SURE</ProtocolAcronym><ProtocolTitle>Short Intensive Treatment For Children With Tuberculous Meningitis</ProtocolTitle><Sponsor>University College London</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="360104"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>400</Patients><Biomarkers>T-Helper Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>400</EnrollmentCount><Interventions>aspirin; isoniazid; levofloxacin; pyrazinamide; ranitidine; rifampicin</Interventions><Reference>ISRCTN40829906; SURE; SURE</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><Sponsor>Beijing Chest Hospital</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="328802"></Trial><Drug id="7017">gatifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>140</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>gatifloxacin; levofloxacin; moxifloxacin; p-aminosalycilic acid; prothionamide</Controls><EnrollmentCount>320</EnrollmentCount><Interventions>clofazimine; gatifloxacin; levofloxacin; moxifloxacin; p-aminosalycilic acid; prothionamide</Interventions><Reference>ChiCTR1800014800</Reference></Row><Row><ArmCount>13</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiological Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="8776"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>156</Patients><Biomarkers>CD4 cells</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>525</EnrollmentCount><Interventions>amikacin sulfate; aminosalicylic acid; capreomycin sulfate; clofazimine; cycloserine; ethambutol hydrochloride; ethionamide; isoniazid; levofloxacin; pyrazinamide; pyridoxine hydrochloride; rifampin; streptomycin sulfate</Interventions><Reference>11215; ACTG 238; CPCRA 026; NCT00000796</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rifapentine-containing tuberculosis treatment shortening regimens (S31/A5349)</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="347338"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2500</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>2500</EnrollmentCount><Interventions>moxifloxacin; rifapentine</Interventions><Reference>CTRI/2018/07/014966</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>TB-TRUST</ProtocolAcronym><ProtocolTitle>Refining MDR-TB Treatment Regimens for Ultra Short Therapy</ProtocolTitle><Sponsor>Huashan Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="372676"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>220</Patients><Biomarkers>Glucose</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>amikacin; clofazimine; cycloserine; ethambutol; isoniazid; kanamycin; levofloxacin; prothionamide; pyrazinamide</Controls><EnrollmentCount>220</EnrollmentCount><Interventions>clofazimine; cycloserine; levofloxacin; linezolid; prothionamide; pyrazinamide</Interventions><Reference>KY2018-331; NCT03867136; TB-TRUST</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>RRHT</ProtocolAcronym><ProtocolTitle>Rifampicin versus Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</ProtocolTitle><Sponsor>Shanghai Public Health Clinical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="334027"></Trial><Drug id="14493">tenofovir disoproxil fumarate</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>230</Patients><Biomarkers>T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>230</EnrollmentCount><Interventions>Viread; efavirenz; ethambutol; isoniazid; lamivudine; pyrazinamide; rifabutin; zidovudine</Interventions><Reference>2017ZX10202101-002; NCT03478033; RRHT</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="353987"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>125</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>delamanid; ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>125</EnrollmentCount><Interventions>OPC-167832; OPC-167832; delamanid</Interventions><Reference>323-201-00003; NCT03678688; OPP1178898</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB</ProtocolTitle><Sponsor>Aeras Global TB Vaccine Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="228651"></Trial><Drug id="53975">AERAS-402</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Creatine kinase; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-2; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>AERAS-402</Interventions><Reference>C-012-402; NCT02430506</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="307654"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>448</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Reference>CAP 020; InDEX; NCT03237182</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>DRAMATIC</ProtocolAcronym><ProtocolTitle>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB</ProtocolTitle><Sponsor>Boston University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="368916"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>WHO regimen therapy</Controls><EnrollmentCount></EnrollmentCount><Interventions>Deltyba; Lamprene; Levaquin; Sirturo; Zyvox</Interventions><Reference>DRAMATIC; H38212; NCT03828201</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>ACT-TB</ProtocolAcronym><ProtocolTitle>Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis</ProtocolTitle><Sponsor>London School of Hygiene and Tropical Medicine</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="341686"></Trial><Drug id="2587">azithromycin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1875</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Standard of care</Controls><EnrollmentCount>1875</EnrollmentCount><Interventions>amoxicillin; azithromycin</Interventions><Reference>15232; ACT-TB; NCT03545373</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>A-042</ProtocolAcronym><ProtocolTitle>Phase Ib, Safety and Immunogenicity Trial of BCG Revaccination, H4:IC31 and H56:IC31 in Healthy, HIV-1-Uninfected Adolescents</ProtocolTitle><Sponsor>Aeras</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="223463"></Trial><Drug id="74849">SSI H56-IC31</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>84</Patients><Biomarkers>Cytotoxic T-Lymphocytes; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>84</EnrollmentCount><Interventions>BCG; H4 + IC31; SSI H56-IC31</Interventions><Reference>A-042; HVTN 602 / AERAS A-042; NCT02378207</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study on Tuberculosis Resistant to Treatment</ProtocolTitle><Sponsor>Indian Council of Medical Research, Tuberculosis Research Centre</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="369747"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>165</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>165</EnrollmentCount><Interventions>Zyvox; bedaquiline; clofazimine; delamanid</Interventions><Reference>CTRI/2019/01/017310; Version Number: 3.1</Reference></Row><Row><ArmCount>8</ArmCount><ProtocolAcronym>TB-LION</ProtocolAcronym><ProtocolTitle>Tuberculosis - Learning the Impact of Nutrition</ProtocolTitle><Sponsor>Boston Medical Center Corp</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="347635"></Trial><Drug id="3412">ivermectin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>120</Patients><Biomarkers>Body Mass Index; Body height; Interferon gamma; Regulatory T-Lymphocytes; Th1 cells; Th2 cells; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>albendazole; ivermectin; metronidazole</Controls><EnrollmentCount>120</EnrollmentCount><Interventions>Nutritional Supplementation Meal; albendazole; ivermectin; metronidazole; multivitamin therapy</Interventions><Reference>6005415; CTRI/2019/05/018968; H-37473; NCT03598842; TB-LION</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)</ProtocolTitle><Sponsor>Oregon Health Sciences University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="279727"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>102</Patients><Biomarkers>Alanine transaminase; Aspartate aminotransferase; Blood cells; C-reactive protein; Erythrocyte sedimentation rate; FEV / FVC ratio; QT interval; Six-minute walk distance</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>102</EnrollmentCount><Interventions>Lamprene</Interventions><Reference>FD-R-5401; NCT02968212</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of faropenem and cefadroxil (in combination with amoxicillin/clavulanic acid and standard TB drugs) in patients with pulmonary tuberculosis: measurement of early bactericidal activity and effects on novel biomarkers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="360329"></Trial><Drug id="4492">faropenem</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>45</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>amoxicillin; cefadroxil; clavulanic acid; ethambutol; faropenem; isoniazid; pyrazinamide; rifampicin</Interventions><Reference>2018-CT0454; 20180710115454; Faropenem_TB; PHRR181108-001980</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18 to 65 years (III-healthy)</ProtocolTitle><Sponsor>Anhui Zhifei Longcom Biopharmaceutical Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="262931"></Trial><Drug id="95442">ESAT-6CFP10</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1802</Patients><Biomarkers>Blood pressure; Interferon gamma</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>1802</EnrollmentCount><Interventions>Bacillus Calmette-Guerin (BCG) vaccine; ESAT-6CFP10; Tuberculin purified protein derivative (TB-PPD)</Interventions><Reference>EC-III-HEALTHY; NCT02795260</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effect of 18-month Regimen Containing Six Anti-tuberculosis Drugs for Patients With MDR-TB</ProtocolTitle><Sponsor>Beijing Chest Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="369109"></Trial><Drug id="11036">linezolid</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>500</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>500</EnrollmentCount><Interventions>amikacin; bedaquiline; clarithromycin; clofazimine; cycloserine; ethambutol; linezolid; moxifloxacin; prothionamide; pyrazinamide; sodium para-aminosalicylate</Interventions><Reference>2018ZX10722301-001; NCT03830671</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>TasP in Correctional Facilities</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="280225"></Trial><Drug id="4728">emtricitabine</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients>419</Patients><Biomarkers>Creatinine; Human immunodeficiency virus RNA; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>419</EnrollmentCount><Interventions>efavirenz; emtricitabine; lamivudine; tenofovir</Interventions><Reference>15-1473; NCT02946762; Z 31501</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide</ProtocolTitle><Sponsor>Huashan Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="183613"></Trial><Drug id="2829">clarithromycin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>152</Patients><Biomarkers>Glucose</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>amikacin; clarithromycin; isoniazid; levofloxacin; prothionamide; pyrazinamide</Interventions><Reference>2013ZX10003008-003; KY2013-260; NCT02120638</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Is Levofloxacin Better Than Rifampicin in the Treatment of Tuberculous Meningitis- a Randomized, Control Study</ProtocolTitle><Sponsor>Sanjay Gandhi Postgraduate Institute of Medical Sciences</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="129005"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>160</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>160</EnrollmentCount><Interventions>levofloxacin; rifampicin</Interventions><Reference>CTRI/2012/11/003155</Reference></Row><Row><ArmCount>6</ArmCount><ProtocolAcronym>DATiC</ProtocolAcronym><ProtocolTitle>Optimal Dosing of First-Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="89135"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>39</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>ethambutol; isoniazid; lopinavir + ritonavir; nevirapine; pyrazinamide; rifampicin</Interventions><Reference>DATiC; DATiC; NCT01637558</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of two Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCG</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10944"></Trial><Drug id="55317">MVA-85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>MVA85A</Interventions><Reference>NCT00465465; TB009</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Healthy Adults</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="102580"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>3573</Patients><Biomarkers>CD4/CD8 ratio; CD40; CD40 ligand; IL-2; Interferon gamma; M72-specific CD4+ cells; M72-specific CD8+ cells; TNF-alpha</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>3595</EnrollmentCount><Interventions>GSK-692342</Interventions><Reference>115616; NCT01755598; PACTR201311000639144</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine</ProtocolTitle><Sponsor>McMaster University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="77668"></Trial><Drug id="71323">Ad5Ag85A</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers>CD4+ T-cell; Cytotoxic T-Lymphocytes; T-Helper Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>Ad5Ag85A</Interventions><Reference>NCT00800670; REB 09-001</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV</ProtocolTitle><Sponsor>AIDS Clinical Trials Group</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="87585"></Trial><Drug id="54488">raltegravir</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>71</Patients><Biomarkers>CD4; Cytotoxic T-Lymphocytes; HIV viral load; Human immunodeficiency virus RNA; T-Helper Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Kaletra; ethambutol; isoniazid; pyrazinamide; pyridoxine; rifampin</Controls><EnrollmentCount>71</EnrollmentCount><Interventions>Kaletra; ethambutol; isoniazid; pyrazinamide; pyridoxine; raltegravir; rifabutin</Interventions><Reference>1U01AI068636; ACTG A5290; NCT01601626</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetic Interaction Study in Indonesian Tuberculosis Patients Indonesia</ProtocolTitle><Sponsor>Radboud University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10860"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>23</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>23</EnrollmentCount><Interventions>isoniazid; moxifloxacin; rifampicin</Interventions><Reference>NCT00306319; Primo study; UMCN-AKF 05.02</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym>TBRU 10</ProtocolAcronym><ProtocolTitle>Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10869"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>70</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>isoniazid</Controls><EnrollmentCount>70</EnrollmentCount><Interventions>gatifloxacin; levofloxacin; linezolid; moxifloxacin</Interventions><Reference>01-553; NCT00396084; TBRU 10; TBRU 10</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>RIFART</ProtocolAcronym><ProtocolTitle>RIFART</ProtocolTitle><Sponsor>Azienda Ospedaliera Spedali Civili di Brescia</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="131240"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>efavirenz; emtricitabine; emtricitabine; lopinavir + ritonavir; rifabutin; rifampicin; tenofovir disoproxil fumarate; tenofovir disoproxil fumarate</Interventions><Reference>EudraCT 2007-007935-14; MI2-RIFART-2005; RIFART</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study</ProtocolTitle><Sponsor>Universitas Padjadjaran</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="67996"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>moxifloxacin; rifampicin</Interventions><Reference>NCT01158755; TB-201006.01</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PK/PD of Ertapenem in Patients with TB</ProtocolTitle><Sponsor>University Medical Center Groningen</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="98848"></Trial><Drug id="12543">ertapenem</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Alanine aminotransferase (ALAT); Aspartate aminotransferase (ASAT); Estimated glomerular filtration rate</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>ertapenem</Interventions><Reference>ETB/V0.2; NCT01730664</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>CARINEMO</ProtocolAcronym><ProtocolTitle>Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients</ProtocolTitle><Sponsor>French National Agency for Research on AIDS and Viral Hepatitis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10948"></Trial><Drug id="3700">nevirapine</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>570</Patients><Biomarkers>Alanine aminotransferase; CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>efavirenz; lamivudine; stavudine</Controls><EnrollmentCount>570</EnrollmentCount><Interventions>Arm A; Arm B; Triomune; ethambutol; ethambutol; isoniazid; isoniazid; lamivudine; nevirapine; pyrazinamide; pyrazinamide; rifampicin; rifampicin; stavudine</Interventions><Reference>ANRS 12146 CARINEMO; ANRS 12146/12214; ANRS 12214; CARINEMO; NCT00495326</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Safety and Immunogenicity of VPM-1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa</ProtocolTitle><Sponsor>Serum Institute of India Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="224781"></Trial><Drug id="55569">VPM-1002</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>416</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>BCG</Controls><EnrollmentCount>416</EnrollmentCount><Interventions>VPM-1002</Interventions><Reference>DOH-27-1114-4798; NCT02391415; VPM1002-ZA-2.13TB</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>RIFART</ProtocolAcronym><ProtocolTitle>RIFART</ProtocolTitle><Sponsor>Azienda Ospedaliera Spedali Civili di Brescia</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="131240"></Trial><Drug id="14493">tenofovir disoproxil fumarate</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>efavirenz; emtricitabine; emtricitabine; lopinavir + ritonavir; rifabutin; rifampicin; tenofovir disoproxil fumarate; tenofovir disoproxil fumarate</Interventions><Reference>EudraCT 2007-007935-14; MI2-RIFART-2005; RIFART</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Evaluation of the Pharmacological Interaction of Lopinavir/ritonavir and Rifampin</ProtocolTitle><Sponsor>Fundacao Oswaldo Cruz (Fiocruz)</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="171009"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>isoniazide; lopinavir + ritonavir; pirazinamide; rifampin</Interventions><Reference>A06-295; NCT00771498</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Challenge Study of BCG in Healthy Volunteers</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="177982"></Trial><Drug id="13624">BCG vaccine, Organon</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>52</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>52</EnrollmentCount><Interventions>BCG SSI; TiceBCG</Interventions><Reference>IRAS ID 146214; NCT02088892; TB031</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd, Syneos Health Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="89066"></Trial><Drug id="17132">pascolizumab</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>32</Patients><Biomarkers>IL-4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>32</EnrollmentCount><Interventions>pascolizumab</Interventions><Reference>2015-CT0301; DSRB 2012/02212; NCT01638520; PHRR160722-001308</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB)</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="83489"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>207</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>207</EnrollmentCount><Interventions>DRMPa200Z regimen; HRZE regimen; MPa100Z regimen; MPa200Z regimen; PA-824; Rifafour; ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyrazinamide; rifampicin</Interventions><Reference>NC-002-(M-Pa-Z); NCT01498419</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>BAM</ProtocolAcronym><ProtocolTitle>A Study of the Interaction Between BCG And MenC Immunization</ProtocolTitle><Sponsor>University of Oxford</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="162886"></Trial><Drug id="11458">Menitorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Anti-Meningitis C antibodies; C-C motif chemokine 2; C-C motif chemokine 3; C-C motif chemokine 4; Cytokines; IgG; Interferon gamma; Interferon-alpha; Interleukin-1 alpha; Interleukin-1 beta; Interleukin-10; Interleukin-12; Interleukin-13; Interleukin-2; Interleukin-6</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>BCG; Infanrix; Menitorix; NeisVac-C; Pentacel; Prevnar 13; Priorix; Rotarix</Interventions><Reference>2013-003488-71; BAM; NCT02002156; OVG-2013/04; UKCRN 15722</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Ethylamine pyrazine Lifestyle Isonicotinic piece IV bioequivalence trials</ProtocolTitle><Sponsor>Shenyang Hongqi Pharmaceutical Co Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="177165"></Trial><Drug id="88505">ethambutol hydrochloride (150 mg) + pyrazinamide (300 mg) + rifampicin (90 mg) + isoniazid (60 mg) (oral tablet, tuberculosis), Shenyang Hongqi Pharmaceutical/Liaoning Hongwuxing Pharmaceutical</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>24</EnrollmentCount><Interventions>ethambutol hydrochloride + pyrazinamide + rifampicin + isoniazid</Interventions><Reference>CTR20131379; SYY-YQ-2013-0405</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>RIFAVIRENZ</ProtocolAcronym><ProtocolTitle>Interaction Between High-Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection</ProtocolTitle><Sponsor>INSERM</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="161096"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>105</Patients><Biomarkers>Blood cells; HIV-1 RNA; Human immunodeficiency virus RNA; T-Helper Lymphocytes; T-cell surface glycoprotein CD4</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>105</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; pyrazinamide; rifampicin; tenofovir+lamivudine</Interventions><Reference>ANRS 12292 RIFAVIRENZ; NCT01986543; RIFAVIRENZ</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="161275"></Trial><Drug id="10172">efavirenz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>355</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>efavirenz; ethambutol; isoniazid; lamivudine; nevirapine; pyrazinamide; rifampicin; zidovudine</Interventions><Reference>NCT00698334; SKS/NACO/2006</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics and Safety of Rifabutin 150 mg qd Versus Rifabutin 300 mg tiw</ProtocolTitle><Sponsor>The HIV Netherlands Australia Thailand Research Collaboration</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="226826"></Trial><Drug id="14681">lopinavir + ritonavir</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers>T-Lymphocytes; T-cell surface glycoprotein CD4; Total body mass</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>Kaletra; rifabutin</Interventions><Reference>HIV-NAT 116; NCT02415985</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of SQ-109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="109063"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>365</Patients><Biomarkers>Visual acuity</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>365</EnrollmentCount><Interventions>SQ-109; ethambutol; isoniazid; moxifloxacin; pyrazinamide; pyridoxine; rifampicin</Interventions><Reference>NCT01785186; PACTR201205000383208; PanACEA-MAMS-TB-01</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Trial of DAR-901</ProtocolTitle><Sponsor>Dartmouth-Hitchcock Medical Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="173446"></Trial><Drug id="90231">DAR-901</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>59</Patients><Biomarkers>Cytokines; Interferon gamma; Interleukin-2; T helper 17 cells; T-Helper 22 cells; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>59</EnrollmentCount><Interventions>BCG; DAR-901</Interventions><Reference>DAR-901-MDES; NCT02063555</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity of a Candidate Tuberculosis Vaccine in Healthy HIV Negative Adolescents</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="59304"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-17A; T-Helper Lymphocytes; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Th1 cytokines</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>GSK-692342</Interventions><Reference>112898; NCT00950612</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>TBTC S29B</ProtocolAcronym><ProtocolTitle>Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="68204"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>37</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>37</EnrollmentCount><Interventions>midazolam; rifapentine</Interventions><Reference>CDC-NCHHSTP-5779; NCT01162486; TBTC S29B; TBTC S29B</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>RIFAQUIN</ProtocolAcronym><ProtocolTitle>An International, Multicenter, Controlled Clinical Trial to Evaluate High-Dose Rifapentine and a Quinolone in the Treatment of Pulmonary Tuberculosis</ProtocolTitle><Sponsor>St Georges University of London</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="153990"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>827</Patients><Biomarkers>Arylacetamide deacetylase; Nuclear receptor subfamily 1 group I member 2; Nuclear receptor subfamily 1 group I member 3; Solute carrier organic anion transporter family member 1B1</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>1250</EnrollmentCount><Interventions>ethambutol; isoniazid; moxifloxacin; pyrazinamide; rifampicin; rifapentine</Interventions><Reference>10.1186/ISRCTN44153044; ISRCTN44153044; RIFAQUIN</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="307654"></Trial><Drug id="11088">sutezolid</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>448</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Reference>CAP 020; InDEX; NCT03237182</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Taima TB: 3-HP Study</ProtocolTitle><Sponsor>Ottawa Hospital Research Institute</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="254050"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>450</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>450</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Reference>20160044-01H; NCT02689089</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study Comparing Rifampicin In A Fixed-dose Combination (Rifampicin + Isoniazid, Myrin 2) And The Reference Drug (Rifampicin, Rimactane)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="164313"></Trial><Drug id="89460">rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>21</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rimactane (rifampicin 300 mg, Novartis Sandoz)</Controls><EnrollmentCount>21</EnrollmentCount><Interventions>rifampicin + isoniazid (fixed dose combination, tuberculosis), Pfizer</Interventions><Reference>B3801001; NCT01311505</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>IMPAACT4TB</ProtocolAcronym><ProtocolTitle>Safety, Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients</ProtocolTitle><Sponsor>Aurum Institute</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="329251"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Human immunodeficiency virus RNA</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>dolutegravir; emtricitabine; isoniazid; rifapentine; tenofovir disoproxil fumarate</Interventions><Reference>3HP DTG AUR1-6-212 IMPAACT4TB; IMPAACT4TB; NCT03435146</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="246089"></Trial><Drug id="71742">TBA-354</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>18</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>TBA-354</Interventions><Reference>NCT02606214; TBA-354-CL-002</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of faropenem and cefadroxil (in combination with amoxicillin/clavulanic acid and standard TB drugs) in patients with pulmonary tuberculosis: measurement of early bactericidal activity and effects on novel biomarkers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="360329"></Trial><Drug id="46931">cefadroxil</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>45</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>amoxicillin; cefadroxil; clavulanic acid; ethambutol; faropenem; isoniazid; pyrazinamide; rifampicin</Interventions><Reference>2018-CT0454; 20180710115454; Faropenem_TB; PHRR181108-001980</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Task Foundation NPC</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="220739"></Trial><Drug id="44284">amoxicillin + clavulanate potassium, GSK</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour e275; ethambutol; isoniazid; pyrazinamide; rifampin</Controls><EnrollmentCount>46</EnrollmentCount><Interventions>amoxicillin + clavulanate potassium, GSK; faropenem; meropenem</Interventions><Reference>NCT02349841; TASK-001</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>NEXT</ProtocolAcronym><ProtocolTitle>An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multidrug-resistant Tuberculosis</ProtocolTitle><Sponsor>University of Cape Town</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="230529"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>300</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>kanamycin; moxifloxacin</Controls><EnrollmentCount>300</EnrollmentCount><Interventions>bedaqualine; ethionamide; isoniazid; levofloxacin; linezolid; pyrazinamide; terizidone</Interventions><Reference>NCT02454205; NEXT; NEXT-5001</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalency Study of Moxifloxacin Tablets, 400 mg Under Fasting Conditions</ProtocolTitle><Sponsor>Dr Reddy's Laboratories Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="218651"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>26</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Avelox</Controls><EnrollmentCount>26</EnrollmentCount><Interventions>moxifloxacin (Dr Reddy's Laboratories Limited)</Interventions><Reference>054-12; NCT02322619</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ-169 Formulation</ProtocolTitle><Sponsor>Innovative Medicines for Tuberculosis</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="328144"></Trial><Drug id="90085">macozinone</Drug><DevStatus id="C1A">Phase 1a Clinical</DevStatus><Patients>32</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>32</EnrollmentCount><Interventions>macozinone</Interventions><Reference>IM-006-11; NCT03423030</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>endTB</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Sponsor>Mdecins Sans Frontires France</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="259506"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>750</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>pryrazinamide</Controls><EnrollmentCount>750</EnrollmentCount><Interventions>Lamprene; bedaquiline; delamanid; levofloxacin; linezolid; moxifloxacin; pryrazinamide</Interventions><Reference>MSF ERB-1555; NCT02754765; endTB</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Clinical Trial of ID93 + GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent</ProtocolTitle><Sponsor>Quratis Co Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="366672"></Trial><Drug id="68617">ID93 vaccine (GLA-SE adjuvant, TB), IDRI/ Quratis</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>ID-93</Interventions><Reference>CT-QTP101-002; NCT03806699</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Investigate the Safety and Efficacy of GC-3107 (BCG Vaccine) in Healthy Adults</ProtocolTitle><Sponsor>GC Pharma</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="321760"></Trial><Drug id="108779">GC-3107</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>GC-3107</Interventions><Reference>GC3107_P1; NCT03363178</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>APT</ProtocolAcronym><ProtocolTitle>Assessing PA-824 for Tuberculosis</ProtocolTitle><Sponsor>Johns Hopkins Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="213394"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>183</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampin</Controls><EnrollmentCount>183</EnrollmentCount><Interventions>isoniazid; pretomanid; pyrazinamide; rifabutin; rifampin</Interventions><Reference>#FD-R-004794-01; APT; NA_00093014; NCT02256696</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>MTBVAC-Ph1b</ProtocolAcronym><ProtocolTitle>Dose-escalation, Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults</ProtocolTitle><Sponsor>Biofabri SL</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="257534"></Trial><Drug id="89744">MTBVAC</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>54</Patients><Biomarkers>Cytokines; Cytotoxic T-Lymphocytes; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>BCG vaccine SSI</Controls><EnrollmentCount>54</EnrollmentCount><Interventions>MTBVAC</Interventions><Reference>MTBVAC-02; MTBVAC-Ph1b; NCT02729571</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB (rhIL-2)</ProtocolTitle><Sponsor>Jiangsu Provincial Peoples Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="289837"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>500</Patients><Biomarkers>Alanine transaminase; Blood urea nitrogen to creatinine ratio; Calcium; Magnesium; Potassium; Thyroid-stimulating hormone</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>amikacin; capreomycin; kanamycin; levofloxacin; para-aminosalicylic acid; pasiniazid; prothionamide; pyrazinamide</Controls><EnrollmentCount>500</EnrollmentCount><Interventions>RhIL-2; amikacin; capreomycin; kanamycin; levofloxacin; para-aminosalicylic acid; pasiniazid; prothionamide; pyrazinamide</Interventions><Reference>NCT03069534; RHIL-2 THERAPY ON MDR-TB</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>endTB</ProtocolAcronym><ProtocolTitle>Evaluating Newly Approved Drugs for Multidrug-resistant TB</ProtocolTitle><Sponsor>Mdecins Sans Frontires France</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="259506"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>750</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>pryrazinamide</Controls><EnrollmentCount>750</EnrollmentCount><Interventions>Lamprene; bedaquiline; delamanid; levofloxacin; linezolid; moxifloxacin; pryrazinamide</Interventions><Reference>MSF ERB-1555; NCT02754765; endTB</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Beijing Chest Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="271641"></Trial><Drug id="3492">levofloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>3900</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampin</Controls><EnrollmentCount>3900</EnrollmentCount><Interventions>ethambutol; isoniazid; levofloxacin; pyrazinamide; rifampin</Interventions><Reference>2015ZX10003001; NCT02901288</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Rifapentine-containing tuberculosis treatment shortening regimens (S31/A5349)</ProtocolTitle><Sponsor>Centers for Disease Control and Prevention</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="347338"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2500</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>2500</EnrollmentCount><Interventions>moxifloxacin; rifapentine</Interventions><Reference>CTRI/2018/07/014966</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>TB-PRACTECAL</ProtocolAcronym><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Sponsor>Medecins Sans Frontieres</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="244304"></Trial><Drug id="13323">pretomanid</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>630</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>630</EnrollmentCount><Interventions>Lamprene; bedaquiline; linezolid; moxifloxacin; pretomanid</Interventions><Reference>1541; NCT02589782; TB-PRACTECAL</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><Sponsor>Beijing Chest Hospital</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="328802"></Trial><Drug id="12978">moxifloxacin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>140</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>gatifloxacin; levofloxacin; moxifloxacin; p-aminosalycilic acid; prothionamide</Controls><EnrollmentCount>320</EnrollmentCount><Interventions>clofazimine; gatifloxacin; levofloxacin; moxifloxacin; p-aminosalycilic acid; prothionamide</Interventions><Reference>ChiCTR1800014800</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of metformin in treatment of non-diabetic pulmonary tuberculosis patients</ProtocolTitle><Sponsor>Veer Surendra Sai Institute of Medical Sciences and Research</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="372893"></Trial><Drug id="6050">metformin hydrochloride</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>150</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>ethambutol; isoniazid; pyrazinamide; rifampicin</Controls><EnrollmentCount>150</EnrollmentCount><Interventions>ethambutol; isoniazid; metformin hydrochloride; pyrazinamide; rifampicin</Interventions><Reference>CTRI/2019/03/017926</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>InDEX</ProtocolAcronym><ProtocolTitle>The Individualized M(X) Drug-resistant TB Treatment Strategy Study</ProtocolTitle><Sponsor>Centre for the AIDS Program of Research in South Africa</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="307654"></Trial><Drug id="4229">rifabutin</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>448</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>448</EnrollmentCount><Interventions>amikacin; amoxicillin + clavulanate; azithromycin; bedaquiline; capreomycin; clarithromycin; clofazimine; cycloserine; delaminid; ethambutol; ethionamide; gatifloxacin; imipenem/cilastatin; isoniazid; kanamycin; levofloxacin; linezolid; meropenem; moxifloxacin; ofloxacin; para-aminosalicylic acid; pretomanid; prothionamide; pyrazinamide; rifabutin; rifampicin; streptomycin; sutezolid; terizidone; thioacetazone; whole genome sequencing</Interventions><Reference>CAP 020; InDEX; NCT03237182</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in HIV-Infected and HIV-Uninfected Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis</ProtocolTitle><Sponsor>B. J. Medical College, Pune, National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="272021"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>72</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>72</EnrollmentCount><Interventions>bedaquiline</Interventions><Reference>11884; CTRI/2017/12/010751; IMPAACT P1108; NCT02906007; P1108</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q-203)</ProtocolTitle><Sponsor>Qurient Therapeutics</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="343604"></Trial><Drug id="85970">telacebec</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Rifafour e-275</Controls><EnrollmentCount>60</EnrollmentCount><Interventions>telacebec</Interventions><Reference>NCT03563599; Q203-TB-P2-ZA001</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym>EMPIRICAL</ProtocolAcronym><ProtocolTitle>Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia</ProtocolTitle><Sponsor>Hospital Universitario 12 de Octubre</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="377163"></Trial><Drug id="44384">ceftriaxone</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>624</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Standard of Care; ampicillin; benzylpenicillin; ceftriaxone; cotrimoxazole; gentamicin; prednisolone; sulfamethoxazole; trimethoprim</Controls><EnrollmentCount>624</EnrollmentCount><Interventions>Standard or Care; rifampicin + isoniazid + ethambutol; rifampicin + isoniazid + pyrazinamide; valganciclovir; valganciclovir</Interventions><Reference>19/096; 2019-001749-42; EDCTP RIA2017MC-2013EMPIRICAL; EMPIRICAL; NCT03915366; PACTR201904797961340; U1111-1231-4736</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>SCRIPT-TB</ProtocolAcronym><ProtocolTitle>Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis</ProtocolTitle><Sponsor>Huashan Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="375813"></Trial><Drug id="15102">rifapentine</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>566</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>566</EnrollmentCount><Interventions>isoniazid; rifapentine</Interventions><Reference>2017ZX10201302-004; NCT03900858; SCRIPT-TB</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Appropriate course of the treatment of tuberculous pleurisy</ProtocolTitle><Sponsor>Capital Medical University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="309137"></Trial><Drug id="82091">ethambutol hydrochloride + rifampicin + isoniazid (fixed dose combination, tuberculosis), Shenyang Hongqi Pharmaceutical</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>474</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>An Si Nuo Kang; isoniazid + rifampin + pyrazinamide + ethambutol</Controls><EnrollmentCount>474</EnrollmentCount><Interventions>An Si Nuo Kang; isoniazid + rifampin + pyrazinamide + ethambutol</Interventions><Reference>ChiCTR-IOR-15006408</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Multicenter, controlled clinical study of the safety, tolerability and efficacy of clofazimine in the treatment of drug-resistant tuberculosis</ProtocolTitle><Sponsor>Beijing Chest Hospital</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="328802"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>140</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>gatifloxacin; levofloxacin; moxifloxacin; p-aminosalycilic acid; prothionamide</Controls><EnrollmentCount>320</EnrollmentCount><Interventions>clofazimine; gatifloxacin; levofloxacin; moxifloxacin; p-aminosalycilic acid; prothionamide</Interventions><Reference>ChiCTR1800014800</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>TB-PRACTECAL</ProtocolAcronym><ProtocolTitle>Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)</ProtocolTitle><Sponsor>Medecins Sans Frontieres</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="244304"></Trial><Drug id="91861">clofazimine (oral, tuberculosis), Novartis</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>630</Patients><Biomarkers>QT interval</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>630</EnrollmentCount><Interventions>Lamprene; bedaquiline; linezolid; moxifloxacin; pretomanid</Interventions><Reference>1541; NCT02589782; TB-PRACTECAL</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase 1 Study to Evaluate Safety, Tolerability, and PK of TBI-223 in Healthy Adults</ProtocolTitle><Sponsor>TB Alliance</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="362067"></Trial><Drug id="107010">TBI-223</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>48</Patients><Biomarkers>Follicle-stimulating hormone; Gait; Heart rate; Respiratory frequency</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>TBI-223</Interventions><Reference>NCT03758612; TBI-223-CL-001</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="8842"></Trial><Drug id="16545">delamanid</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>54</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>rifafour e-275</Controls><EnrollmentCount>54</EnrollmentCount><Interventions>OPC-67683</Interventions><Reference>242-06-101; NCT00401271</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study on Tuberculosis Resistant to Treatment</ProtocolTitle><Sponsor>Indian Council of Medical Research, Tuberculosis Research Centre</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="369747"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>165</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>165</EnrollmentCount><Interventions>Zyvox; bedaquiline; clofazimine; delamanid</Interventions><Reference>CTRI/2019/01/017310; Version Number: 3.1</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity of Two Formulations of Tuberculosis Vaccines GSK-692342 Given at 0, 1 Months to Healthy Adults</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9520"></Trial><Drug id="9490">MTB72F vaccine (tuberculosis), GSK/ IAVI</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>110</Patients><Biomarkers>IFN-gamma; TNF-alpha</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>110</EnrollmentCount><Interventions>GSK-692342</Interventions><Reference>106227; 106228; 108736; 108738; NCT00397943</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>PRACTECAL-PRO</ProtocolAcronym><ProtocolTitle>Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial</ProtocolTitle><Sponsor>Medecins Sans Frontieres, Netherlands</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="379769"></Trial><Drug id="51310">bedaquiline</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>54</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls>Directly observed therapy</Controls><EnrollmentCount>54</EnrollmentCount><Interventions>bedaquiline; clofazimine; linezolid; moxifloxacin; pretomanid</Interventions><Reference>NCT03942354; PRACTECAL-PRO; PRACTECAL-PRO</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>TBCOX2</ProtocolAcronym><ProtocolTitle>Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic</ProtocolTitle><Sponsor>Oslo University Hospital</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="235355"></Trial><Drug id="22216">etoricoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>39</Patients><Biomarkers>Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-2; Interleukin-2 receptor alpha chain ; Monocytes; Myeloid-derived suppressor cells; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor necrosis factor</Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>39</EnrollmentCount><Interventions>SSI H56-IC31; SSI H56-IC31; etoricoxib; etoricoxib</Interventions><Reference>2014-004986-26; 2015/692; NCT02503839; TBCOX2</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating Whole Blood Bactericidal Activity of Bortezomib Against Mycobacterium Tuberculosis in Healthy Volunteers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="263359"></Trial><Drug id="15954">bortezomib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>bortezomib</Interventions><Reference>2015/00743</Reference></Row></ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2>